Identification and characterization of Chlamydia trachomatis type III secretion substrates by Cunha, Maria Sarmento de Matos Paiva Raposo da
Maria Sarmento de Matos Paiva Raposo da Cunha 
Identification and characterization of Chlamydia 
trachomatis type III secretion substrates 
Oeiras, 
August, 2016 
Dissertation presented to obtain the Ph.D degree in Biology 
Instituto de Tecnologia Química e Biológica António Xavier | Universidade Nova de Lisboa 
Maria Sarmento de Matos Paiva Raposo da Cunha 
Dissertation presented to obtain the Ph.D degree in Biology 
Instituto de Tecnologia Química e Biológica António Xavier | Universidade Nova de Lisboa 
Oeiras, August, 2016 
Identification and characterization of Chlamydia 






Financial support from Fundação para a Ciência e a Tecnologia 
through fellowship SFRH/BD/62728/2009 awarded to Maria Paiva 
























































By Maria Sarmento de Matos Paiva Raposo da Cunha 
 
 
First Edition: March 2016 
Second Edition: August 2016 
 
Front Cover: 





Instituto de Tecnologia Química e Biologia António Xavier 
Av. Da Republica EAN, 2780-157 Oeiras, Portugal 





Copyright© 2016 by Maria Paiva Raposo da Cunha 
All Rights Reserved 






From left to right: Prof. Sérgio Joaquim Raposo Filipe, Dr. Didier Jacques 
Cabanes, Dr. Agathe Subtil, Maria da Cunha, Prof. Luís Jaime Mota, Prof. 
Hermínia Maria Francisco Roncon Garcez de Lencastre (president of the 
Jury) and Dr. Raquel de Sá Leão Domingues da Silva. 
 
Supervisor 
Prof. Luís Jaime Mota, Head of Infection Biology Laboratory and Professor 
Auxiliar da Faculdade de Ciências e Tecnologia da Universidade Nova de 
Lisboa, Portugal. 
Jury 
Dr. Agathe Subtil, CNRS Research Director, Head of Laboratory at Institut 
Pasteur, Paris, France. 
Dr. Didier Jacques Cabanes, Principal Investigator, I3S- Instituto de 
Investigação e Inovação em Saúde, IBMC (Instituto de Biologia Molecular e 
Celular), Universidade do Porto, Portugal. 
Prof. Sérgio Joaquim Raposo Filipe, Professor Auxiliar da Faculdade de 
Ciências e Tecnologia da Universidade Nova de Lisboa, Portugal. 
Dr. Raquel Sá Leão Domingues da Silva, Investigadora Principal, Instituto 




I will start by thanking my supervisor, Prof. Jaime Mota, for accepting 
me as a PhD student, for all the helpful discussions, challenging 
ideas, continuous guidance throughout this study and for reviewing 
this dissertation. His expertise and scientific rigor have greatly 
contributed to my learning experience. 
 
I thank the Fundação para a Ciência e Tecnologia for financial 
support provided through fellowship SFRH/BD/62728/2009.  
 
I am also grateful to ITQB NOVA for receiving me as a PhD student 
and to the institutions that made this thesis possible by providing all 
the necessary conditions for this work to progress: ITQB NOVA and 
UCIBIO and Department of Life Sciences at FCT NOVA. I also thank 
IGC and CEDOC for the microscopy facilities. 
 
I thank Prof. João Paulo Gomes and Prof. Sérgio Raposo Filipe for 
being part of my thesis commission, for their cooperation and 
scientific discussions. 
 
I thank my colleagues at the infection Biology lab: Filipe, Lia, Sara, 
Irina, Nuno, Catarina and Joana, for the stimulating discussions and 
also for so many fun moments shared in the lab. A special thanks to 
Filipe, always ready to help with his IT expertise. 
 
I thank Rita Fior and Prof. Isabel Sá Nogueira for having incentivized 
me to resume my scientific career after a five-year interruption. 
 
À minha mãe um agradecimento muito especial, pelo seu apoio 
incondicional, pela imensa paciência e ânimo e por estar sempre 
disponível para me ajudar. E ao Pedro, pela paciência e carinho com 
os seus netos emprestados. 
 
Ao meu Pai, que apesar da distância, tem estado sempre presente 
em todos os momentos importantes da minha vida. To my sisters, 




Ao meu irmão Manel e à Mariana, sempre presentes na minha vida, 
por me incentivarem e ajudarem a nunca desistir. 
 
Agradeço a toda a minha grande família alargada: aos meus Tios e 
Primos, aos meus Sogros, aos meus Cunhados e Cunhadas: todos 
têm sido exemplo e fonte de inspiração. 
 
Ao André, pelos quase 15 anos de caminhada a dois, pela paciência, 
por me apoiar e incentivar sempre e por preencher a minha vida.  
 
E finalmente aos meus queridos filhos, João, André, Mariana e 
Manel, a quem dedico este trabalho, que consigam ultrapassar 




Maria da Cunha, Catarina Milho, Filipe Almeida, Sara V. Pais, 
Vítor Borges, Rui Maurício, Maria José Borrego, João Paulo 
Gomes, and Luís Jaime Mota (2014). Identification of type III 
secretion substrates of Chlamydia trachomatis using Yersinia 
enterocolitica as a heterologous system; BMC Microbiology, 14:40. 
doi: 10.1186/1471-2180-14-40. 
 
Maria da Cunha and Luís Jaime Mota. The Chlamydia trachomatis 
type III secretion substrates CT142, CT143, and CT144 could be part 


















































































Chlamydiae are a large group of Gram-negative obligate intracellular 
bacteria that only grow within a membrane-bound vacuole in 
eukaryotic host cells. All Chlamydiae share a unique biphasic 
developmental cycle, in which the non-replicative elementary bodies 
(EBs) invade host cells and remain restricted within the bacterial 
vacuole, known as inclusion. Soon after invasion, EBs develop into 
replicative RBs that grow and divide by binary fission. Later in the 
cycle, RBs undergo a secondary differentiation into EBs, which are 
released from the host cell to initiate new rounds of invasion.  
 
The most famous representative of Chlamydiae is Chlamydia 
trachomatis, an important human pathogen. Different C. trachomatis 
serovars are capable of significant differences in terms of infection, 
being the most frequent cause of infectious blindness (trachoma) in 
the developing world and of sexually transmitted bacterial diseases 
worldwide. Like all Chlamydiae, C. trachomatis encodes for a type III 
secretion system (T3SS), which is used to manipulate host cells 
through the delivery of effector proteins into their cytosol or 
membranes. Although a limited number of C. trachomatis effectors 
have been characterized, several C. trachomatis genes have been 
hypothesized to encode for effector proteins. However, this work 
started under the assumption that many C. trachomatis type III 
secretion (T3S) effectors remained to be identified. 
 
To identify previously uncharacterized C. trachomatis T3S substrates, 
we performed a screen using Yersinia enterocolitica as heterologous 
host. We identified 23 C. trachomatis proteins whose first 20 amino 




TEM-1 by Y. enterocolitica. In addition, we found that 10 of these 23 
proteins (CT053, CT105, CT142, CT143, CT144, CT161, CT338, 
CT429, CT656, and CT849) were also type III secreted in their full-
length versions by Y. enterocolitica, providing additional support that 
they are T3S substrates. Real-time quantitative PCR analysis of 
genes encoding the 10 likely T3S substrates of C. trachomatis 
showed that all (except ct161) were expressed during infection of 
host cells. Furthermore, CT053, CT105, CT142, CT143, CT161, 
CT338, and CT429 were delivered by Y. enterocolitica into host cells, 
further suggesting they could be effector proteins. 
 
Most C. trachomatis isolates maintain a highly conserved virulence 
plasmid, and recent work revealed that plasmid-encoded Pgp4 is a 
transcriptional regulator of plasmid genes and of multiple 
chromosomal genes, including ct142, ct143 and ct144, which encode 
for proteins that were identified as possible effectors in our screen for 
T3S substrates. Altogether, this strongly suggests that these proteins 
could be virulence factors. We therefore aimed to characterize the 
expression and subcellular localization of CT142, CT143, and CT144 
during infection of host cells by C. trachomatis. Transcription linkage 
showed that ct142, ct143 and ct144 are organized in an operon and 
that their expression in C. trachomatis is likely driven by σ66, the 
homolog of the Escherichia coli main σ factor. Using anti-CT142 or 
anti-CT143 antibodies, expression of CT142 or CT143, respectively, 
was detected by immunoblotting from 20-30 h post-infection of HeLa 
cells with C. trachomatis serovar L2 strain 434/Bu. 
Immunofluorescence microscopy with anti-CT143 antibodies revealed 
that at 15 h post-infection CT143 co-localized with a cytosolic 
bacterial marker (Hsp60), while from 20 h post-infection CT143 
appeared as intra-inclusion globular structures that did not overly co-
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localize with the bacterial signal. This suggested that CT143 could be 
secreted into the lumen of the inclusion. 
 
Using recently developed methods for transformation of C. 
trachomatis, we then constructed strains carrying plasmids 
expressing CT142, CT143, or CT144 with a C-terminal 2x 
hemagglutinin (2HA) epitope tag (CT142-2HA, CT143-2HA, CT144-
2HA) under the control of the ct142 promoter. Immunofluorescence 
microscopy of HeLa cells infected by these C. trachomatis strains 
revealed that CT142-2HA, CT143-2HA, or CT144-2HA localized 
within the bacteria at 15 h post-infection and within the lumen of the 
inclusion from 20 h post-infection, as had been observed for 
endogenous CT143. Moreover, immunofluorescence microscopy of 
HeLa cells infected by C. trachomatis carrying a plasmid 
simultaneously expressing CT142, CT143, and CT144-2HA under the 
control of the ct142 promoter, revealed co-localization between 
CT144-2HA and CT143. Immunoprecipitation experiments using Y. 
enterocolitica as heterologous host indicated that CT142 could self-
interact, bind to CT143, and possibly to CT144.  
 
In conclusion, this work revealed several C. trachomatis proteins that 
could be effectors subverting host cell processes: CT053, CT105, 
CT142, CT143, CT144, CT161, CT338, CT429, CT656, and CT849. 
Three of these proteins were further characterized (CT142, CT143 
and CT144) and we propose that they could form a complex in the 
inclusion lumen after their secretion by the bacteria. While the 
function of this putative complex remains to be determined, the timing 
of expression and localization of CT142, CT143, and CT144 suggests 
that these proteins could be involved in: (i) metabolic reactions within 







O filo Chlamydiae inclui um grande número de bactérias, com reação 
de Gram-negativa, que vivem obrigatoriamente num compartimento 
vacuolar membranar (inclusão de Chlamydia) no interior de células 
eucarióticas. As bactérias pertencentes ao filo Chlamydiae têm um 
ciclo de desenvolvimento que inclui duas formas morfologicamente 
distintas: os corpos elementares (EBs; elementary bodies), capazes 
de entrar em células hospedeiras mas incapazes de se replicarem, e 
os corpos reticulares (RBs; reticulate bodies), incapazes de entrar em 
células hospedeiras mas com capacidade replicativa. 
 
Chlamydia trachomatis é uma importante bactéria patogénica 
humana, que pertence às Chlamydiae. Esta espécie contém 
diferentes serovares que apresentam diferenças significativas em 
termos de infeção, sendo  a maior causa bacteriana de doenças 
sexualmente transmitidas e de tracoma, uma doença ocular infeciosa 
que pode levar à cegueira, que é muito comum em países em 
desenvolvimento. 
 
C. trachomatis, assim como todas as Chlamydiae, contém um 
sistema de secreção do tipo III que lhe permite injetar proteínas 
efetoras no citosol ou nas membranas das células hospedeiras, e 
deste modo manipular funções essenciais da célula hospedeira em 
seu benefício. No entanto, atualmente, apenas um pequeno número 
de proteínas efetoras foram identificadas em C. trachomatis. 
 
No presente estudo, o principal objetivo foi identificar novas proteínas 
efetoras do sistema de secreção do tipo III de C. trachomatis. Para 




como hospedeiro heterólogo: i) identificámos 23 proteínas de C. 
trachomatis com sinais de secreção, localizados nos primeiros 20 
aminoácidos de cada proteína, que são reconhecidos pelo sistema 
de secreção do tipo III de Y. enterocolitica; ii) destas 23 proteínas 
selecionadas, 10 delas são também transportadas para o meio 
extracelular, na sua sequência polipeptídica completa, pelo sistema 
de secreção do tipo III de Y. enterocolitica. Deste modo, neste 
rastreio, encontrámos 10 prováveis proteínas efetoras do sistema de 
secreção do tipo III de C. trachomatis (CT053, CT105, CT142, 
CT143, CT144, CT161, CT338, CT429, CT656, e CT849). Para além 
disso, CT053, CT105, CT142, CT143, CT161, CT338 e CT429 têm 
também a capacidade de serem transportadas para o citosol de 
células hospedeiras infectadas por Y. enterocolitica. Finalmente, com 
exceção do gene que codifica para CT161, todos os genes que 
codificam para estas proteínas são expressos em células infetadas 
por C. trachomatis. 
 
A maior parte das estirpes de C. trachomatis contém um plasmídeo 
de virulência. Estudos recentes, mostraram que uma proteína (Pgp4) 
codificada no plasmídeo é um regulador transcricional, não apenas 
de genes do próprio plasmídeo, como também de genes 
cromossomais, incluindo ct142, ct143 e ct144. O facto de CT142, 
CT143 e CT144 terem sido também detetados no nosso rastreio 
confere-lhes uma maior probabilidade de serem proteínas envolvidas 
na virulência de C. trachomatis. Foi assim realizada a caracterização 
de ct142, ct143 e ct144 em termos de organização genética. 
Verificou-se que estes genes se localizam num operão cujo local de 
início da transcrição foi determinado. Analisando a região promotora 
encontrámos regiões −10  e −35, em relação ao local de início da 
transcrição, com grande semelhança em relação a sequências de 
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consenso definidas para reconhecimento da RNA polimerase 
associada ao factor σ66, homólogo do principal fator σ de Escherichia 
coli. Utilizando anticorpos anti-CT142 e anti-CT143 procedemos 
também a uma análise de expressão (CT142 e CT143) e localização 
subcelular (CT143) das proteínas em estudo. Verificámos, por 
immunoblotting, que ambas as proteínas são expressas em células 
HeLa infetadas pela estirpe 434/Bu do serovar L2 de C. trachomatis, 
a partir das 20 h após infeção. No caso de CT143, observámos, por 
microscopia de imunofluorescência, que às 15 h após infeção a 
proteína se localiza no interior da bactéria, enquanto que a partir das 
20 h após infeção a proteína se localiza no lúmen da inclusão de C. 
trachomatis, em aglomerados que não co-localizam com marcadores 
bacterianos (Hsp60). Esta observação sugere que a proteína possa 
ser transportada para o lúmen da inclusão. 
 
De seguida, empregando métodos recentemente descritos para 
transformação de C. trachomatis, construímos estirpes de C. 
trachomatis, contendo plasmídeos que expressam, a partir do 
promotor de ct142, as proteínas CT142, CT143 e CT144 contendo 
dois epitopo da proteína hemaglutinina (2HA) na sua extremidade 
carboxílica. Por microscopia de imunofluorescência, foram 
observadas células HeLa infetadas com cada uma das estirpes 
construídas. Verificou-se que CT142-2HA, CT143-2HA e CT144-2HA 
apresentam o mesmo tipo de localização no lúmen da inclusão que a 
proteína CT143 endógena: às 15 h após infeção as proteínas 
localizam-se no interior da bactéria enquanto que a partir das 20 h de 






Para além disso, resultados apresentados neste trabalho apontam 
para que estas três proteínas possam formar um complexo proteico: 
i) estudos de co-immunoprecipitação usando Y. enterocolitica como 
hospedeiro heterólogo sugerem que CT142 poderá interagir com 
CT142, com CT143 e talvez com CT144 e ii) a partir de estudos de 
imunofluorescência em células infetadas com uma estirpe de C. 
trachomatis que expressa as três proteínas no mesmo plasmídeo 
(CT142-CT143-CT144-2HA), verificámos que CT144-2HA e CT143 
co-localizam no lúmen da inclusão. 
 
Em conclusão, este trabalho contribuiu para expandir os 
conhecimentos sobre as proteínas de C. trachomatis transportadas 
através de um mecanismo de secreção do tipo III, sendo que dez 
prováveis proteínas efetoras foram reveladas neste estudo: CT053, 
CT105, CT142, CT143, CT144, CT161, CT338, CT429, CT656, e 
CT849. De entre elas, CT142, CT143 e CT144 foram caracterizadas 
em mais detalhe e os resultados obtidos sugerem que estas 
proteínas sejam transportadas pelo sistema de secreção de C. 
trachomatis para o lúmen da inclusão e que aí formem um complexo 
proteico. Apesar da função deste presumível complexo não ter sido 
ainda determinada, o tipo de localização destas proteínas, assim 
como a altura do ciclo de desenvolvimento de C. trachomatis em que 
são expressas, sugerem que: i) as proteínas possam participar em 
reações metabólicas dentro do lúmen da inclusão; ii) estejam 
envolvidas no final do ciclo de desenvolvimento, no processo de 
libertação dos EBs ou iii) estejam envolvidas no início do ciclo de 




This dissertation is divided into five chapters. Chapter I consists of a 
general introduction on Chlamydiae and on Chlamydia trachomatis in 
particular, including a brief historic and taxonomic description as well 
as an epidemiologic characterization of the different C. trachomatis 
serovars. General characteristics on the biology of C. trachomatis, its 
developmental cycle and interactions with the host cell are 
addressed. This chapter also comprehends a section on the 
importance of secretion systems in pathogenic bacteria with a 
particular emphasis on the type III secretion system (T3SS) of C. 
trachomatis. I also briefly describe recently devised methods for 
genetic manipulation in Chlamydia. 
 
The results presented on Chapter II consist of published material. 
They describe a screen where we used Yersinia enterocolitica as 
heterologous host to identify candidate chlamydial T3S effector 
proteins, first by identifying T3S signals in the selected proteins and 
secondly by analyzing the capacity of the proteins containing T3S 
signals to be secreted by Y. enterocolitica as full length proteins. We 
identified ten likely T3S substrates of C. trachomatis (CT053, CT105, 
CT142, CT143, CT144, CT161, CT338, CT429, CT656, and CT849) 
and could detect translocation into host cells by Y. enterocolitica of 
CT053, CT105, CT142, CT143, CT161, CT338, and CT429. 
 
Chapter III and Chapter IV include results that are part of a 
manuscript in preparation. Chapter III comprises a characterization of 
the genes encoding three of the proteins that were highlighted in the 
screen described in Chapter II (CT142, CT143 and CT144) in terms 




results that confirm that ct142, ct143 and ct144 are transcriptionally 
regulated by the C. trachomatis virulence plasmid. Additionally, in this 
chapter we describe the production of antibodies against CT142 and 
CT143 that constituted valuable tools for further expression studies 
(CT142 and CT143) and subcellular localization studies (CT143) in 
HeLa cells infected by C. trachomatis. Both CT142 and CT143 were 
found to be expressed in infected cells. Furthermore CT143 was 
found to be secreted into the lumen of the inclusion where it appears 
as globular structures that do not co-localize with bacterial markers. 
 
The results presented in Chapter IV, were based on the recently 
described transformation methods in C. trachomatis that allow ectopic 
expression of proteins from a plasmid. We observed that ectopically 
expressed CT142-2HA, CT143-2HA and CT144-2HA show a 
subcellular localization similar to the endogenous CT143, 
supplementing the results obtained in Chapter III. This chapter also 
includes immunoprecipitation experiments using Y. enterocolitica as 
heterologous host that suggest that CT142 can self-interact, bind to 
CT143, and perhaps also to CT144, implying that these proteins 
could form a complex in the lumen of the inclusion.  
 
Finally, Chapter V consists of a general discussion regarding the 
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The Chlamydiae are a separate phylum in the domain Bacteria 
comprising a large group of microorganisms that have in common an 
obligate intracellular lifestyle and a unique conserved biphasic 
developmental cycle. Chlamydiae depend on a eukaryotic host for 
replication, which takes place in a vacuolar compartment inside the 
host cell. In addition, they have evolved to colonize a wide variety of 
vertebrate and non-vertebrate hosts as well as free-living amoebae 
(Horn, 2008). 
 
1.1.1. History and taxonomy 
Chlamydial organisms were first described in 1907, after the 
identification of intracytoplasmic vacuoles containing large numbers 
of microorganisms in conjuctival cells from scrapings of trachoma 
cases (Halberstaedter & von Prowazec, 1907, 1909). At the time, 
these organisms were thought to be protozoa that were embedded or 
hidden in what appeared to be a mantle, thus naming them 
“chlamydozoa”, after the Greek word “chlamys” which stands for 
mantle. After this report, similar type of vacuolar microorganisms 
were described in scrapings from adults with urethritis and cervicitis 
and newborns with nongonococcal conjunctivitis (Lindner, 1910), in 
samples obtained from patients with lymphogranuloma venereum 
(LGV) (Durand et al., 1913) and in samples from humans and birds 
during a worldwide pandemic (1929-1930) of an atypical and acute 
pneumonia caused by contact with psittacine birds (Bedson et al., 
1930; Coles, 1930; Lillie, 1930). In 1935, Miyagawa considered these 
organisms to be viruses (Miyagawa et al., 1935) as they could be 
passed through bacterial filters and were unable to grow on artificial 






microscopy when Chlamydiae were finally classified as bacteria 
(Moulder, 1966). The main reason for this re-classification was the 
fact that DNA, RNA and ribosomes were observed in these 
microorganisms as well as a cell wall apparently similar to the one 
present in Gram-negative bacteria. 
 
The Chlamydiae phylum includes a total of nine families (Taylor-
Brown et al., 2015). The Chlamydiaceae family, the most widely 
studied, consists of one single genus (Chlamydia) and was for a long 
time considered the only family in this order. The members of the 
other 8 families (Parachlamydiaceae, Waddliaceae, Simkaniaceae, 
Rhabdochlamydiaceae, Criblamydiaceae, Piscichlamydiaceae, 
Chlavichlamydiaceae and Parilichamydiaceae) were described more 
recently and have often been referred to as “Chlamydia-like” 
organisms, “Chlamydia-related” bacteria, or “Environmental 
Chlamydia”. Although many of these microorganisms were isolated 
from environmental sources, they have been found to infect a variety 
of hosts such as free-living amoeba, bivalves, spiders, reptiles and 
fishes. Additionally, some of these recently described species, have 
been described as emerging human pathogens: Parachlamydia sp. 
as mucosal pathogens in humans and other animals (Corsaro & 
Greub, 2006), Simkania negevensis associated with respiratory 
disease in humans (Husain et al., 2007; Lieberman et al., 2002) and 
Waddlia chondrophila, an abortive agent in cattle that has also been 
associated with miscarriages in humans (Horn, 2008; Lamoth et al., 
2015). However, none of the strains were ever isolated from human 
patients and the associations were mainly based on serological and 
molecular data (Horn, 2008; Lamoth et al., 2015). 
 
 




1.1.2. The Chlamydiaceae family  
In 1999, Everett and co-workers made a controversial proposal to 
divide the Chlamydiaceae family in two genera: Chlamydia (C. 
trachomatis, C. suis and C. muridarum) and Chlamydophila (C. 
pecorum, C. pneumoniae, C. caviae, C. felix, C. psittaci and C. 
abortus) (Everett et al., 1999). This division was based on differential 
clustering of the 16S rRNA. However, the majority of chlamydial 
researchers found this classification to be inadequate because it was 
based on limited sequence data and, most of all, it did not take into 
account the unique conserved biological properties of the species. As 
a consequence, in 2009 it was proposed that the Chlamydiaceae 
should be reunited into a single genus, Chlamydia (Greub, 2010; 
Sachse et al., 2015; Stephens et al., 2009). 
 
There are currently 11 species of Chlamydia described that are 
characterized by major differences in host range, tissue tropism and 
disease pathology (reviewed in Nunes & Gomes, 2014; Sachse et al., 
2015) (Fig. 1.1). C. trachomatis is a human specific pathogen and is 
the most medically significant Chlamydia species, capable of causing 
ocular and genital infections (further detailed in section 1.1.3., below). 
However, to date, 10 additional Chlamydia species have been 
characterized and one new candidate species has been proposed: 
• C. pneumoniae is the other major human pathogen and is a 
prevalent cause of respiratory infections (Blasi et al., 2009; 
Kern et al., 2009). It is distributed worldwide being responsible 
for 10-20% of community acquired pneumonia in adults, 
exacerbations of chronic bronchitis, pharyngitis and asthma 
(Blasi et al., 2009; Kern et al., 2009) and it is also associated 
with asthma in children (Asner et al., 2014). It has also been 






nervous system disorders and Alzheimer’s disease 
(Benagiano et al., 2012; Roulis et al., 2013). Furthermore, C. 
pneumoniae is able to infect other mammals (horses, 
marsupials) and reptiles leading to respiratory and vascular 
pathologies (Bodetti et al., 2002). 
• C. psittaci is primarily a pathogen of avian species causing 
respiratory diseases that have a considerable impact on 
poultry farming (Knittler et al., 2014). It is able to infect 
approximately 450 different bird species, including psittacine 
birds, pigeons, ducks, geese and turkeys. Yet, transmission 
between humans and birds is possible through inhalation of 
droplets dispersed in the air containing the microorganism, 
causing severe respiratory diseases (Van Droogenbroeck et 
al., 2009; Knittler et al., 2014; Moroney et al., 1998). 
• C. abortus is of economic relevance since it is able to colonize 
the placenta of sheep and goats causing abortions 
(Longbottom et al., 2013). Pregnant women who are exposed 
are also at risk of miscarriage (Longbottom & Coulter, 2003). 
• C. muridarum infects mice and is able to colonize the lungs 
and genital tract (Ramsey et al., 2009). 
• C. avium  was found in pigeons and members of the psittacine 
family of birds (parrots, parakeets and macaws) (Sachse & 
Laroucau, 2014; Sachse et al., 2014). Infections appear to be 
asymptomatic but are widely disseminated. 
• C. gallinacea was identified in domestic poultry (chicken, 
guinea fowl and turkey) (Sachse & Laroucau, 2014; Sachse et 
al., 2014). As in C. avium, infections are widely disseminated 
but appear to be asymptomatic. 




• C. pecorum is a pathogen of livestock (cattle, sheep, goats 
and pigs) (Bachmann et al., 2014a; Fukushi & Hirai, 1992) 
causing polyarthritis, conjunctivitis, pneumonia and 
encephalomyelitis (Poudel et al., 2012). It is also capable of 
infecting the marsupial Koala causing ocular and genital 
infections (Polkinghorne et al., 2013).  
• C. felis has been related to conjunctivitis in cats (Cai et al., 
2002) and a few cases of conjunctivitis in humans have also 
been reported (Hartley et al., 2001). 
• C. caviae infects guinea pigs and causes conjunctivitis and 
genital tract infections (Read et al., 2003). 
• C. suis is restricted to infections in swine and is associated 
with pneumonia, conjunctivitis and reproductive disorders 
(Donati et al., 2014; Schautteet & Vanrompay, 2011). 
 
Recently, a new candidate chlamydial species has been proposed, C. 
ibidis, which infects Feral African Sacred Ibises (Vorimore et al., 
2013). This strain appears to be relatively innocuous in avian hosts 









Figure 1.1. Phylogenetic reconstruction of the Chlamydiaceae species whose 
genomes are fully sequenced. Each chlamydial species is associated to its natural 
host and cases of zoonotic transmission are depicted with arrows. C. suis, C. avium 
and C. gallinacea are not represented due to lack of sequence data. The 
Chlamydiaceae tree topology is based on the accumulation of single-nucleotide 
polymorphisms (SNPs) on 600 orthologous genes shared among the species. 
(Reprinted from Nunes et al, 2014, with permission from Elsevier). 
 
1.1.3. Chlamydia trachomatis 
The earliest reliable descriptions of trachoma, the blinding disease, 
are found in Ebers papyrus that appear to have been written between 
1553 and 1550 BC (Taylor, 2008). This suggests that C. trachomatis 
was present in early civilizations and consequently trachoma is most 
probably a disease that has been closely related to humans for 
millennia. The knowledge that C. trachomatis was also the cause of 
sexually transmitted diseases was much more recent than for 
trachoma. A significant advance in the knowledge of C. trachomatis 
 
 




was the isolation of the microorganism in embryonated chickens eggs 
in China by T’ang and collaborators in 1957 (T’ang et al., 1957). It 
then became possible to preserve and propagate these bacteria 
providing resources for future studies. 
 
C. trachomatis isolates have been classified into 15 main serovars 
based on a micro-immunofluorescent test that detects differential 
serospecificity of its Major Outer Membrane Protein (MOMP) 
(Schachter, 1999; Yuan et al., 1989). C. trachomatis serovars A-C 
and Ba infect ocular epithelial cells leading to conjunctivitis, with 
severe inflammation and scarring of the conjunctiva ultimately leading 
to trachoma, the world’s leading cause of preventable blindness 
(Whitcher et al., 2001; Wright et al., 2008). C. trachomatis serovars A 
and B are found in underdeveloped countries, ranging from Latin 
America, to Sub-Saharan Africa or Asia. C. trachomatis serovar C is 
rarely isolated but it is present in communities of Australia Northern 
territory. C. trachomatis serovars D-K represent the genital track 
strains (non invasive ano-urogenital infections) and are the main 
cause of bacterial sexually transmitted disease worldwide (World 
Health Organization, 2011). Within this group C. trachomatis serovars 
E and F represent approximately 50% of the uro-genital tract 
infections in heterosexual populations while C. trachomatis serovar G 
appear to be more prevalent in rectal tissues of man who have sex 
with men (MSM) (Christerson et al., 2012). In genital tract infections, 
C. trachomatis replicates mainly in epithelial cells of the urethra in 
men, or in epithelial cells of the endocervix of women causing 
inflammation, edema and mucosal discharge. Ascending uterine 
infections can lead to pelvic inflammatory disease, tubal scarring, 
ectopic pregnancies and infertility. C. trachomatis can also be 






(Bébéar, C., and de Barbeyrac, 2009; Shaw et al., 2011). The more 
invasive C. trachomatis LGV strains belong to serovars L1, L2 and L3 
and are responsible for a systemic disease (lymphogranuloma 
venereum) characterized by an infection of regional draining lymph 
nodes (Schachter, 1978). The C. trachomatis LGV strains are 
endemic in Africa, Southeast Asia, South America and the Caribbean. 
 
1.1.3.1 Impact of C. trachomatis infections on human health 
Taking into account the huge potential to cause human diseases as 
well as its ample tissue tropism, C. trachomatis has been considered 
a global health problem. Trachoma is endemic in 51 countries and is 
responsible for the visual impairment of 2.2 million people (1.2 million 
are irreversibly blind) (World Health Organization, 2014). The rate of 
cases of C. trachomatis sexually transmitted disease reported to the 
ECDC in Europe in 2012 were 184 per 100000 population (ECDC, 
2014) and close to 100 million new cases of C. trachomatis sexually 
transmitted infections are believed to occur annually worldwide 
(World Health Organization, 2011). Despite being effectively treated 
with antibiotics [azithromycin and doxycycline are the most widely 
used (Kong & Hocking, 2015)], a major concern with chlamydial 
genital infections is that 70% to 85% of infected women and over 50% 
of infected men are asymptomatic (Shaw et al., 2011). 
 
Chlamydial infections represent a significant financial burden to 
health care systems in order to treat acute genital infections including 
pelvic inflammatory disease and tubal infertility. Moreover, chlamydial 
infections have also been associated to other diseases: are 
considered to be a risk factor for the transmission of HIV (Shaw et al., 
2011; Xiridou et al., 2013) or human papillomavirus (HPV) 
(Luostarinen et al., 2013; Silva et al., 2014); could be linked with 




cervical cancer in women (Chumduri et al., 2013; González et al., 
2014; Shanmughapriya et al., 2012; Weitzman & Weitzman, 2014) 
and may also be involved in chlamydia-related reactive arthritis 
(Taylor-Robinson & Keat, 2015). 
 
1.1.3.2. Experimental models to study pathogenesis of C. trachomatis  
C. trachomatis interaction with host cells has been studied mainly 
through the use of non-polarized cell cultures. The most widely used 
cell lines are HeLa 229, derived from human cervical carcinoma 
(Scherer et al., 1953) and McCoy, a mouse fibroblast cell line 
(Gordon et al., 1972). The use of cell cultures as a model to study C. 
trachomatis has contributed greatly not only to our knowledge of 
chlamydial biology but also for the characterization of a variety of 
interactions between the bacteria and its host cell (Scidmore, 2005). 
However, the studies of chlamydial pathogenesis as a whole cannot 
be done using tissue culture alone, thus animal models have been 
crucial for the study of C. trachomatis infections and vaccine 
development. 
 
Diseases caused by Chlamydia are mainly based on chronic 
inflammation elicited by re-infection or persistent infection. The 
majority of information regarding host responses to Chlamydia 
infections has derived from murine, guinea pig, pig or non-human 
primate models (De Clercq et al., 2013; Neuendorf et al., 2015; 
O’Meara et al., 2014).  
 
Regarding pathogenesis, animal models of chlamydial ocular and 
genital infections lead to pathologies that are highly similar to those 
observed in humans (scarring sequelae in ocular infections or lower 






inflammatory pathologies). However, none of the available animal 
models have been found to perfectly reproduce the immune 
responses that occur during human C. trachomatis infections, which 
has greatly limited the development of an effective human vaccine 
against C. trachomatis (De Clercq et al., 2013). Attempts to develop a 
human vaccine against C. trachomatis go back to the 1960’s when 
clinical trials with inactivated EBs took place. An initial early protection 
in vaccinated individuals was achieved but upon second challenge it 
resulted in more severe symptoms when compared to the placebo 
group. This constituted a major obstacle for further clinical 
development of vaccines against C. trachomatis. However, advances 
in the development of a candidate vaccine have taken place recently 
(Kari et al., 2011a; Mabey et al., 2014; Stary et al., 2015). 
 
1.1.3.3. C. trachomatis genomic studies 
The C. trachomatis serovar D was the first chlamydial genome to be 
sequenced (Stephens et al., 1998) and revealed a single 1,042,519 
bp (~1 Mbp) circular chromosome and a 7,493 bp plasmid. It has 894 
gene-coding sequences and the average size of the genes is 1050 
bp. This is a relatively small genome when compared to free-living 
bacteria or even to the related Chlamydia-like bacteria (~2 Mbp), 
suggesting that during adaptation to its host Chlamydia lost a large 
number of genes (Mendonça et al., 2011). 
 
Genome analysis revealed that Chlamydia possess the minimal 
machinery required for DNA replication, transcription and translation, 
for type III secretion machinery, for basic lipid metabolism and for 
essential functions in aerobic respiration (Stephens et al., 1998; Yao 
et al., 2015). However, Chlamydia have several incomplete metabolic 
pathways such as the tricarboxilic acid cycle or the biosynthesis of 




aminoacids (Stephens et al., 1998), therefore relying on the host to 
obtain basic nutrients. 
 
Genome sequences from all the different C. trachomatis serovars are 
now available and they all share a high degree in similarity regarding 
size and synteny. Most genes are shared between the different 
chlamydial species and there is a high level of genomic similarity (> 
98%) between different serovars. This observation is striking when 
considering the divergence in tissue tropism and disease outcome. In 
fact, a small region in the genome of about 10 to 50 kb (45-49 genes 
for C. trachomatis), the Plasticity Zone (PZ), contains the highest 
degree of genetic divergence between the different serovars and is 
likely responsible for most of the phenotypic and host specificity 
differences observed (Nunes & Gomes, 2014). Genes located in this 
PZ include: i) the trpRBA operon, (incomplete trp operon) present 
only in the genital strains, allowing these bacteria to synthesize 
tryptophan from indole, a product that can be found within the genital 
tract microflora. This mechanism is thought to be of great importance 
for the survival of genital strains since the presence IFN-γ elicited by 
the host immune response limits the availability of tryptophan 
(Caldwell et al., 2003); ii) the gene encoding the chlamydial cytotoxin, 
ct166, which is involved in the disassembly of cytoskeleton actin 
filaments during bacterial internalization (“cytopathic effect”) (Bothe et 
al., 2015; Thalmann et al., 2010). This gene may be active, truncated 
or deleted among C. trachomatis strains. Ocular and genital strains 
retain remnants of a larger ancestral cytotoxin gene that is still intact 
in other Chlamydia spp. (Bachmann et al., 2014b; Lo et al., 2012; 
Nunes & Gomes, 2014) (see section 1.4.9.4, below). In the case of 
the LGV strains ct166 is completely deleted (Carlson et al., 2004); iii) 






(MACPF) (Nunes & Gomes, 2014) or iv) gene encoding 
phospholipase D enzymes (PLD), that could be involved in the 
acquisition of host lipids (Nelson et al., 2006). 
 
In addition, there are other genes outside the PZ that contribute to the 
variability among different C. trachomatis serovars. These include 
genes encoding for: the highly variable Pmps (polymorphic outer 
membrane proteins) (Becker & Hegemann, 2014; Crane et al., 2006; 
Gomes et al., 2006), the Inc family of proteins (see section 1.4.8.7, 
below), the TTS effectors (see section 1.4.8, below) and biotin and 
pyrimidine pathways (Nunes & Gomes, 2014). 
 
1.1.3.4. The C. trachomatis plasmid 
Chlamydial plasmids are highly conserved and have so far found to 
be present in seven species of Chlamydia: C. trachomatis, C. 
psitacci, C. pneumoniae, C. suis, C. felis, C. muridarum and C. caviae 
(Lovett et al., 1980; Pickett, 2005). Their length is about 7.5 kb, they 
are present in the quantity of 4 -10 copies per cell and are non 
integrative and non-conjugative (Pickett, 2005; Rockey, 2011). 
 
The C. trachomatis plasmid has been the most studied and is the 
most conserved among Chlamydia species (Ferreira et al., 2013). It 
contains non-coding RNAs (Abdelrahman et al., 2011) as well as 8 
ORFs that have recently been described (Gong et al., 2013; Song et 
al., 2013): 
• ORF 1 (pgp7) and ORF2 (pgp8) encode for proteins that are 
homologues of an integrase and recombinase, respectively, 
and are involved in regulation of plasmid replication; 
• ORF 3 (pgp1) encodes for a homologue of a DNA helicase; 




• ORF4 (pgp2) encodes for a protein of unknown function;  
• ORF5 (pgp3) encodes for a protein that has been 
demonstrated to localize in the inclusion lumen and cytosol of 
infected cells (Li et al., 2008), indicating it might be a secreted 
protein (see section 1.4.10.5., below); Pgp3 has been 
reported to represent a major virulence factor in C. muridarum 
pathogenesis in mice (Liu et al., 2014a) and more recently has 
been found to neutralize the anti-chlamydial activity of human 
cathelicidin LL-37, a host anti-microbial peptide secreted by 
both genital tract epithelial cells and infiltrating neutrophils 
(Hou et al., 2015). 
• ORF 6 (pgp4) encodes for a protein that has been found to act 
as a transcriptional regulator of plasmid encoded pgp3 and 
also of multiple chromosomal genes, including glgA, that is 
involved in the accumulation of glycogen in the inclusion 
(Song et al., 2013); 
• ORF7 (pgp5) from C. muridarum encodes for a protein that 
has been proposed to be involved in the suppression of 
plasmid dependent gene expression, suggesting that Pgp5 
can negatively regulate the same plasmid dependent genes 
that are upregulated by Pgp4 (Liu et al., 2014b); 
• ORF8 (pgp6) encodes for a protein that may be involved in 
plasmid replication. 
It has been proposed that pgp1, pgp2, pgp6-8 are required for 
plasmid maintenance while pgp3-5 are not required for the 








Naturally occurring plasmidless clinical isolates are rare. C. 
trachomatis serovar L2 strain 25667R is a naturally occurring 
plasmidless strain that has been well characterized (Carlson et al., 
2008). When compared to the serovar L2 strain 434/Bu the majority 
of the in vitro virulence characteristics were similar, including growth 
kinetics, plaquing efficiency and plaque size. The only in vitro 
phenotypic differences were the lack of accumulation of glycogen 
granules in the inclusion lumen and the absence of the typical 
Brownian-like movement characteristic of C. trachomatis strains. 
However, most in-vivo infections with plasmid deficient strains in 
murine or non-human primate models are either asymptomatic or 
show significantly reduced pathology (Kari et al., 2011a; O’Connell et 
al., 2007; Olivares-Zavaleta et al., 2010). These observations, 
together with the strong selection observed to maintain the plasmid 
implies a fundamental role for the plasmid in pathogenesis. The 
molecular basis of plasmid-mediated virulence is not clearly 
understood but is thought to involve plasmid related gene products 
(including chromosomal genes that are transcriptionally regulated by 
Pgp4) that could function as TLR2 (O’Connell et al., 2011) or TNF-α 
(Dong et al., 2014; Murthy et al., 2011) receptor antagonists. 
 
1.2. The Chlamydia developmental cycle 
During its developmental cycle (Fig. 1.2), Chlamydia exhibits two 
main forms: an infectious, non-replicating elementary body (EB) of 
approximately 0.3 µm of diameter, and a non-infectious but actively 
replicating reticulate body (RB) of approximately 1 µm of diameter 
(Fig. 1.3) (AbdelRahman & Belland, 2005). An intermediate form (IF) 
has also been observed by electron microscopy and described as a 
differentiation step between the RB and EB in the later stages of the 




cycle (Fig. 1.3) (Berger et al., 1999; Wilkat et al., 2014). Another 
morphologic form might also appear during the developmental cycle, 
the aberrant body (AB). It is non infectious and non replicative and is 





Figure 1.2. Schematic representation of the Chlamydia developmental cycle. 
The cycle begins with the attachment of EBs to the plasma membrane of host 
epithelial cells, in a process where early bacterial effectors (depicted in red) have 
been shown to play a major role. The EB is involved in a host-derived membrane 
forming an early inclusion, where the EB is converted into an RB. The inclusion 
membrane is rapidly modified by insertion of bacterial proteins (depicted in blue). 
RBs replicate by binary fission, which is accompanied by inclusion expansion through 
acquisition of host-derived nutrients. Late in the cycle, replication becomes 
asynchronous and RBs start re-differentiating back into EBs. The cycle is completed 
with the release of the infectious EBs by cell lysis or extrusion, allowing for other 
rounds of infection. (Adapted from Valdivia, 2008). 
 
The chlamydial cell wall includes general features of a Gram-negative 
cell envelope: inner membrane, periplasmic space with peptidoglycan 
(PG) and an outer membrane containing lipopolysaccharides (LPS). 
However, the ‘Chlamydial Anomaly’ debated for a long time the 
presence of PG in Chlamydia. It was puzzling that Chlamydia had in 
its genome genes that encode for peptidoglycan biosynthesis and 






conversely, attempts to detect or purify PG in chlamydial species 
were proven unsuccessful. Recently, however, the presence of PG in 
Chlamydia was finally established (Jacquier et al., 2015; Liechti et al., 
2014; Packiam et al., 2015). 
 
1.2.1. The elementary body 
The EBs (infectious form) are small, round and have adapted to 
extracellular survival (Fig. 1.3). They possess an electron dense 
nucleoid, a structure that is unique to Chlamydiae. Two histone-like 
proteins Hc1 and Hc2 (Wagar & Stephens, 1988) are thought to 
contribute to the nucleoid structure by inducing conformational 
changes in the DNA (Barry et al., 1992, 1993; Brickman et al., 1993). 
The location of the nucleoid in the cell suggests an association with 
the bacterial inner-membrane. EBs have a relatively hydrophobic 
surface and a net negative surface charge at neutral pH. The outer 
membrane of EBs is formed of a rigid network of inter and intra-
molecular disulphide bonds between the cysteine-rich proteins that 
are part of the chlamydial outer-membrane complex (OmcA, OmcB 
and MOMP) (Aistleitner et al., 2015; Wang et al., 2014): 
• OmcA and OmcB are present exclusively in EBs. OmcA is a 
lipoprotein with a structure similar to murein lipoproteins found 
in other Gram-negative bacteria (Everett et al., 1994). OmcB, 
is the second most abundant outer membrane protein thought 
to contribute to cell-wall rigidity and osmotic stability of the 
EBs. It is thought to be localized at the inner surface of the 
outer membrane but also to be surface exposed (Fadel & 
Eley, 2007) 
• MOMP (Major Outer Membrane Protein) is the chlamydial 
protein that is present in largest quantity in EBs and RBs and 




share the characteristics of other Gram-negative bacterial 
porins (Feher et al., 2013). 
Other components of the outer membrane include the group of 
Polymorphic Membrane Proteins (Pmps), which can be differentially 
expressed and distributed in the surface of the outer membrane. 
These have also been described as antigenic determinants 
(Vasilevsky et al., 2016). 
 
1.2.2. The reticulate body 
RBs are the replicating form of the bacteria and divide by binary 
fission during the mid-phase of the development cycle. They are 
larger than EBs with diffuse fibrillar nucleic acids loosely packed in 
the cytoplasm, which contrasts with the highly condensed nucleoid 
structure of the EBs (Fig. 1.3) (Barry et al., 1992; Hackstadt et al., 
1985; Moulder, 1991). Additionally they have a high metabolic 
activity, as they are responsible for uptake and transport of nutrients 
and abundant protein synthesis (Omsland et al., 2012). 
In comparison to EBs, the disulphide-bond network is reduced in 
RBs: OmcA and OmcB are absent and MOMP is present in a 
reduced form (Newhall & Jones, 1983), leading to a more flexible and 
osmotically fragile life stage. The permeability of the outer membrane 
is enhanced by the reduction state of disulfide bonds between 









Figure 1.3. Transmission electron micrograph representing chlamydial 
particles at various stages of development. R, large reticulate bodies that undergo 
binary fission; I, intermediate bodies that constitute a differentiation step between 
RBs and EBs and E, condensed elementary bodies. Scale bar, 700 nm. (Reprinted 
from Berger et al, 1999, with permission from the American Society for Microbiology). 
 
1.2.3. Attachment and entry 
The infectious form of C. trachomatis, the EB, attaches to and is 
internalized by the host cell. Multiple redundant mechanisms are 
likely to occur to ensure chlamydial entry and they depend not only on 
the chlamydial species but also on the host cell type being invaded. 
The interaction of EBs with host cells is thought to occur in a two step 
process: a initial step that consists of a reversible, electrostatic 
interaction of heparan sulphate-like glycosaminoglycans (Davis & 
Wyrick, 1997; Su et al., 1996; Zhang & Stephens, 1992), followed by 
a high affinity irreversible binding of the EB to one or several cellular 
receptors. Several surface proteins of EBs have been proposed to 
play a role at this stage of infection as adhesins or ligands for 




receptor interactions. These include MOMP (Su et al., 1996), OmcB 
(Fadel & Eley, 2007) or PmpD (Wehrl et al., 2004). 
 
Chlamydiae are able to infect a wide variety of cultured cell types, 
suggesting that receptor(s) mediating invasion are ubiquitous or that 
multiple receptors can be used (Bastidas et al., 2013). To date 
several host receptors have been proposed for Chlamydia entry: 
heparan sulphate (Chen & Stephens, 1994, 1997; Chen et al., 1996; 
Wuppermann et al., 2001), Toll-like receptor 2 (TLR2) (O’Connell et 
al., 2006), TLR4 (Heine et al., 2003), mannose-6-phosphate receptor, 
the estrogen receptor (reviewed in Cocchiaro & Valdivia, 2009), 
growth factors and their respective receptors (Elwell et al., 2008; Kim 
et al., 2011), as well as the protein disulfide isomerase (PDI) (when 
present at the cell surface) (Abromaitis & Stephens, 2009). Clathrin 
(Hybiske & Stephens, 2007a) and cholesterol-rich microdomains 
(Jutras et al., 2003; Norkin et al., 2001; Stuart et al., 2003) are 
additional host factors that may play a role in chlamydial uptake into 
non-phagocytic cells. 
 
To date, a small number of chlamydial proteins delivered into host 
cells have been identified to play a major role in the entry step 
(discussed ahead in section 1.4.8.): TarP (Translocated Actin-
Recruiting Phosphoprotein) is delivered into the host cell and 
contributes to bacterial internalization by directly nucleating actin 
polymerization (Jewett et al., 2006) or by indirectly inducing the 
reorganization of the actin cytoskeleton at attachment sites (Bastidas 
et al., 2013; Carabeo et al., 2004, 2007); CT694, was found to 
interact with human AHNAK, an actin-binding protein, and interfere 






Early Phosphoprotein), a scaffolding protein that is thought to mediate 
signaling events (Chen et al., 2014). 
 
1.2.4. Intracellular development 
Upon uptake, the EBs are sequestered in a membrane bound 
compartment that initially resembles the host plasma membrane. The 
disulphide bonds present in EBs are reduced during internalization 
(Hackstadt et al., 1985) followed by nucleoid decondensation and 
initiation of bacterial transcription. New bacterial proteins start being 
produced within 15 minutes and RNA expression can be detected as 
early as one hour post-infection (Belland et al., 2003; Plaunt & Hatch, 
1988). RBs replicate by binary fission inside the inclusion. Very 
rapidly bacterial Inclusion membrane (Inc) proteins (discussed ahead 
in section 1.4.8.7) are produced and inserted in this newly formed 
membrane compartment. These proteins share a common bi-lobular 
hydrophobicity motif that likely spans the inclusion membrane. They 
are thought to recruit to the inclusion key regulators of membrane 
trafficking, such as Rab GTPases (Rzomp et al., 2003, 2006) or 
SNAREs, (Delevoye et al., 2008; Paumet et al., 2009; Südhof & 
Rothman, 2009), which may function to regulate trafficking and or 
fusogenic properties of the inclusion (Moore & Ouellette, 2014). The 
modification of the inclusion membrane circumvents normal trafficking 
through the host endocytic pathway and by this manner chlamydial 
inclusions are dissociated from late endosomes and lysosomes 
(Fields & Hackstadt, 2002; Scidmore et al., 2003), thus escaping from 
one of the major host defense mechanism. 
 
As early as 2 h after entry into host cells, early inclusions are 
transported along microtubules in a dynein-dependent manner to the 
perinuclear region of the host cell, near the centrosome (Grieshaber 




et al., 2003). They remain in close proximity to the Golgi apparatus 
and are able to intersect a subset of Golgi-derived vesicles containing 
sphingomyelin (Hackstadt et al., 1996) and cholesterol (Carabeo et 
al., 2003). 
 
Chlamydial infection of human epithelial cells induces Golgi 
fragmentation and generates ministacks surrounding the bacterial 
inclusion (Heuer et al., 2009) that most likely provide the main source 
of lipids for the inclusion. Alternative lipid transport pathway include 
interception of (i) multivesicular bodies (MVBs), endocytic organelles 
that sort endocytosed proteins and lipids to different destinations 
(Woodman & Futter, 2008), (ii) lipid droplets (LDs), eukaryotic neutral 
lipid storage organelles (Kumar et al., 2006) and peroxisomes that 
contribute to the synthesis of plasmogens (Boncompain et al., 2014). 
In fact, intact LDs and peroxisomes have been found to be 
transported into the inclusion lumen (Boncompain et al., 2014; 
Cocchiaro et al., 2008). 
 
Additionally, the inclusion is thought to interact with other host 
organelles including the endoplasmic reticulum (ER) (Agaisse & 
Derré, 2014), lysosomes (Ouellette et al., 2011), and mitochondria 
(Derré et al., 2007; Matsumoto et al., 1991) (Fig. 1.4). Lysosomes 
might be a source of essential amino acids, while interaction with 
mitochondria were only seen in C. psittaci and C. caviae. 
 
Taken together all these interactions allow for the acquisition of the 
necessary nutrients for bacterial replication as well as for inclusion 









Figure 1.4. Model for chlamydial and host-cell interactions. The initial cell 
invasion step involves actin recruitment and remodeling. Upon uptake, EBs are 
surrounded by a membrane bound vacuolar compartment. The early inclusion is 
rapidly modified by the insertion of the bacterial Inc proteins that inhibit the 
association with the endocytic pathway or lysosomes. Early inclusions are 
transported along microtubules to the perinuclear region, where EBs are converted in 
RBs that divide and promote inclusion growth. Chlamydial infections generate Golgi 
ministacks surrounding the bacterial inclusion that most likely provide the main 
source of lipids for the chlamydial inclusion. Alternative lipid transport pathways 
include interception of: multivesicular bodies (MVBs) and Lipid Droplets (LDs) 
Additionally, the inclusion is thought to interact with the endoplasmic reticulum (ER), 
lysosomes and mitochondria. (Reprinted from Bastidas et al, 2013, with permission 
from Elsevier). 
 
1.2.5. Inclusion expansion 
The inclusion must expand to accommodate the higher number of 
bacteria as RBs divide. After establishing near the perinuclear region, 
the inclusion is surrounded by host actin and intermediate filaments 
that form a dynamic scaffold. This provides structural integrity to the 
chlamydial vacuole and minimizes immune detection (Kumar & 
Valdivia, 2008). Following a period of rapid cell division, RBs begin to 




re-differentiate back into EBs. Expression of late-cycle genes occurs 
at this point, including genes that encode for components of the outer 
membrane complex (e.g. OmcA and OmcB) and proteins involved in 
the condensation of the chromosome (e.g. HctA and HctB). 
 
1.2.6. Exiting the host cell 
Once the developmental cycle is completed, EBs must be released to 
initiate new rounds of infection. The release of EBs might occur by 
two mutually exclusive mechanisms: cell lysis or extrusion (Hybiske & 
Stephens, 2007b; Todd & Caldwell, 1985) (Fig. 1.5). Lysis consists of 
an ordered sequence of inclusion, nucleus and plasma membrane 
ruptures. This calcium dependent-mechanism is mediated by 
proteases and is accompanied by death of the host cell. Extrusion, on 
the other hand, results in the pinching of the inclusion into separable 
compartments, protrusion out of the cell within a membrane 
compartment and ultimately detachment from the host cell, leaving 
the original cell and inclusion intact. The amount of bacteria packaged 
within extrusions is variable and the rate of extrusion is slow when 
compared with cell lysis. Extrusion requires actin polymerization, N-
WASP, Myosin II and Rho GTPases. Differences in cell exit 
mechanisms strongly correlate with in vivo host cell invasiveness and 
consequently this is possibly an important determinant of 
pathogenesis: more aggressive strains such as the LGV strains tend 
to be more lytic, whereas non-LGV genital or ocular strains tend to be 









Figure 1.5. Alternative mechanisms for host cell exit. Once the cycle is completed 
EBs must be released to initiate new rounds of infection. This can occur by two 
mutually exclusive ways. (A) Cell lysis, which consists of an ordered event of 
membrane permeabilizations and (B) Extrusion that results in the pinching of the 




Persistence in Chlamydia has been described as a viable but non-
cultivable growth stage resulting in a long-term infection within the 
host cell (Hogan et al., 2004). It is important to note that persistent 
forms of Chlamydiae have been primarily studied in culture. During 
the persistent stage, chlamydial metabolism is slowed and cell 
division as well as RB-EB differentiation is halted. This state is 
characterized by morphologically enlarged and aberrant RBs, often 
called aberrant bodies (ABs) that are viable but non-infectious      




(Fig. 1.6). ABs have lower levels of outer membrane components 
MOMP and OmcB (Beatty et al., 1993; Hogan et al., 2003) and 
enhanced expression of heat shock proteins (Beatty et al., 1994). 
 
Several factors have been described to induce a persistence state 
(reviewed in Schoborg, 2011): cytokines (IFN-γ); nutrient starvation; 
growth in non-permissive cells; iron deprivation; antibiotics; heat-
shock; co-infection with Herpes Simplex Virus (HSV); or 
chlamydiophage infection. However, persistence is a reversible state 
since bacteria can be maintained for a long time in culture, but once 




Figure 1.6. Electron micrographs of C. trachomatis infected cells showing 
normal or aberrant chlamydial inclusions, 48 h post-infection. (A) A typical 
inclusion, with EBs and RBs. (B) Treatment of cells with IFN-γ results in smaller 
inclusions containing enlarged and aberrant RBs, the Aberrant Bodies (ABs) 
(highlighted with arrows) that are viable but non-infectious. Scale bars, 5 µm. 
(Reprinted from Beatty et al, 1994, with permission from American Society for 
Microbiology). 
 
Even though the concept of persistence has been recognized for 
decades, definitive in vivo evidence is not conclusive. Aberrant 






enter this developmental state to establish chronic infections has not 
yet been determined (Hogan et al., 2004; Wyrick, 2010). 
 
An old paradigm in the field is that in virtually all animal hosts, 
including birds and mammals, Chlamydia spp. reside in the 
gastrointestinal (GI) tract for long periods of time in the absence of a 
clinical disease (Rank & Yeruva, 2014). Based on this, a different 
view on chlamydial persistence related to the survival of Chlamydia 
as commensal bacteria in the GI tract has been proposed (Rank & 
Yeruva, 2014). 
 
1.2.8. Regulation of gene expression during the developmental cycle 
Chlamydia genes are expressed in three major temporal classes that 
correspond to the main stages of the developmental cycle (Belland et 
al., 2003; Nicholson et al., 2003; Shaw et al., 2000): 
• Early genes are transcribed as early as 1 to 3 h after bacterial 
entry when the EB is beginning to convert into an RB and play 
a role in establishing the initial intracellular niche.  
• Mid cycle genes include the majority of the chlamydial genes 
and are thought to play a role in RB growth and replication.  
• Late genes include a small number of genes that are involved 
in the final stages of infection, namely in the RB to EB 
conversion and EB function. 
 
Transcription in Chlamydia is thought to be regulated by three main 
mechanisms: alternative forms of RNA polymerase (Barta et al., 
2015; Belland et al., 2003; Douglas & Hatch, 2000; Shaw et al., 2000; 
Yu & Tan, 2003), DNA supercoiling (Cheng & Tan, 2012; Hatfield & 
Benham, 2002; Niehus et al., 2008; Orillard & Tan, 2015) and 




transcription factors (Bao et al., 2012; Rosario & Tan, 2012; Rosario 
et al., 2014). There are also reports of interactions of type III secretion 
chaperones (see section 1.4.7. below) with RNA polymerase (Hanson 
et al., 2015), regulation by small RNAs (Tattersall et al., 2012) and 
transcription from tandem promoters (Rosario & Tan, 2016). 
Together, the mechanisms of regulation of gene expression result in 
a hierarchically organized and timely regulated transcription of genes. 
 
1.3. Modification of the host response during infection 
In the initial stages of infection, Chlamydia is recognized by host 
pattern recognition receptors (PRRs) through specific pathogen-
associated molecular patterns (PAMPs). Candidate chlamydial 
PAMPs described to date include bacterial LPS (Ingalls et al., 1995) 
which are recognized by TLR4 (Heine et al., 2003) or Hsp60 which is 
recognized by TLR4 or TLR2 (Bulut et al., 2002, 2009; Costa et al., 
2002; Kol et al., 1999; Vabulas et al., 2001). Additionally, several 
studies indicate that cytosolic PRR may also be activated by PG or by 
the highly crossed-linked and immunogenic outer membrane proteins 
(MOMP, OmcB or OmcA) (reviewed in Bastidas et al., 2013). 
Recognition of PAMPs by their receptors leads to the activation of 
diverse inflammatory signaling pathways, including the NF-κB 
pathway or MAPK pathway, with subsequent production of cytokines 
and chemokines.  
 
Upon infection there is an acute localized inflammatory response 
mediated mainly by polymorphonuclear lymphocytes (PMNs) 
recruited by cytokines and chemokines that are released by epithelial 
cells (Kelly & Rank, 1997; Rank et al., 2000, 2008). Early responses 






constitute an important step for the adaptive responses (Rank et al., 
2010). The recruitment of immune cells that mediate innate and 
adaptive immune response upon infection with C. trachomatis are in 
the majority of cases sufficient to clear primary infections. However, 
inflammatory responses from recurring infections seem to be the 
main cause for the detrimental scarring and pathologies observed 
(Darville & Hiltke, 2010; Stephens, 2003). 
 
During the intracellular stages of C. trachomatis infection the 
accessibility of PAMPs is minimized by the recruitment of actin and 
intermediate filaments to the periphery of the inclusion (Kumar & 
Valdivia, 2008). Moreover, Chlamydia has the ability of subverting 
host signaling pathways in order to avoid activation of innate immune 
responses and promote bacterial and host survival. Two well-studied 
examples of this mechanism are the modulation of NF-kB responses 
and the inhibition of apoptosis. 
 
NF-kB acts as a central regulator of immune responses. The NF-kB 
subunits p65 (relA) and p50 form a heterodimeric complex that is 
translocated into the nucleus where it acts as a transcription factor of 
cytokines and other antimicrobial factors (Hayden et al., 2006). 
Different chlamydial proteins have been described to interfere with 
the NF-kB signaling pathway during infection:  
i) ChlaDub1 (deubiquitinase) inhibit ubiquitin-mediated 
protein degradation of the NF-kB retention factor (IκB) and 
consequently block nuclear translocation of NF-kB (Le 
Negrate et al., 2008); 
ii) CT441 (a protease) blocks NF-kB activation directly 
through the proteolysis of the RelA subunit (Lad et al., 
2007a, b). 




iii) iii) CPAF (Chlamydial Protease-Like Activity Factor) has 
been implicated in the degradation of p65 during infection 
(Christian et al., 2010). 
 
It is thought that Chlamydia regulates apoptosis in a temporal 
manner: preventing host cell death early in the developmental cycle, 
while promoting its occurrence in the final stages of the cycle. Several 
mechanisms have been proposed to interfere with the apoptotic 
pathway (reviewed in Bastidas et al., 2013): CPAF mediated 
degradation of the pro-apoptotic BH3 proteins and subsequent 
inhibition of cytochrome c release; recruitment of certain BH3-only 
proteins away from their functional site at the mitochondria; 
upregulation and stabilization of Mcl-1 (major anti-apoptotic protein) 
or activation of caspase 3. The molecular basis for most of the anti-
apoptotic pathways still remains to be elucidated but clearly 
Chlamydia seems to have adopted redundant mechanisms. 
 
1.4. The Chlamydia type III secretion system 
1.4.1. The general importance of secretion systems in pathogenic 
bacteria 
Type III, type IV and type VI secretion systems are specialized 
nanomachines used by many Gram-negative bacteria to deliver 
effector proteins into eukaryotic or prokaryotic target cells (Costa et 
al., 2015). While these secretion systems are often associated with 
bacterial virulence, the most widespread function of type IV secretion 
systems (T4SSs) is the transfer of DNA between bacteria during 
conjugation (Ilangovan et al., 2015), the most common function of 
type VI secretion systems appears to be bacterial antagonism 






(T3SSs) are also used in the establishment of symbiotic relationships 
between bacteria and eukaryotic hosts (Galán et al., 2014). 
Nevertheless, it is unquestionable that T3SSs, T4SSs, and T6SSs 
have an essential role in bacterial virulence. 
 
In terms of bacterial virulence, T3SSs and T4SSs have been well 
characterized and they have been reported in a wide range of 
obligate intracellular, facultative intracellular and extracellular 
pathogens, such as Brucella spp. (T4SS; Boschiroli et al., 2002), 
Chlamydia trachomatis (T3SS; Stephens et al., 1998), Coxiella 
burnetti (T4SS; Seshadri et al., 2003), enterohemorrhagic and 
enteropathogenic Escherichia coli (EHEC and EPEC, respectively; 
T3SS; Jarvis et al., 1995; McDaniel et al., 1995), Helicobacter pylori 
(T4SS; Censini et al., 1996), Legionella pneumophila (T4SS; Segal et 
al., 1998; Vogel et al., 1998), Pseudomonas aeruginosa (T3SS; Yahr 
et al., 1996) Salmonella spp. (T3SS; Galán, 1996; Ochman et al., 
1996; Shea et al., 1996), Shigella spp. (T3SS; Maurelli et al., 1985; 
Parsot et al., 1995; Sasakawa et al., 1988), or Yersinia spp, (T3SS; 
Perry et al., 1998). 
 
As mentioned above, T6SSs have been mainly described as a way to 
target other bacterial cells with lethal toxins. However, T6SS effectors 
have also been implicated in the subversion of eukaryotic host cells 
(Hachani et al., 2015). Many bacterial species possess this type of 
secretion system, including the human pathogens S. enterica and P. 
aeruginosa or the plant pathogen Rhizobium leguminosarum (Filloux 
et al., 2008). 
 
In addition, Gram-positive bacteria such as Mycobacterium 
tuberculosis and Staphylococcus aureus have also been described to 




possess specialized secretion systems that transport proteins across 
their rigid cell wall. This secretion system has been referred to as type 
VII secretion system (Abdallah et al., 2007). In M. tuberculosis at 
least one protein delivered by this system has been associated with 
modulating host cellular responses, such as suppression of pro-
inflammatory responses and induction of apoptosis or cell necrosis 
(Simeone et al., 2009, 2012). 
 
Evolution of protein delivery systems such as T3SS, T4SS or T6SS 
were most likely driven by the need to deliver multiple proteins in a 
coordinated way in order to modulate host cellular processes. Protein 
effectors are known to target most cellular compartments, organelle 
membranes, the nucleus and cytoskeleton components (Tosi et al., 
2013). General knowledge on effector functions is crucial for 
understanding cellular physiopathology associated with bacterial 
pathogens as well as fundamental aspects of host-pathogen 
interactions. 
 
1.4.2. Type III secretion systems 
T3SS are present in many Gram-negative bacteria that are 
pathogens of animals and plants [reviewed by (Cornelis, 2006; Galán 
et al., 2014)]. They consist of: i) the components of a secretion 
machinery known as injectisome (basal structure and a 2-3 nm hollow 
needle or a long pilus protruding from the bacterial surface); ii) a 
translocon; iii) effector proteins, which have the capacity to modulate 
a variety of cellular functions (Galán, 2009) but display little sequence 
similarity between different bacterial species; iv) specific T3S 
chaperones; v) regulatory proteins. While a subset of proteins that 
compose the injectisome are highly conserved across different 






T3SSs have been extensively studied in Yersinia spp., Salmonella 
spp. or Shigella spp., which led to the comprehensive understanding 
of the assembly and function of the injectisome as well as to the 
identification of numerous effector proteins. Early phylogenetic 
analysis revealed that T3SSs are evolutionary related to the flagellar 
apparatus (Pallen et al., 2005). More recently, it has been described 
that T3SSs suffered loss of essential flagellar motility genes and 
acquired components that enabled protein secretion across the 
bacterial envelope and translocation through eukaryotic membranes 
(Abby & Rocha, 2012). 
 
The injectisome is a multi-protein complex that allows translocation 
across the two bacterial membranes. The translocon is a pore 
complex formed within a host cell membrane by two type III secreted 
proteins (the translocators) and is connected to the needle through a 
tip complex (formed by another type III secreted translocator protein), 
thereby creating a continuous channel between the cytosol of the 
bacteria and the host cell that enables the one-step delivery of 
effector proteins. Secretion of some T3S substrates requires specific 
strictly bacterial cytosolic chaperones, characterized by an acidic pI 
(4-5), a low molecular mass (15-20 kDa), formation of dimers, and 
lack of ATPase activity. The activity of T3SSs is regulated at 
transcriptional and post-translational levels to ensure its functioning at 
the right time and place and in the appropriate environmental 
conditions. It is normally thought that most T3SSs are activated upon 
contact of the bacteria with a host cell membrane, although, for 
example, the T3SS of intravacuolar Salmonella appears to be 
activated by pH sensing (Yu et al., 2010).  




1.4.3. Discovery and unique features of the Chlamydia T3SS 
Genome sequence revealed that all Chlamydia species, including the 
environmental Chlamydia, contain a set of genes capable of encoding 
a complete T3SS (Horn et al., 2004; Read et al., 2000, 2003; 
Stephens et al., 1998). Unlike other Gram-negative bacteria where 
the T3S genes are located on a virulence plasmid or arranged in 
pathogenicity islands, in Chlamydia the genes coding for components 
of the T3SS are grouped in three major loci. Furthermore, in other 
Gram-negative bacteria T3S genes have often a G + C content lower 
than their respective genomes, while in Chlamydia the G + C content 
does not differ from the remaining genome. Additionally there is no 
evidence of transposons, insertion sequence elements or horizontal 
gene transfer that would suggest recent acquisition of the T3SS 
(reviewed in Mueller et al., 2014). 
 
Recent cryo-electron tomography studies in C. trachomatis revealed 
polarity in EBs (Nans et al., 2014, 2015a): one pole is characterized 
by an inner membrane tubular invagination while the opposite pole 
exhibits an asymmetric widening of the periplasmic space that 
contains the T3SSs. This pole faces the target cells, promoting 
contact of T3SS with host plasma membrane. Interestingly, once 
internalized in early vacuoles both EB polarity and T3SS are lost.  
 
Additionally, cryo-electron tomography data has revealed the first 
intact structures of C. trachomatis T3SS (Nans et al., 2015b) and 
revealed key structural distinctions between the chlamydial T3SS 
when compared with the same system in other bacteria, in particular 
the basal body is more elongated with a pronounced convex structure 
(with a length of 34 nm and a diameter that ranges from 14 to 20 nm) 






like structure on the outer membrane surface. Furthermore, this work 
compared C. trachomatis T3SS structures in the presence or 
absence of host cell membranes, revealed a compaction of the basal 
body in the presence of host cell membrane that suggested a pump-
action conformational change related to effector injection. 
 
The nominations of the different components of the T3SS in 
Chlamydia is as follows: contact dependent secretion (Cds) refers to 
the components of the basal apparatus; secreted or mobile 
components are sometimes denoted as Chlamydia outer proteins 
(Cops) and cytoplasmic T3S chaperones are referred to as specific 
Chlamydia chaperone (Scc), SycE-like chaperones (Slc) or 
multicargo chlamydial specific chaperone (Mcsc). The major 
components of the Chlamydia T3SS have been reviewed in (Dai & Li, 
2014; Ferrell & Fields, 2015; Mueller et al., 2014) and are 
schematically represented in Fig. 1.7. 
 
1.4.4. The C. trachomatis injectisome 
Chlamydia genomes encode proteins homologous to essential 
components of the injectisomes of other bacteria (Yersinia, 
Salmonella) where the T3SSs have been studied in further detail. 
Largely based on this, it has been possible to establish a 
function/localization for each of the Cds proteins of C. trachomatis 
(Fig. 1.7): 
• CdsQ (C-Ring protein) is predicted to be at the base of the 
injectisome and it has been shown by yeast two-hybrid to 
interact with multiple chlamydial proteins (Spaeth et al., 2009). 
The base of the secretion apparatus is proposed to serve as 
docking site for chaperone-substrate complexes (Spaeth et 




al., 2009) and may play a central role in regulating the 
recognition of effector proteins. 
• The basal body is formed by three structural proteins: CdsC, 
CdsD and CdsJ (Betts-Hampikian & Fields, 2010; Meriläinen 
et al., 2016; Nans et al., 2015b). CdsJ is a lipoprotein, 
predicted to span the periplasmic space and associate with 
integral membrane proteins CdsR-V. It is also thought to 
interact with the inner membrane protein CdsD. 
• CdsV is predicted to be inserted in the inner membrane but 
has also been found to face the cytoplasmic domain of the 
inner membrane (Nans et al., 2015b) where it may interact 
with other components of the apparatus, chaperones or even 
effector proteins. 
• The outer membrane ring of the injectisome, necessary for the 
needle to cross the outer membrane, is composed of the 
secretin CdsC that is thought to form a rosette-like hexameric 
structure (Nans et al., 2015b). However, CdsC is 
phylogenetically separated from other secretins and contains 
a large Chlamydia-specific N-terminal domain (Abby & Rocha, 
2012).  
• CdsF is able to polymerize into multi-subunit complexes 
forming the needle-like projection (Betts et al., 2008). In other 
T3SSs a tip protein located at the terminus of the needle 
serves a role in activating the system and/or allowing for 
translocon assembly (Mueller et al., 2008). However, to date 
there is no evidence of a corresponding structure in 
Chlamydia. 
• CdsU is suggested to contribute to changes in substrate 






ATPase (Nans et al., 2015b; Stone et al., 2008) while CdsL 
functions as its regulator (Stone et al., 2011). 
• CT398, recently named CdsZ, (Barta et al., 2015) was found 
to interact with CdsL as well as with the alternative sigma-
factor RpoN (σ54), implying that CdsZ may interact with RNA 
polymerase. 
 
1.4.5. The C. trachomatis translocon 
CopB and CopD are T3S substrates (Fields et al., 2005; Ho & 
Starnbach, 2005) and are components of the invasion-related 
translocon that forms a pore in the host cell membrane (Bulir et al., 
2014, 2015) (Fig. 1.7), allowing the translocation of subsequent 
secreted effectors across the host membrane. Interestingly, 
Chlamydia encodes for potential duplicators of the translocator 
proteins: CopB2 and CopD2. The expression levels of CopB and 
CopB2 vary during the developmental cycle (late cycle and mid-cycle, 
respectively), raising the possibility for the existence of two different 
translocons: CopB acting during early and late stages of infection 
while CopB2 acting during mid-developmental cycle (Chellas-Géry et 
al., 2011). 
 
1.4.6. The C. trachomatis gatekeeper 
CopN is an homolog of the Yersinia T3S substrate YopN (Fields & 
Hackstadt, 2000) that has been shown to associate with other 
proteins and block secretion prior to activating signals (Silva-Herzog 
et al., 2011), functioning as a gatekeeper (Archuleta & Spiller, 2014; 
Barison et al., 2013). Once activated, the T3S apparatus is thought to 
secrete CopN, followed by the translocator proteins. Secretion of the 
translocators results in a complete T3SS at which point effectors can 
be injected into the host cell (Fig. 1.7). Moreover, CopN has been 




shown to localize at the inclusion membrane and might also function 
as an effector protein by modulating host microtubules within infected 
eukaryotic cells (Archuleta et al., 2011; Fields & Hackstadt, 2000; 




Figure 1.7. Schematic representation of the predicted composition of T3S 
apparatus in Chlamydia. The needle-like structure protrudes from the bacterial 
surface and enables translocation of effector proteins from the bacterial cytoplasm 
into the host cell cytosol or membranes. (Adapted from Betts-Hampikian & Fields, 
2010; Peters et al., 2007; Spaeth et al., 2009). 
 
1.4.7. The C. trachomatis T3S chaperones 
Several roles have been associated with T3S chaperones, including: 
i) protecting their substrates from degradation, ii) keeping their 






preventing premature/unproductive interactions with the respective 
substrate and iv) directly promoting the secretion of their substrates 
via direct interactions with components of the injectisome. In addition 
T3S chaperones have also been shown to modulate RNA polymerase 
through interactions with σ66 subunit (Hanson et al., 2015; Rao et al., 
2009). It has also been speculated that T3S chaperones might help to 
establish a hierarchy in secretion of protein substrates. 
 
T3S chaperones have been divided into 3 classes: class I 
chaperones bind effectors, class II chaperones bind pore-forming 
translocators, while class III chaperones bind subunits of the 
injectisome or flagellar substructures. Class I chaperones are the best 
studied. They share low sequence similarity between each other but 
share a conserved three-dimensional (3D) structure. This group can 
be further divided depending on the number of effectors with which 
they can associate. Currently, there are only two chaperones 
identified that are dedicated to effectors (Slc1/CT043 and 
Mcsc/CT260) and both are multicargo chaperones. Slc1/CT043 is a 
known chaperone for TarP, CT694 and TepP (Brinkworth et al., 2011; 
Chen et al., 2014; Pais et al., 2013) and Mcsc/CT260 has been 
shown to bind and stabilize at least Cap1 and two other Inc proteins, 
CT225 and CT618 (Spaeth et al., 2009). It is surprising, however, that 
given the number of chlamydial candidate effectors indicated to date 
there is such a limited number of chaperones described. 
 
CT584 has also been indicated as a potential chaperone (Pais et al., 
2013) that interacts with CT082, an identified T3S substrate (Hovis et 
al., 2013; Pais et al., 2013). Other studies based on biophysical 
characterizations have also suggested Cpn0803 (the C. pneumoniae 
orthologue of CT584) to act as the tip complex protein (Markham et 




al., 2009). However, subsequent determination of the three-
dimensional structure of the protein did not support the hypothesis 
(Stone et al., 2012). 
 
Class II chaperones described to date include Scc2/CT576, 
chaperone for CopB (Fields et al., 2005) and Scc3/CT862 chaperone 
for CopB2 (Fields et al., 2005). In addition CP0432 (Scc1) and 
CP0033 (Scc4) (the C. pneumoniae orthologues of CT088 and 
CT663, respectively) promote CopN secretion as a heterodimeric 
chaperon (Silva-Herzog et al., 2011), while Scc3 (CT862) inhibits 
CopN secretion (Silva-Herzog et al., 2011). 
Finally, CdsE and CdsG belong to Class III chaperones and have 
been identified as chaperones for CdsF, the needle component (Betts 
et al., 2008). 
 
1.4.8. The C. trachomatis T3S effector proteins 
In C. trachomatis T3S effectors have been shown to be translocated 
into the host cell cytosol or into the inclusion membrane (Betts et al., 
2009; Valdivia, 2008). Even though C. trachomatis is thought to have 
5-10% of its genome encoding for proteins with putative T3S signals 
(Arnold et al., 2009; Samudrala et al., 2009), only very few T3S 
effectors have been characterized to date: 
 
1.4.8.1 TarP 
TarP (Translocated Actin Recruiting Phosphoprotein) is conserved 
among all Chlamydia spp., was identified using the heterologous 
T3SS of Y. enterocolitica and is the most thoroughly studied 
Chlamydia effector: it is synthesized at late stages of the 
developmental cycle when it is packaged into EBs; it is secreted 






is mainly involved in actin recruitment and remodeling events that 
occur in the invasion step of the chlamydial developmental cycle. C. 
trachomatis TarP exhibits different functional domains (N-terminal 
tyrosine repeat units and C-terminal actin binding domains) that vary 
in number across different serovars. This characteristic may account 
for differences in tissue tropism and invasiveness (Jewett et al., 2010; 
Lutter et al., 2010). 
 
Tyrosine phosphorylation at the N-terminus of TarP is C. trachomatis-
specific and correlates with interactions with several signaling 
pathways, such as EGF receptor, MAPK cascades, Rac/WAVE2/ARP 
2/3 signaling and with humoral and cellular immune signaling (Clifton 
et al., 2004; Jewett et al., 2008; Jiwani et al., 2012; Mehlitz et al., 
2010). On the other hand, TarP-mediated actin nucleation and actin 
filament biding is restricted to the C-terminal half of the protein. 




CT694 is present only in C. trachomatis and C. muridarum and was 
identified by transcriptome analyses to be expressed late in the 
developmental cycle (Belland et al., 2003). This suggested that 
CT694 could play a role in the early events of host cell entry, such as 
TarP. CT694 has been shown to cause endocytic and other toxic 
effects in yeast (Sisko et al., 2006). In addition, using the 
heterologous T3SS of Y. enterocolitica and further characterization, 
CT694 was identified as an invasion-related effector found to be 
secreted minutes after contact with the host cell (Hower et al., 2009). 
It was described to interact with actin indirectly, by interfering with 
AHNAK-mediated actin mobilization. Interaction with AHNAK is 




through a C-terminal domain and affects the formation of host cell 
actin stress fibers. It also contains a membrane localization domain 
(not necessary for AHNAK binding) that resembles membrane 
localization domains found in effector proteins from Yersinia, 
Pseudomonas and Salmonella spp. CT694 may influence actin 
dynamics by manipulating the activity of Rho GTPases (Bullock et al., 
2012). It has been hypothesized that CT694 may play a similar role 
as the Salmonella SopE effector (containing an analogous membrane 
localization domain) (Zhou & Galán, 2001) which implies that CT694 
could negatively regulate the actin cytoskeleton alterations caused by 
the activity of TarP. 
 
1.4.8.3. TepP 
TepP/CT875 (Translocated early phosphoprotein) was identified in a 
search to identify new interacting partners of the chaperone Slc1. 
This protein is highly conserved in all C. trachomatis serovars; it 
shares 49% identity with its orthologue in C. muridarum and shares 
less than 25% identity with potential orthologues of other Chlamydia 
spp.. TepP was found to be translocated early during bacterial entry 
and it is tyrosine-phosphorylated upon translocation into host cells by 
host kinases (Chen et al., 2014). It has been shown to act 
downstream of TarP by recruiting scaffolding proteins like Crk to the 
nascent inclusion which in turn might recruit other proteins mediating 
a series of signaling events that are important in establishing an early 











1.4.8.4. CT619, CT620, CT621, CT711 and CT712 
All pathogenic Chlamydia species contain four or five proteins with a 
domain of unknown function (DUF582) unique to the genus 
Chlamydia (CT619, CT620, CT621, CT711 and CT712 in C. 
trachomatis) and were all identified as putative T3S substrates based 
on amino-terminal signal recognition by the heterologous T3SS of S. 
flexneri (Muschiol et al., 2011; Subtil et al., 2005). In addition, C. 
trachomatis CT620, CT621, and CT711 were shown to be expressed 
in the mid and late stages of the chlamydial developmental cycle. 
Immunolocalization studies detected CT620 and CT621 both in the 
cytoplasm and nucleus of the host cell, showing these proteins are 
undoubtedly effectors that could target nuclear cell functions. 
Additionally, CT620 and CT621 were also found to be secreted into 
the lumen of the inclusion, where they do not associate with bacterial 
markers (Muschiol et al., 2011). Based on these observations it is 




In silico analysis of CT737 identified a conserved SET domain, 
present in proteins that are involved in chromatin remodeling. SET 
domain proteins are present in all eukaryotes (Dillon et al., 2005), but 
are also present in pathogenic bacteria or viruses that interact with 
eukaryotic cells (Alvarez-Venegas et al., 2007; Hamon et al., 2007). 
CT737 was identified as a histone methyltransferase conserved 
among all Chlamydia spp., and as a putative T3S substrate based on 
amino-terminal signal recognition by the heterologous T3SS of S. 
flexneri. In addition, CT737 was found to be secreted by C. 
trachomatis and translocated into the host nucleus where it 
associates with chromatin (Pennini et al., 2010). 





CT847 is conserved among all Chlamydia spp. and was identified 
using the T3SS of Y. enterocolitica as heterologous host. Yeast-two 
hybrid studies using CT847 as bait to screen a HeLa cDNA library 
identified an interaction with mammalian Grap2 cyclin D-interacting 
protein (GCIP), a multi-functional ubiquitously expressed protein that 
is degraded during chlamydial infection (Chellas-Géry et al., 2007). 
 
1.4.8.7. Inc proteins 
The Inc family of proteins contain two major characteristics: an N-
terminal T3S signal that is necessary for their translocation out of the 
bacteria (Almeida et al., 2012; Dehoux et al., 2011; Subtil et al., 2001) 
and a large bi-lobed hydrophobic domain of 40-60 residues 
(Bannantine et al., 1998) that is predicted to enable the insertion of 
these proteins into the inclusion membrane. It is thought that at least 
one segment of these proteins is facing the cytoplasm of the host cell 
where interactions with host proteins are likely to occur. A 
bioinformatics analysis of chlamydial genomes identified 59 putative 
Incs in C. trachomatis and 107 in C. pneumoniae, thus the inc genes 
are thought to represent 7-10% of the genomes of Chlamydia 
(Dehoux et al., 2011). These proteins are thought to have a central 
role in the biogenesis and maintenance of the inclusion. Depending 
on the host protein they associate with, these proteins should play a 
major role in avoiding endocytic membrane fusion that would prevent 
destruction of the bacteria or, on the contrary, promoting exocytic 
vesicle fusion with nutrient rich membrane compartments (see section 
1.2.4., below). It has also been proposed that some Inc proteins, 
lacking a long stretch of amino acids predictably facing the host cell 
cytosol, might interact with other Inc proteins in the inclusion 






structural role in maintaining the integrity of the inclusion rather than 
an effector function (Gauliard et al., 2015; Moore & Ouellette, 2014). 
 
It is important to note that this group of proteins is not conserved 
among all chlamydial species. However, very few variations among 
Inc proteins are likely to contribute to C. trachomatis serovar-specific 
differences in inclusion maintenance that might contribute to tropism 
and invasiveness specific characteristics (Almeida et al., 2012; Lutter 
et al., 2012). 
 
Thus far, the role of a number of C. trachomatis Inc proteins has been 
elucidated: 
• IncA/CT119 is involved in the homotypic fusion of C. 
trachomatis inclusions by interaction with SNARE proteins 
(Delevoye et al., 2008; Suchland et al., 2000). 
• IncB/CT232, CT101, CT222 and CT850 were found to localize 
in inclusion membrane microdomains that are enriched in 
activated Srk kinases and in cholesterol. These microdomains 
are also in close association with the microtubule network and 
with centrosomes (Mital et al., 2010). 
• CT850 has been reported to interact with dynein (Mital et al., 
2015). 
• CT229 and CT813 are thought to play a role in intercepting 
host vesicular trafficking by their respective interaction with 
host protein Rab4 (Rzomp et al., 2006) and VAMP7-8 
(Delevoye et al., 2008). 
• CT813 was recently renamed InaC (inclusion membrane 
protein for actin assembly) (Kokes et al., 2015). It was 
described to bind host ARF and 14-3-3 proteins and to 




modulate F-actin assembly and Golgi redistribution around the 
chlamydial vacuole. 
• IncD/CT115 has been shown to mediate the recruitment of 
lipid protein CERT and the ER-protein VAPB to contact sites 
between the inclusion membrane and the ER (Agaisse & 
Derré, 2014). 
• IncE has been recently found to bind to the SNX5/6 
components of the retromer, which re-localizes SNX5/6 to the 
inclusion membrane and promotes inclusion membrane 
tubulation (Mirrashidi et al., 2015). 
• IncG/CT118 was also found to interact with the mammalian 
signal transducer protein 14-3-3-β at the inclusion membrane 
(Scidmore & Hackstadt, 2001). 
• IPAM/CT223 (inclusion protein acting on microtubules), 
recruits the centrosomal protein CEP170 to hijack the 
microtubule organizing functions of the host cell (Dumoux et 
al., 2015). 
• CT228 recruits elements of the myosin phosphate pathway 
and is associated to regulation of host cell exit (Lutter et al., 
2013). 
 
1.4.9. Probable C. trachomatis T3S effector proteins 
There is an additional group of proteins that due to multiple lines of 
evidence are generally pointed out as likely T3SS effectors, but in fact 
they have not clearly been demonstrated to be so. This group of 










CADD/CT610 (Chlamydia protein associating with death domains) 
has orthologues in C. trachomatis, C. pneumoniae and C. muridarum. 
It induces apoptosis in a variety of mammalian cell lines when 
ectopically expressed. Immunolocalization studies revealed that this 
protein localizes at the periphery of the inclusion, suggesting that it 
could be secreted from the bacteria (Stenner-Liewen et al., 2002). In 
fact, it was identified as putative T3SS substrate based on amino-
terminal signal recognition by the heterologous T3SS of S. flexneri 
(Subtil et al., 2005). 
 
1.4.9.2. Cap1 
Cap1/CT529 (class I accessible protein-1) localizes to the inclusion 
membrane but does not possess the bilobal hydrophobic domain 
characteristic of the Inc family of proteins (Fling et al., 2001). 
 
1.4.9.3. ChlaDub1 and ChlaDub2 
ChlaDub1/CT868 and ChlaDub2/CT867, are predicted cysteine 
proteases, likely to have deubiquitinating and deneddylating activities 
on host cell proteins (Misaghi et al., 2006). They are present in all 
Chlamydia species except for C. pneumoniae and their catalytic 
domains share similarities to other eukaryotic ubiquitin-like proteases. 
Additionally ChlaDub1/CT868 has also been found to have the 
capacity to suppress the NF-κB pathway (Le Negrate et al., 2008) 
(see also section 1.3., above). 
 
1.4.9.4. Cytotoxin CT166 
CT166 is present in the plasticity zone (PZ) of C. trachomatis genital 
serovars D-K, in C. muridarum and in C. caviae. Protein database 
alignment revealed homologies with the N-terminal 




glucosyltransferase domain of Clostridium difficile large cytotoxins A 
and B. Ectopic expression of CT166 results in an immediate cytotoxic 
phenotype in host cells (Belland et al., 2001). CT166 has been 
suggested to induce actin reorganization, that may involve the 
glycosylation of Rac1 (Thalmann et al., 2010). 
 
1.4.9.5. Lda1/CT156, Lda2/CT163 and Lda3/CT473  
The Lda proteins (Lipid droplet associated) were found to be 
translocated into the eukaryotic host and have affinity for host cell 
lipid droplets (LD). They are proposed to contribute to the recruitment 
of LD into the inclusion lumen (Kumar et al., 2006). Lda1/CT156 and 
Lda2/CT163 are C. trachomatis specific while Lda3/CT473 and Lda4 
are present in all Chlamydia species. 
 
1.4.9.6. Pls1 and Pls2 
Pls1/CT049 and Pls2/CT050 (Pmp-like secreted proteins), are 
conserved among Chlamydia spp., do not contain classical signal 
peptides but are secreted into the inclusion lumen, where they 
localize in globular structures that closely associate with the inclusion 
membrane, not co-localizing with bacterial markers. They appear to 
be important for the development of the inclusion but their functional 
mechanisms remain unknown (Jorgensen & Valdivia, 2008). 
 
1.4.9.7. Chlamydial glycogen enzymes 
Recently, the bacterial glycogen metabolism enzymes (GlgA, GlgB, 
GlgX, GlgP and MalQ) were reported to be secreted into the inclusion 
lumen through T3SS (Gehre et al., 2016), suggesting that de novo 








1.4.10. C. trachomatis T3S-independent effector proteins 
Chlamydial effector proteins might also reach the cytosol of infected 
cells via T3S-independent mechanisms. The proteases CPAF/CT858 
(Chlamydial protease-like activity factor) and Tsp/CT441 are identified 
chlamydial effectors that before reaching the cytosol of host cells, are 
translocated into the lumen of the inclusion by a type II secretion 
system (Betts et al., 2009; Zhong, 2011).  
 
1.4.10.1. CPAF 
CPAF has been identified as a factor involved in the maintenance and 
growth of the chlamydial inclusion by cleaving host proteins (the 
cytoskeleton intermediate filament vimentin, the nuclear envelope 
lamin-associated protein [LAP1]) and also by disrupting cell division 
(Brown et al., 2012, 2014; Kumar & Valdivia, 2008; Snavely et al., 
2015). It has also been shown to target bacterial factors (Hou et al., 
2013; Jorgensen et al., 2011). However, the molecular mechanisms 
by which CPAF acts are still not clearly understood.  
 
1.4.10.2. CT441 
Tsp/CT441 (tail specific protease) is a PDZ domain protein containing 
tail specific protease. Tsp was not detected outside the inclusion 
using standard immunofluorescence assays but it was found to 
cleave the host NF-κB in C. trachomatis infected cells (Lad et al., 
2007a, b), suggesting that an undetectable amount of Tsp might be 
secreted into the host cell cytosol. 
 
1.4.10.3. CT823 
cHtrA/CT823 (chlamydial high temperature requirement protein A 
protease) also contains an N-terminal signal sequence and by  
immunofluorescence assays was found to localize both inside the 




inclusion and in the cytoplasm of infected cells (Zhong, 2011). 
However, a host cell target for cHtrA has not been identified.  
 
1.4.10.4. CT311 and CT795 
Additionally, two other proteins of unknown function, CT311 and 
CT795, are also predicted to reach the lumen of the inclusion via-sec 
dependent pathway and, using standard immunofluorescence 
assays, were found to localize both inside the inclusion and in the 
cytoplasm of infected cells, showing a pattern of distribution similar to 
CPAF (Lei et al., 2011; Qi et al., 2011). 
 
1.4.10.5. Pgp3 
Pgp3 (plasmid ORF5) is the only plasmid protein found to be secreted 
into the inclusion lumen and cytosol of infected cells, showing a 
similar cytosolic distribution as CPAF (Li et al., 2008). It is not clear 
how Pgp3 is secreted out of the bacteria since no signal peptide has 
been detected and it has never been characterized as being a T3SS 


















1.4.11. The chlamydial T3SS during the developmental cycle 
Recently a working model for the T3SS during the chlamydial 
developmental cycle has been proposed (Ferrell & Fields, 2015). In 
this model the authors hypothesize the existence of four different 
phases of the T3SS during the chlamydial developmental cycle (Fig. 
1.8): 
• T3SS in recently converted elementary bodies (EBs): EBs 
possess a complete assembled T3SS. Before reaching a new 
cell, early secretion of effectors is prevented by the 
intermolecular disulphide bonding among needle protein 
(CdsF) subunits in EBs (Betts et al., 2008; Betts-Hampikian & 
Fields, 2011) as well as by positioning of the gatekeeper 
protein (CopN) on the bacterial cytoplasmic side of the 
apparatus. 
• T3SS in invading EBs: during the invasion step secretion 
activity is activated upon contact with the host plasma 
membrane. This results in secretion of CopN, deployment of 
the translocon proteins CopB and CopD and consequent 
secretion of early effectors. 
• T3SS in RBs: secretion in intracellular RBs is maintained by 
association of RBs with the inclusion membrane and is 
accompanied by de novo expression of T3SS genes. 
• T3SS in RB-EB conversion: RB to EB conversion is 
associated with detachment of the RBs from the inclusion 
membrane and consequent loss of secretion capacity by 
association of CopN to the cytoplasmic side of the T3SS, 
preventing further secretion from the recently converted EB. 
 
 






Figure 1.8. Proposed model for T3S during chlamydial developmental cycle. 
Infectious EBs contain a complete T3SS that is activated upon contact with the host 
cell plasma membrane (PM). This results in secretion of CopN followed by CopB and 
CopD (translocator proteins). The chaperone Slc1 is thought to mediate hierarchical 
secretion of T3SS invasion related effectors. During intracellular development the 
association of RBs with the inclusion membrane mediates secretion and new T3SS 
apparatuses are synthesized (light gray). T3S is halted when CopN re-associates 
with the cytoplasmic components of the apparatus, which coincides with RB 
dissociation from the inclusion membrane and respective RB-EB conversion. 












1.5. Genetic manipulation of C. trachomatis 
Like other intracellular obligate microorganisms it has been very 
challenging to develop genetic tools to manipulate C. trachomatis. 
Host cell restrictive growth constitutes a major barrier to genetic 
transformation, making simple procedures such as cloning extremely 
difficult. In the past 10 years, however, significant advances in the 
genetic manipulation of intracellular pathogens have emerged (Beare 
et al., 2011). Coxiella burnetti, the causative agent of Q-fever (Maurin 
& Raoult, 1999), is the example that has the most complete set of 
genetic tools available. The reason for having such a complete array 
of genetic tools is due mainly to the development of a medium that 
supports axenic growth of Coxiella (Omsland et al., 2009). Attempts 
for developing axenic growth media for Chlamydia have taken place 
(Omsland et al., 2012), but so far they were only successful in 
supporting metabolic activity of EBs and RBs, not yet supporting 
replication or differentiation between the different chlamydial forms. 
 
Advances in genetic manipulation of C. trachomatis also started 
taking place in the last decade. After the event of C. trachomatis 
genome sequencing (Stephens et al., 1998) it was noticed that DNA 
repair and recombination systems were well represented in the 
genome, indicating that C. trachomatis is capable of recombination. 
The first attempt to obtain C. trachomatis transformants was in 1994, 
when Priscilla Wyrick and collaborators tried electroporation of EBs 
with a shuttle vector based on the chlamydial plasmid and an E. coli 
cloning vector. No stable transformants were isolated although 
inclusions were present for up to 4 passages under chloramphenicol 
selection (Tam et al., 1994). In 2009, Binet and Maurelli attempted an 
approach using electroporation of EBs. The idea was to obtain 




recombinants of C. psittaci generated by homologous recombination. 
However, this technique was limited to the 16S rRNA region and only 
allowed integration of a short 1kb marker at very low frequencies 
(Binet & Maurelli, 2009). 
 
In 2011, Ian Clarke and his collaborators developed a reproducible, 
plasmid-based genetic transformation system for C. trachomatis 
based on chemical transformation (CaCl2 instead of electroporation) 
and using penicillin for selection (Wang et al., 2011). Selection with 
penicillin is useful in Chlamydia because non-transformed strains 
form aberrant inclusions (easily distinguished under a light inverted 
microscope) (see Fig 1.6) in the presence of the antibiotic. In 
contrast, transformed bacteria having the β-lactamase gene in a 
plasmid can recover from the aberrant state and consequently form 
normal inclusions. 
 
In 2013, Agaisse and Derré took a step further and developed a 
series of versatile shuttle vectors (p2TK-SW2) that could be used to 
express C. trachomatis proteins fused to three different fluorescent 
tags (GFP, m-Cherry or CFP) and under control of the incDEFG 
operon promoter and terminator (Agaisse & Derré, 2013). Other 
groups also created different shuttle vectors, based on a Tet-inducible 
promoter (Bauler & Hackstadt, 2014; Wickstrum et al., 2013). 
 
Further advances in genetic manipulation of C. trachomatis have 
taken place: chemical mutagenesis has been described and a library 
of mutants has been generated (Kari et al., 2011b; Kokes et al., 2015; 
Nguyen & Valdivia, 2012); specific chlamydial genes have been 
knocked down using dendrimer-delivered antisense RNA (Mishra et 






& Fisher, 2013) or more recently a novel suicide vector was described 
that is dependent on inducible expression and allows rapid 
fluorescent reported allelic exchange mutagenesis (FRAEM). This 
method has the great advantage of allowing the monitoring of 
mutagenesis by fluorescent microscopy (Mueller et al., 2016). 
 
A broader approach to chlamydia genetics, using all the recently 
developed methods will definitively help to elucidate the role of many 
proteins whose function remains unknown. In consequence, many 
aspects regarding the chlamydial developmental cycle that are still 
unclear are most likely to be solved.  




1.6. Aims of this project 
It is believed that C. trachomatis may possess more than 100 T3S 
substrates (Valdivia, 2008) and that these proteins play a key role 
during the C. trachomatis developmental cycle. These potential 
effectors are presumably translocated into host epithelial cells at 
various stages of infection to mediate cell invasion, establishment of a 
protective replicative vacuole, evasion of innate immune responses or 
host cell exit. The majority of T3S effector proteins recognized to date 
are involved in the entry step or belong to the Inc family of effectors. 
Many other effector proteins are predicted to exist and to play a role 
in other stages of the chlamydial developmental cycle.  
 
The overall purpose of this project was to provide insights on the 
identity and function of novel chlamydial T3S effectors. In particular, 
the specific objectives were:   
- Screen for candidate chlamydial T3S effectors by using Y. 
enterocolitica T3SS as a heterologous system.  
- Identify novel chlamydial T3S effectors in infected cells by 
analyzing the subcellular localization of candidate effectors. 
- Use recently developed transformation methods in C. 
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Chlamydia trachomatis uses a type III secretion (T3S) system to 
manipulate host cells, through the delivery of effector proteins into 
their cytosol and membranes. In this Chapter, we aimed to find 
previously unidentified C. trachomatis T3S substrates. We first 
analyzed the genome of C. trachomatis strain L2 434/Bu for genes 
encoding mostly uncharacterized proteins that did not appear to 
possess a signal of the general secretory pathway and which had not 
been previously experimentally shown to be T3S substrates. We 
selected several genes with these characteristics and analyzed T3S 
of the encoding proteins using Yersinia enterocolitica as a 
heterologous system. We identified 23 C. trachomatis proteins whose 
first 20 amino acids were sufficient to drive T3S of the mature form of 
β-lactamase TEM-1 by Y. enterocolitica. We found that 10 of these 23 
proteins were also type III secreted in their full-length versions by Y. 
enterocolitica, providing additional support that they are T3S 
substrates. Seven of these 10 likely T3S substrates of C. trachomatis 
were delivered by Y. enterocolitica into host cells, further suggesting 
that they could be effectors. Finally, real-time quantitative PCR 
analysis of expression of genes encoding the 10 likely T3S substrates 
of C. trachomatis showed that 9 of them were clearly expressed 
during infection of host cells. In conclusion, using Y. enterocolitica as 
a heterologous system, we identified 10 likely T3S substrates of C. 
trachomatis (CT053, CT105, CT142, CT143, CT144, CT161, CT338, 
CT429, CT656, and CT849) and could detect translocation into host 
cells of CT053, CT105, CT142, CT143, CT161, CT338, and CT429. 
Therefore, we revealed several C. trachomatis proteins that could be 








Chlamydia trachomatis is an obligate intracellular human pathogen 
that undergoes a developmental cycle involving the inter-conversion 
between two morphologically distinct forms: a non-replicative 
infectious form, the elementary body (EB), and a replicative non-
infectious form, the reticulate body (RB) (AbdelRahman & Belland, 
2005). Throughout its developmental cycle, C. trachomatis uses a 
type III secretion system (T3SS) to translocate several effector 
proteins across the host cell plasma membrane and the inclusion 
membrane (Betts et al., 2009; Valdivia, 2008). These T3S effectors 
are thought to play a central role in bacterial invasion (Jewett et al., 
2010; Lane et al., 2008) and exit of host cells (Lutter et al., 2013), and 
in the subversion of various host cell processes (Chellas-Géry et al., 
2007; Delevoye et al., 2008; Derré et al., 2011; Hower et al., 2009; 
Mital et al., 2010; Pennini et al., 2010; Rzomp et al., 2006; Scidmore 
& Hackstadt, 2001). There are, however, chlamydial effectors, such 
as CPAF/CT858 or CT441, which are not T3S substrates (Betts et al., 
2009). 
 
Given their likely central role during infection, considerable efforts 
have been placed in identifying chlamydial effectors. This is not a 
trivial task because the amino acid sequence of most effectors does 
not display significant similarity to proteins of known function. 
Additionally, T3S substrates, which should comprise the bulk of 
Chlamydia effectors, contain no easily recognizable secretion signal. 
Moreover, in spite of the recent development of systems for 
transformation of Chlamydia (Gérard et al., 2013; Wang et al., 2011), 
for a long time no methods have been available for genetic 
manipulation of these bacteria. To overcome these obstacles, 





chlamydial effectors have been searched: i) by systematic phenotypic 
analyses of yeast Saccharomyces cerevisiae expressing individual 
chlamydial proteins (Sisko et al., 2006); ii) by using Salmonella (Ho & 
Starnbach, 2005) Shigella (Furtado et al., 2013; Muschiol et al., 2011; 
Pennini et al., 2010; Subtil et al., 2005), or Yersinia (Chellas-Géry et 
al., 2007; Clifton et al., 2004; Fields & Hackstadt, 2000; Hovis et al., 
2013; Hower et al., 2009; Pais et al., 2013) as genetically tractable 
heterologous host bacteria carrying well characterized T3SSs; or iii) 
by complex computational predictions of T3S signals (Arnold et al., 
2009; Löwer & Schneider, 2009; Samudrala et al., 2009). The 
subsequent use of specific antibodies enabled to detect translocation 
into host cells of some of the C. trachomatis proteins singled out in 
these searches, such as in the case of Tarp/CT456 (Clifton et al., 
2004), CT694 (Hower et al., 2009), CopN/CT089 (Fields & Hackstadt, 
2000), Cap1/CT529 (Fling et al., 2001), CT620 (Muschiol et al., 
2011), CT621 (Hobolt-Pedersen et al., 2009; Muschiol et al., 2011), 
CT711 (Muschiol et al., 2011), lipid-droplet associated (Lda) proteins 
Lda1/CT156, Lda2/CT163, and Lda3/CT473 (Kumar et al., 2006), 
Nue/CT737 (Pennini et al., 2010), or of a group of proteins containing 
a hydrophobic motif thought to mediate their insertion into the 
inclusion membrane (Inc proteins) (Li et al., 2008; Mital et al., 2010). 
Moreover, the direct use of antibodies raised against particular C. 
trachomatis proteins (CT311, CT622, CT795, GlgA/CT798, 
HtrA/CT823, or Pgp3) revealed their presence in the host cell cytosol 
or nucleus of infected cells (Gong et al., 2011; Lei et al., 2011, 2013; 
Li et al., 2008; Lu et al., 2013; Qi et al., 2011). Finally, the in vitro 
deubiquitinase activity of ChlaDUB1/CT868 and of ChlaDUB2/CT867 
(Misaghi et al., 2006), and the capacity of ChlaDUB1/CT868 to 
suppress the NF-κB pathway in transfected cells (Le Negrate et al., 






In this Chapter, we have surveyed the genome of C. trachomatis 
mostly for genes encoding uncharacterized proteins that were not 
described before as T3S substrates. We then used Yersinia 
enterocolitica as a heterologous system to identify 10 novel likely T3S 
substrates of C. trachomatis and real-time quantitative PCR (RT-
qPCR) to show that 9 of the genes encoding these proteins are 
clearly expressed during the bacterial developmental cycle. 
Furthermore, we showed that 7 of the 10 likely T3S substrates of C. 
trachomatis could be translocated into host cells by Y. enterocolitica. 
Therefore, we identified several novel putative effectors of C. 
trachomatis. 
  





2.3. MATERIALS AND METHODS 
Cell culture, bacterial strains and growth conditions 
HeLa 229 (ATCC) cells were maintained in DMEM (Life 
Technologies) supplemented with 10% (v/v) FBS (Life Technologies) 
at 37oC in a humidified atmosphere of 5% (v/v) CO2. C. trachomatis 
serovar L2 strain 434/Bu (L2/434; from ATCC) was propagated in 
HeLa 229 cells using standard techniques (Scidmore, 2005). 
Escherichia coli TOP10 (Life Technologies) was used for construction 
and purification of the plasmids. Y. enterocolitica ΔHOPEMT (MRS40 
pIML421 [yopHΔ1-352, yopOΔ65-558, yopP23, yopE21, yopM23, yopT135]), 
deficient for the Yersinia Yop T3S effectors H, O, P, E, M, and T, but 
T3S-proficient (Iriarte & Cornelis, 1998) and T3S-deficient Y. 
enterocolitica ΔHOPEMT ΔYscU (MRS40 pFA1001 [yopHΔ1-352, 
yopOΔ65-558, yopP23, yopE21, yopM23, yopT135, yscUΔ1-354) (Almeida et 
al., 2012) were used for T3S assays. The yscU gene encodes an 
essential component of the Y. enterocolitica T3S system, and the 
yscUΔ1-354 mutation is non-polar (Sorg et al., 2007). E. coli or Y. 
enterocolitica were routinely grown in liquid or solid LB medium with 
the appropriate antibiotics and supplements. Plasmids were 
introduced into E. coli or Y. enterocolitica by electroporation. 
 
DNA manipulations, plasmids, and primers 
The plasmids used in this work and their main characteristics are 
detailed Table A1 (Annexes). The DNA primers used in their 
construction are shown in Table A2 (Annexes). Plasmids were 
constructed and purified with proof-reading Phusion DNA polymerase 
(Thermo Fisher Scientific), restriction enzymes (Thermo Fisher 
Scientific), T4 DNA Ligase (Life Technologies), DreamTaq DNA 






Kit and ZymocleanTM Gel DNA Recovery kit (Zymo Research), and 
purified with GeneElute Plasmid Miniprep kit (Sigma-Aldrich), 
according to the instructions of the manufacturers. In brief, to analyze 
T3S signals we constructed plasmids harboring hybrid genes 
encoding the first 20 amino acids of each C. trachomatis protein, and 
the mature form of TEM-1 β-lactamase (TEM-1) (Charpentier & 
Oswald, 2004). These hybrids were made using as vector plasmid 
pLJM3, a low-copy plasmid which enables expression of the cloned 
genes driven by the promoter of the Y. enterocolitica yopE gene 
(Marenne et al., 2003), either by overlapping PCR or by using a 
cloning strategy previously described for the construction of plasmids 
encoding Inc-TEM-1 hybrid proteins (Almeida et al., 2012). To 
analyze secretion of full-length C. trachomatis proteins, we 
constructed plasmids expressing the proteins C-terminally tagged 
with a HA epitope. For this, the genes were amplified by PCR from 
chromosomal DNA of C. trachomatis L2/434 using a reverse primer 
with a sequence complementary to the transcribed strand of the DNA 
encoding the HA-epitope. PCR products digested with the appropriate 
enzymes were ligated into pLJM3 (Marenne et al., 2003).  The 
accuracy of the nucleotide sequence of all the inserts in the 
constructed plasmids was checked by DNA sequencing. 
 
Y. enterocolitica T3S assays 
T3S assays were done as previously described (Sorg et al., 2007). 
We used Y. enterocolitica ΔHOPEMT or ΔHOPEMT ΔYscU strains 
carrying the plasmids described in Table A1 (Annexes). The proteins 
in bacterial pellets and culture supernatants were analyzed by 
immunoblotting, and the amounts of protein in bacterial pellets and/or 
culture supernatants were estimated from images of immunoblots 
with Image Lab (Bio-Rad). Where appropriate, we calculated the 





percentage of secretion as the ratio between the amounts of secreted 
protein (in the culture supernatant fraction) relative to the total amount 
of protein (in the culture supernatant and in the bacterial pellet 
fractions). The results from the quantifications are the average ± SEM 
from at least three independent experiments. Detailed results for each 
protein analyzed are in Table A4 (Annexes) and Table A5 (Annexes). 
 
Y. enterocolitica translocation assays 
Analyses of protein translocation into host cells by Y. enterocolitica 
were done essentially as previously described (Denecker et al., 2002; 
Grosdent et al., 2002). In brief, Y. enterocolitica strains were grown in 
BHI (Scharlau) medium overnight at 26oC with continuous shaking 
(130 rpm). Bacteria were then diluted to OD600 of 0.2 in fresh BHI and 
cultured in the same conditions for 2 h. Subsequently, the yop 
regulon was induced by incubation for 30 min in a shaking water bath 
(130 rpm) at 37oC. Bacteria were then washed with DMEM 
supplemented with 10% (v/v) FBS and added to HeLa 229 cells, 
grown overnight in 24-well plates (1x105 cells/well), by using a 
multiplicity of infection of 50. The infected cells were incubated at 
37oC in a humidified atmosphere of 5% (v/v) CO2. After 3 h of 
incubation, extracellular bacteria were killed by adding gentamicin (50 
µg/ml), and the cells were incubated in the same conditions for 
additional 2 h. The infected cells were then harvested on ice, washed 
with PBS, ressuspended in PBS containing 0.1% (v/v) Triton X-100 
and a protease inhibitor cocktail (Sigma-Aldrich), and incubated for 10 
min on ice. The samples were then centrifuged (15,000 g for 15 min 
at 4oC) and Triton-soluble and Triton-insoluble HeLa cell lysates were 
loaded on 12% (v/v) SDS-PAGE. After electrophoresis, the gels were 








The following antibodies were used for immunoblotting: rat 
monoclonal anti-HA (3F10; Roche; 1:1000), mouse monoclonal anti-
TEM-1 (QED Bioscience; 1:500), rabbit polyclonal anti-SycO (1:1000) 
(Letzelter et al., 2006), and mouse monoclonal anti-tubulin (clone B-
5-1-2; Sigma-Aldrich; 1:1000). Immunoblot detection was done with 
horseradish peroxidase-conjugated secondary antibodies (GE 
Healthcare and Jackson ImmunoResearch), Western Lightning Plus-
ECL (Perkin Elmer), and a ChemiDoc XRS+ system (BioRad) or 
exposure to Amersham Hyperfilm ECL (GE Healthcare). All 
quantitative analyses were done with immunoblot images obtained 
using ChemiDoc XRS+ (BioRad). 
 
Real-time quantitative PCR 
The expression of the newly identified candidate T3S substrates 
during the developmental cycle of C. trachomatis L2/434 was 
estimated by determining mRNA levels at different times post-
infection by RT-qPCR. These experiments were done as previously 
described (Almeida et al., 2012). Primers (Table A2; annexes) were 
designed (Borges et al., 2010) using Primer Express (Applied 
Biosystems). The RT-qPCR assays were done using the ABI 7000 
SDS, SYBR green chemistry, and optical plates (Applied 
Biosystems), as previously described (Borges et al., 2010). At each 
time point, raw RT-qPCR data for each gene were normalized against 
the data obtained for the 16S rRNA transcript, as it was previously 
demonstrated that this is an adequate endogenous control (Borges et 










2.4.1 Selection of C. trachomatis proteins analyzed in this work 
To search for previously unidentified T3S substrates of C. 
trachomatis, we first surveyed the genome of strain L2/434 for genes 
encoding mostly uncharacterized proteins, or with a putative 
biochemical activity compatible with the function of a T3S effector 
(e.g., proteases). Among these genes, we selected those encoding 
proteins not predicted to have a signal sequence characteristic of the 
general secretory pathway (according to Psortb v3.0) and that had 
not been previously analyzed experimentally for the presence of a 
T3S signal. This singled out 32 proteins (CT016, CT017, CT031, 
CT051, CT053, CT080, CT105, CT142, CT143, CT144, CT153, 
CT161, CT172, CT273, CT277, CT289, CT309, CT330, CT338, 
CT386, CT425, CT568, CT583, CT590, CT631, CT635, CT656, 
CT696, CT702, CT837, CT845, and CT849; we used the 
nomenclature of the annotated C. trachomatis serovar D strain UW3 
(D/UW3) (Stephens et al., 1998); the names of the corresponding 
genes as annotated for strain L2/434 (Thomson et al., 2008) can be 
found in Table A4 (Annexes). Furthermore, for comparison purposes, 
we considered proteins that had been tested for the presence of a 
T3S signal using Shigella flexneri as a heterologous bacteria: eight 
proteins whose first ∼40 amino acids of the corresponding C. 
pneumoniae homologs did not drive secretion of an adenylate cyclase 
(Cya) reporter protein by S. flexneri (CT066, CT429, GrgA/CT504, 
CT538, CT584, CT768, CT779, CT814), and three proteins whose N-
terminal region of the C. pneumoniae homologs drove secretion of a 
Cya reporter protein by S. flexneri (CT203, CT577, CT863) (Subtil et 
al., 2005). Please note that at the time this work was initiated 






afterwards described as a transcriptional activator (Bao et al., 2012). 
Finally, throughout this study we used as positive controls a C. 
trachomatis bona-fide T3S effector (CT694) (Hower et al., 2009) and 
a C. trachomatis likely T3S substrate (CT082) that we had previously 
identified  (Pais et al., 2013), and which was recently independently 
confirmed (Hovis et al., 2013), and as negative control a predicted 
ribosomal protein (RplJ/CT317). 
 
In summary, in experiments that will be described below, we analyzed 
T3S signals in 46 C. trachomatis proteins (∼5% of all proteins 
encoded by the L2/434 strain): 32 hypothetical proteins previously not 
analyzed experimentally for T3S signals, 11 proteins whose C. 
pneumoniae homologs were previously analyzed for T3S signals 
using S. flexneri as heterologous system, and 3 controls. In the 
selection of these proteins, we did not consider predictions made by 
any of the published in silico methods that suggest putative T3S 
substrates (Arnold et al., 2009; Löwer & Schneider, 2009; Samudrala 
et al., 2009; Wang et al., 2013). 
 
2.4.2 Identification of T3S signals in C. trachomatis proteins 
To identify T3S signals in the selected 46 C. trachomatis proteins, we 
analyzed secretion of fusions to TEM-1 of the first 20 amino acids of 
each of these proteins by T3S-proficient Y. enterocolitica ΔHOPEMT. 
We previously showed that the first 20 amino acids of C. trachomatis 
T3S substrates were sufficient for an efficient secretion of TEM-1 
fusion by Y. enterocolitica in a T3S-dependent fashion (data not 
shown). These experiments revealed 24 C. trachomatis proteins 
whose first 20 amino acids drove secretion of TEM-1 hybrid proteins 
by Y. enterocolitica (Fig. 2.1A). Owing to lack of expression, or very 
low expression levels, it was not possible to conclude if the TEM-1 





hybrids comprising the N-terminal region of CT590, CT845 and 
CT863 were secreted (Fig. 2.1A). By individually introducing the 
plasmids encoding the TEM-1 hybrid proteins that were secreted into 
T3S-deficient Y. enterocolitica ΔHOPEMT ΔYscU and performing 
T3S assays, we confirmed that secretion of the proteins was 
dependent on a functional T3SS (Fig. 2.1B). The percentage of 
secretion of the different hybrid proteins that were secreted varied 
considerable, between 56% (SEM, 4) for CT69420-TEM-1 to 5% 
(SEM, 2) for CT14320-TEM-1 (Fig. 2.1A). Overall, this confirmed a 
T3S signal in CT203, which has been previously shown to be a T3S 
substrate (Subtil et al., 2005), and revealed T3S signals in 23 
previously unrecognized T3S substrates of C. trachomatis. The 
























Figure 2.1. Identification of T3S signals in C. trachomatis proteins using Y. 
enterocolitica as a heterologous system. Y. enterocolitica T3S-proficient 
(ΔHOPEMT) (A) and T3S-defective (ΔHOPEMT ΔYscU) (B) were used to analyze 
secretion of hybrid proteins comprising the first 20 amino acids of selected C. 
trachomatis proteins fused to the mature form of TEM-1 β-lactamase (TEM-1). 
Immunoblots show the result of T3S assays in which proteins in culture supernatants 
(S, secreted proteins) and in bacterial pellets (P, non-secreted proteins) from 
∼2.5x108 and ∼5x107 bacteria, respectively, were loaded per lane. TEM-1 hybrids of 
the known C. trachomatis T3S substrates CT082 (Hovis et al., 2013; Pais et al., 
2013) and CT694 (Hower et al., 2009) were used as positive controls and a TEM-1 
hybrid of the C. trachomatis ribosomal protein RplJ was used as a negative control. 
SycO is a strictly cytosolic Yersinia T3S chaperone (Iriarte & Cornelis, 1998; Letzelter 
et al., 2006). Immunodetection of SycO ensured that the presence of TEM-1 hybrid 
proteins in the culture supernatants was not a result of bacterial lysis or 
contamination. The percentage (%) of secretion of each TEM-1 hybrid was calculated 
by densitometry, as the ratio between the amount of secreted and total protein. The 
threshold to decide whether a protein was secreted was set to 5% (dashed line), 
based on the % of secretion of a non-secreted Yersinia protein (da Cunha et al., 
2014). Data are the mean ± SEM from at least 3 independent experiments (see also 
Table A4, annexes). 
 
2.4.3 Analysis of the secretion of the newly identified candidate 
T3S substrates of C. trachomatis as full-length proteins 
We next analyzed if the 23 C. trachomatis proteins carrying newly 
identified T3S signals, and also CT203 and the controls (CT082, 
CT694 and RplJ), were secreted as full-length proteins by Y. 
enterocolitica ΔHOPEMT. The rationale for these experiments was 
that some proteins cannot be type III secreted even with a T3S signal 
grafted at their N-termini (Akeda & Galán, 2005; Feldman et al., 2002; 
Lee & Schneewind, 2002; Sorg et al., 2005), possibly because the 
secretion channel is too narrow (inner diameter of 2-3 nm (Cornelis, 
2006)) to accommodate tightly folded proteins. Based on this, we 
predicted that if the full-length version of chlamydial proteins were 
type III secreted by Yersinia this would be an additional indication that 
they can be T3S substrates. However, lack of secretion of the full-






as they may require Chlamydia-specific chaperones, not present in 
Yersinia (Stebbins & Galán, 2001). 
To analyze secretion of full-length C. trachomatis proteins by Y. 
enterocolitica we used plasmids expressing the chlamydial proteins 
with an HA tag at their C-termini. The plasmids were introduced into 
Y. enterocolitica ΔHOPEMT and T3S assays were performed. In 
these experiments, the percentage of secretion of the positive 
controls (CT694-HA and CT082-HA) was between 20-30% and the 
percentage of secretion of the negative control (RplJ-HA) was 0.13% 
(SEM, 0.05). Based on these results, in experiments involving full-
length proteins of newly identified chlamydial T3S substrates we set a 
conservative threshold of 2% to decide whether a protein was 
secreted or not. This defined a group of 11 proteins that in their full-
length version were secreted by Y. enterocolitica ΔHOPEMT: CT053-
HA, CT105-HA, CT142-HA, CT143-HA, CT144-HA, CT161-HA, 
CT338-HA, CT429-HA, CT583-HA, CT656-HA, and CT849-HA (Fig. 
2.2A and 2.2C). To test if secretion of these proteins was dependent 
on a functional T3SS, the plasmids carrying their encoding genes, as 
well as plasmids encoding positive controls CT694-HA or CT082-HA, 
were individually introduced into T3S-deficient Y. enterocolitica 
ΔHOPEMT ΔYscU. With the exception of CT583-HA, which for 
unknown reasons was very poorly expressed by Y. enterocolitica 
ΔHOPEMT ΔYscU, these assays indicated that the other 10 proteins 
analyzed were type III secreted (Fig. 2.2B). 
 
Secretion of full-length CT153-HA, CT172-HA, CT203-HA, CT386-HA 
or CT425-HA by Y. enterocolitica could occasionally be seen by 
immunoblotting (Fig. 2.2A); however, the results were not always 
reproducible and their individual average percentage of secretion was 
in all cases below 2% (Fig. 2.2C). We did not detect significant 





amounts of CT273-HA, CT289-HA, CT309-HA, or CT631-HA in 
culture supernatants (Fig. 2.2A), but as their levels of expression 
were either extremely low (CT273-HA, CT289-HA, and CT309-HA) or 
undetectable (CT631-HA) it was not possible to draw conclusions 
about secretion of these proteins. Furthermore, CT016-HA, and 
possibly CT696-HA (barely visible in Fig. 2.2A), were 
immunodetected in the culture supernatant fraction in a form that 
migrated on SDS-PAGE at a molecular weight much lower than the 
one predicted from their amino acid sequence (27 kDa and 46 kDa, 
respectively), while in the bacterial pellet fraction their migration on 
SDS-PAGE corresponded roughly to their predicted molecular weight 
(Fig. 2.2A). This suggests that the proteins could be cleaved during 
secretion, unstable in the culture supernatant, or their encoding 
genes possess internal Shine-Dalgarno sequences. Regardless of 
the exact reason, we could not confidently analyze whether CT016-
HA and CT696-HA were secreted or not. The results obtained in this 
section are summarized in Table A5, annexes. 
 
Overall, the full set of T3S assays revealed 10 proteins (CT053, 
CT105, CT142, CT143, CT144, CT161, CT338, CT429, CT656, and 
CT849) as newly identified likely T3S substrates of C. trachomatis, 




















Figure 2.2. Analysis of the T3S of C. trachomatis full-length proteins by Y. 
enterocolitica. Y. enterocolitica T3S-proficient (ΔHOPEMT) (A) and T3S-defective 
(ΔHOPEMT ΔYscU) (B) were used to analyze secretion of full-length C. trachomatis 
proteins with a C-terminal HA epitope tag. Immunoblots show the result of T3S 
assays in which proteins in culture supernatants (S, secreted proteins) and in 
bacterial pellets (P, non-secreted proteins) from ∼5x108 and ∼5x107 bacteria, 
respectively, were loaded per lane. The known C. trachomatis T3S substrates CT082 
(Hovis et al., 2013; Pais et al., 2013) and CT694 (Hower et al., 2009) were used as 
positive controls, and the C. trachomatis ribosomal protein RplJ was used as a 
negative control. SycO is a strictly cytosolic Yersinia T3S chaperone (Iriarte & 
Cornelis, 1998; Letzelter et al., 2006) and its immunodetection ensured that the 
presence of HA-tagged proteins in the culture supernatants was not a result of 
bacterial lysis or contamination. (C) The percentage (%) of secretion of each protein 
by Y. enterocolitica ΔHOPEMT was calculated by densitometry, as the ratio between 
the amount of secreted and total protein. The threshold to decide whether a protein 
was secreted was set to 2% (dashed line), based on the % of secretion of RplJ-HA. 
Data are the mean ± SEM from at least 3 independent experiments (see also Table 
A5, annexes). 
 
2.4.4. CT053, CT105, CT142, CT143, CT161, CT338, and CT429 
can be translocated into host cells by Y. enterocolitica 
We next analyzed if the newly identified likely T3S substrates of C. 
trachomatis had the capacity of being translocated into host cells, by 
using Y. enterocolitica as a heterologous system. For this, Y. 
enterocolitica ΔHOPEMT harboring plasmids encoding C-terminal 
HA-tagged newly identified likely T3S substrates of C. trachomatis 
(CT053-HA, CT105-HA, CT142-HA, CT143-HA, CT144-HA, CT161-
HA, CT338-HA, CT429-HA, CT656-HA, or CT849-HA), a positive 
control (CT694-HA) or a negative control (RplJ-HA), were used to 
infect human epithelial HeLa cells. We then used Triton X-100 
fractionation of the infected cells followed by immunoblotting analysis 
of Triton-soluble and insoluble HeLa cell lysates to monitor protein 
translocation into host cells. As expected, we found CT694-HA in the 
Triton-soluble fraction, which showed that this protein was delivered 
into the cytoplasm of HeLa cells, and only detected RplJ-HA in the 






remained within the bacteria (and that the fractionation procedure did 
not lyse the bacteria). Among the 10 likely T3S substrates of C. 
trachomatis under analysis, we could not detect CT656-HA or CT849-
HA in both the Triton-soluble and Triton-insoluble fractions. It is 
possible that in the experimental conditions used in this study CT656-
HA or CT849-HA are translocated in minute and undetectable 
amounts and/or that they are degraded either after translocation or 
within the bacteria. Regardless of the exact scenario, these results 
did not enable us to conclude about the capacity of CT656-HA and 
CT849-HA of being translocated into host cells. However, we could 
consistently detect CT053-HA, CT105-HA, CT142-HA, CT143-HA, 
CT161-HA, CT338-HA and CT429-HA in the Triton-soluble fraction 
(Fig. 2.3), indicating that these proteins were injected into the 
cytoplasm of HeLa cells by Y. enterocolitica. We could also 
occasionally detect small amounts of CT144-HA in the Triton-soluble 
fraction (barely visible in Fig. 2.3).  
 
In summary, these experiments showed that CT053-HA, CT105-HA, 
CT142-HA, CT143-HA, CT161-HA, CT338-HA and CT429-HA have 
the capacity of being translocated into infected host cells further 
suggesting that the endogenous C. trachomatis proteins could be 
effectors. The results do not preclude that CT144, CT656 or CT849 
could be effectors, but the evidence is not as strong as for the other 7 
proteins. 







Figure 2.3. Translocation of C. trachomatis proteins into the cytoplasm of HeLa 
cells by Y. enterocolitica. HeLa cells were left uninfected (UI) or infected with Y. 
enterocolitica ΔHOPEMT strains expressing the indicated HA-tagged proteins. After 
3 h of infection, extracellular bacteria were killed by the addition of gentamicin and 
the infected cells were incubated for additional 2 h. The infected cells were then 
fractionated into Triton-soluble and Triton-insoluble cell lysates that were 
subsequently analyzed by immunoblotting using anti-HA, anti-SycO and anti-tubulin 
antibodies, as indicated. Presence of HA-tagged proteins in the Triton-soluble cell 
lysates is indicative of translocation into the cytoplasm of HeLa cells. SycO is a 
strictly cytosolic Yersinia T3S chaperone (Iriarte & Cornelis, 1998; Letzelter et al., 
2006) and its immunodetection ensured that the presence of HA-tagged proteins in 
the Triton-soluble cell lysates was not a result of bacterial lysis during the 
fractionation. Additionally, the incapacity to detect HA-tagged RplJ (a C. trachomatis 
ribosomal protein) in the Triton-soluble cell lysates further indicated that this fraction 
did not contain bacteria or non-translocated bacterial proteins. Tubulin served as a 
loading control of the Triton-soluble cell lysates. The images shown are 







2.4.5. Expression of genes encoding newly identified likely T3S 
substrates during development of C. trachomatis 
To test if the newly identified likely T3S substrates, and possible 
effectors, of C. trachomatis (CT053, CT105, CT142, CT143, CT144, 
CT161, CT338, CT429, CT656, and CT849) were expressed during 
infection, and to gain insights of when they could be acting during the 
developmental cycle, we analyzed by RT-qPCR the mRNA levels of 
their encoding genes during the developmental cycle of strain L2/434, 
at 2, 6, 12, 20, 30 and 42 h post-infection. While ct053, ct105, ct142, 
ct143, ct144, ct338, ct429, ct656, and ct849 displayed significant 
mRNA levels in more than one of the time-points analyzed, ct161 
showed only vestigial levels of expression throughout the cycle (Fig. 
2.4). The mRNA levels of ct105 and ct338 were > 5-fold higher at 2-6 
h post-infection than in any other of the time-points analyzed (Fig. 
2.4), suggesting that the encoded proteins should function at early-
cycle. The mRNA levels of ct053 and ct429 were higher between 6 
and 20 h post-infection (Fig. 2.4), suggesting that the encoded 
proteins might act from early to mid cycle. The mRNA levels of ct142, 
ct143, ct144 and ct849 were higher at the later time points analyzed 
(30-42 h post-infection). However, while ct142, ct143, and ct144 were 
expressed at similar levels at 30 and 42 h post-infection, ct849 
showed a distinct peak of expression at 30 h post-infection (Fig. 2.4). 
Therefore, CT142, CT143, CT144 could function either at late or early 
cycle, and CT849 might probably acts at late cycle. Finally, the mRNA 
levels of ct656 were constant at all time-points analyzed (Fig. 2.4), 
suggesting that CT656 could function throughout the cycle. 
Regarding ct161, when comparing the higher mRNA levels detected 
for each of the genes analyzed, those of ct161 were > 6-fold lower 
than those of any of the other genes tested (Fig. 2.4). Therefore, in 
the experimental conditions used, CT161 may not be expressed by 





strain L2/434. In summary, the RT-qPCR experiments supported that 
CT053, CT105, CT142, CT143, CT338, and CT429, and also CT144, 
CT656, or CT849, could be C. trachomatis T3S effectors, possibly 




Figure 2.4. mRNA levels of newly identified putative effectors during the 
developmental cycle of C. trachomatis. The mRNA levels of ct053, ct105, ct142, ct143, 
ct144, ct161, ct338, ct429, ct656, and ct849 were analyzed by RT-qPCR during the 
developmental cycle of C. trachomatis strain L2/434, at the indicated time-points. The 
expression values (mean ± SEM) resulted from raw RT-qPCR data (105) of each gene 







Earlier studies using heterologous systems have led to the 
identification of several bona-fide or putative C. trachomatis T3S 
effectors (Chellas-Géry et al., 2007; Fields & Hackstadt, 2000; Hovis 
et al., 2013; Hower et al., 2009; Muschiol et al., 2011; Pais et al., 
2013; Pennini et al., 2010; Song et al., 2013; Subtil et al., 2005). 
While these and other analyses covered a significant portion of all C. 
trachomatis proteins, we hypothesized that there could be previously 
unidentified T3S substrates. By combining basic bioinformatics 
searches, exhaustive T3S assays, translocation assays, and 
analyses of chlamydial gene expression in infected cells, we revealed 
10 C. trachomatis proteins (CT053, CT105, CT142, CT143, CT144, 
CT161, CT338, CT429, CT656, and CT849) as likely T3S substrates 
and possible effectors. In particular, CT053, CT105, CT142, CT143, 
CT338, and CT429 were type III secreted by Y. enterocolitica, could 
be translocated into host cells, and their encoding genes were clearly 
expressed in C. trachomatis strain L2/434. Therefore, these 6 
proteins have a high likelihood of being effectors. However, additional 
future studies are required to show that all of these 10 proteins are 
indeed translocated by C. trachomatis into host cells and to show that 
they are bona-fide effectors, i.e., that they interfere with host cell 
processes. 
 
Among the likely T3S effectors of C. trachomatis that we identified, 
CT105 and CT142 have been previously singled out as possible 
modulators of host cell functions, based on the phenotypic 
consequences of their ectopic expression in yeast S. cerevisiae 
(Sisko et al., 2006).  In addition, the genes encoding CT142, CT143, 
and CT144 have been shown to be markedly transcriptionally 





regulated by a protein (Pgp4) encoded by the Chlamydia virulence 
plasmid (Song et al., 2013) . This plasmid is present in almost all C. 
trachomatis clinical isolates (Rockey, 2011), and studies in animal 
models of infection showed that it is a virulence factor in vivo  (Kari et 
al., 2011; Olivares-Zavaleta et al., 2010). Additional studies are 
needed to understand if the putative effector function of CT142, 
CT143, and CT144 can partially explain the virulence role of the 
chlamydial plasmid. Furthermore, the predicted amino acid sequence 
of CT849 reveals a domain of unknown function (DUF720) that can 
only be found in Chlamydia proteins. In C. trachomatis, besides 
CT849, a DUF720 domain is found in CT847, a T3S effector that 
interacts with human Grap2 cyclin D-interacting protein (GCIP) 
(Chellas-Géry et al., 2007), and in CT848, which has been indicated 
as a T3S substrate using S. flexneri as a heterologous system (Subtil 
et al., 2005). Therefore, this further supports a possible role of CT849 
as an effector. In contrast with CT105, CT142, CT143, CT144 or 
CT849, no significant information is available or could be retrieved 
about CT053, CT338, CT429, or CT656. 
 
CT161 is a possible T3S substrate and effector, but we could not 
detect significant levels of ct161 mRNA during the developmental 
cycle of strain L2/434. The ct161 gene is localized within the 
“plasticity zone”, a chromosomal region of rare high genetic diversity 
among C. trachomatis strains. In fact, although C. trachomatis 
includes strains showing remarkably different tropisms (strains that 
can spread into lymph nodes and cause lymphogranuloma venereum 
[LGV], such as L2/434, and strains causing infections usually 
restricted to the mucosa of the conjunctiva and genitals), their 
genomes are all highly similar (Harris et al., 2012). Preliminary data 






seems to be more expressed in some ocular and urogenital isolates 
(data not shown). We are currently investigating the possibility that 
ct161 is a pseudogene in LGV strains, perhaps inactivated by a 
mutation in its promoter region. Interestingly, CT161 has been shown 
by yeast two-hybrid to bind CT274 (a possible chlamydial T3S 
chaperone) (Spaeth et al., 2009). Another feature of this protein is 
that part of its amino acid sequence (residues 40-224, out of 246) 
shows 28% of identity to a region of Lda2/CT163 (residues 167-361, 
out of 548), a known C. trachomatis translocated protein (Kumar et 
al., 2006).  
 
Among the proteins for which we found a secretion signal but could 
not demonstrate their T3S as full-length proteins, we highlight CT153 
and GrgA/CT504. Regarding CT153, this protein possesses a 
membrane attack complex/perforin (MACPF) domain (Ponting, 1999), 
and there is previous evidence that it may be translocated by C. 
trachomatis (Taylor et al., 2010) , which is consistent with our data. 
The ct504 gene has been recently shown to encode a transcriptional 
activator, GrgA (Bao et al., 2012). Therefore, T3S of CT50420-TEM-1 
could be a false positive. However, if GrgA is a T3S substrate, as our 
data suggests, it could have a function within the host cell, and 
similarly to what has been described in the T3SSs of Yersinia 
(Pettersson et al., 1996) or Shigella (Botteaux et al., 2009; Parsot et 
al., 2005), it could be discarded by secretion once its intra-bacterial 
regulatory activity needs to be shut down. 
 
We found T3S signals in 56% proteins analyzed (26 out of 46, 
including controls). This high percentage of proteins showing a T3S 
signal suggests that some should be false positives. It is conceivable 
that within a single bacterium non-secreted proteins possess T3S 





signals but are not targeted to the T3SS machinery because they also 
carry signals (e.g. DNA-, membrane-, or protein-binding) that 
preferentially direct them to other location within the bacterial cell. To 
help differentiating between true or false positives among chlamydial 
proteins carrying a T3S signal we analyzed their secretion as full-
length proteins. This is because, as explained above in the Results 
section, not all proteins have folding characteristics compatible with 
T3S (Akeda & Galán, 2005; Feldman et al., 2002; Lee & Schneewind, 
2002; Sorg et al., 2005). However, we cannot exclude that some of 
the C. trachomatis full-length proteins that were not type III secreted 
by Yersinia have a T3S chaperone that maintains them in a secretion-
competent state (Stebbins & Galán, 2001) and enables their secretion 
during infection by C. trachomatis. Intriguingly, CT082 or CT694 have 
dedicated T3S chaperones, CT584 and Slc1, respectively (Pais et al., 
2013), and, in agreement with what we previously observed (Pais et 
al., 2013), they were both secreted as full-length proteins in the 
absence of the chaperones. Considering that T3S chaperones have 
various functions (Feldman & Cornelis, 2003; Parsot et al., 2003), the 
chaperone role of CT584 or Slc1 should be different from maintaining 
their substrates in a secretion-competent state. 
 
Eleven of the Chlamydia proteins that we analyzed have been 
previously studied for T3S using S. flexneri has a heterologous 
system (Subtil et al., 2005). In the majority of the cases the outcome 
of the experiments was identical; however, differently from what was 
shown in Shigella, we detected a T3S signal in the N-terminal of 
CT429 (which was also secreted as a full-length protein), 
GrgA/CT504, and CT779 and we did not detect a T3S signal in 
CT577. Evidence for a T3S signal in only one of the heterologous 






explanations for these discrepancies, when considering that different 
heterologous systems (Shigella and Yersinia) and reporter proteins 
(Cya and TEM-1) were used, and that the N-terminal regions in the 
hybrid proteins consisted in different lengths of amino acids and were 
in some cases from different Chlamydia species.  
 
We compared the data from our T3S assays (including the controls, 
CT082, CT694, and RplJ) with predictions of T3S substrates by in 
silico methods (Effective T3S (Arnold et al., 2009), SIEVE (Samudrala 
et al., 2009), Modlab (Löwer & Schneider, 2009), and T3_MM (Wang 
et al., 2013)) using resources available in the Web (Effective T3S, 
Modlab and T3_MM, and Table 3 from Samudrala et al., 2009) 
(SIEVE), as detailed in Table A6 (Annexes). When considering the 
analysis of T3S signals in TEM-1 hybrids, the vast majority of proteins 
(60%; 12 out of 20) in which we did not find a T3S signal were also 
predicted not to be secreted by each of the in silico methods. In 
contrast, the vast majority of proteins (58%; 15 out of 26) in which we 
detected a T3S signal were also predicted to be secreted by at least 
one of the in silico methods. The correlation between our 
experimental data and the in silico predictions was more striking 
when considering the T3S of full-length proteins. Among the 16 full-
length proteins for which we could not find definitive evidence of T3S, 
10 (i.e., 62.5%) were also predicted not to be secreted by each of the 
in silico methods, but among the 11 proteins that we showed or 
confirmed to be T3S substrates, 10 (i.e., 83%) were also predicted to 
be secreted by at least one of the in silico methods. Overall, this 
indicates some correlation between our experimental data and the in 
silico methods that predict T3S substrates. However, for many 
proteins, each of these in silico methods generates different 
predictions Table A6 (Annexes). It is possible that the quantitative 





data on T3S such as the one we generated in this and in a previous 
study (Almeida et al., 2012), can be used to normalize and improve 
the predictive value of such methods.  
 
In conclusion, we found 10 C. trachomatis proteins (CT053, CT105, 
CT142, CT143, CT144, CT161, CT338, CT429, CT656, and CT849) 
with a high likelihood of being T3S substrates, and therefore possible 
effectors delivered by the bacteria into host cells. For 6 of these 
proteins (CT053, CT105, CT142, CT143, CT338, and CT429), the 
hypothesis that they could be effectors was supported by their 
capacity of being translocated into host cells and by the expression of 
their encoding genes by C. trachomatis. The identification of all C. 
trachomatis effectors is a crucial step towards a comprehensive 
understanding of the mechanisms by which this pathogen subverts 
host cells. The recently developed methods for genetic manipulation 
of Chlamydia indicate that it should be possible to ectopically express 
candidate effectors in C. trachomatis (Agaisse & Derré, 2013; Wang 
et al., 2011), which would facilitate the analysis of their translocation 
into host cells. Our work highlights C. trachomatis proteins that should 
be prioritized in such studies, thus aiding the future identification of 
chlamydial effectors. Furthermore, the quantitative analysis of T3S of 
TEM-1 hybrid proteins that we carried out could help to further 
develop the in silico methods for identification of T3S substrates 
(Arnold et al., 2009; Löwer & Schneider, 2009; Samudrala et al., 
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Chlamydia trachomatis virulence is related to a type III secretion 
system (T3SS) and to a highly conserved virulence plasmid. In 
Chapter II, we described the identification of new candidate T3SS 
effector proteins of C. trachomatis, including CT142, CT143, and 
CT144. In this Chapter, transcription linkage analyses indicated that 
ct142, ct143 and ct144 are organized in an operon. Furthermore, the 
transcription start site of ct142 was determined by 5´rapid 
amplification of cDNA ends (5´RACE). Real-time quantitative PCR 
revealed that ct142, ct143, and ct144 showed 38-fold, 35-fold and 7-
fold higher mRNA levels, respectively, at 30 h p.i. in wild-type C. 
trachomatis than in a strain lacking the virulence plasmid, as 
expected from the recently described role of this plasmid in promoting 
expression of these genes. Furthermore, by immunoblotting using 
antibodies against CT142 and CT143, we detected expression of the 
proteins at 30 h p.i. in extracts of HeLa cells infected by wild-type C. 
trachomatis, but not in cells infected by plasmidless C. trachomatis. 
Immunofluorescence microscopy using antibodies against CT143 
revealed intra-inclusion globular structures that did not co-localize 
with the bacteria. Overall, these results support that expression of 
ct142, ct143 and ct144 is regulated by the C. trachomatis virulence 
plasmid and suggest that CT143 could be secreted into the lumen of 







The characteristic developmental cycle of the obligate intracellular 
bacterium Chlamydia trachomatis involves two morphological distinct 
forms, the infectious but non-replicative elementary bodies (EBs) and 
non-infectious but replicative reticulate bodies (RBs). During the 
cycle, C. trachomatis resides within host cells in a membrane-bound 
vacuole, known as inclusion. The inclusion constitutes a barrier 
between the host and the pathogen, thus restricting their interactions. 
One of the ways Chlamydia evolved to overcome this obstacle is to 
encode for a type III secretion system (T3SS), used by many bacterial 
pathogens to manipulate eukaryotic host cells by injecting them with 
effector proteins (Cornelis, 2006). It is believed that C. trachomatis 
may possess more that 100 T3SS substrates (Valdivia, 2008) and 
that these proteins play a key role during the C. trachomatis infectious 
cycle. 
 
As until recently C. trachomatis had been genetically intractable, for a 
long time searching for its T3SS effectors relied on using 
heterologous bacteria (Chapter II; Fields & Hackstadt, 2000; Clifton et 
al., 2004; Hower et al., 2009; Subtil et al., 2005). However, other 
methods are needed to confirm that a given protein is indeed a T3SS 
effector. Before transformation of C. trachomatis was described 
(Wang et al., 2011), the main approach for these validation studies 
was to use specific antibodies against candidate effectors to analyze 
their expression and subcellular localization. For example, C. 
trachomatis CopN (CT089), Tarp (CT456), and CT694, or Chlamydia 
caviae CCA00037 (homologous to C. trachomatis CT671) were all 
first shown to be secreted by the Yersinia enterocolitica or Shigella 
flexneri T3SSs (Clifton et al., 2004; Fields & Hackstadt, 2000; Hower 





et al., 2009; Subtil et al., 2005). Subsequently, by probing with 
specific antibodies, it was possible to show by immunofluorescence 
microscopy that these proteins are transported into host cells by 
detecting specific labeling at the inclusion membrane (Fields & 
Hackstadt, 2000), in close association with EBs during the initial 
invasion of host cells (Clifton et al., 2004; Hower et al., 2009), or in 
the host cell cytosol (Subtil et al., 2005). 
 
Most C. trachomatis isolates maintain a highly conserved plasmid 
(Lovett et al., 1980; Pickett, 2005). Naturally occurring plasmidless 
clinical isolates are rare. Although C. trachomatis strains with and 
without the virulence plasmid display similar in vitro infectivity 
characteristics (Carlson et al., 2008), recent studies have shown that 
plasmid deficient strains are attenuated for virulence in mouse and 
non-human primate models (Kari et al., 2011; O’Connell et al., 2007; 
Sigar et al., 2014). Together with the strong selection to maintain the 
plasmid in C. trachomatis strains, these observations are indicative of 
an important role of the plasmid in C. trachomatis pathogenesis.  
 
A recent work revealed that the plasmid encoded Pgp4 protein is a 
transcriptional regulator of plasmid genes and of multiple 
chromosomal genes, including ct142, ct143 and ct144 (Song et al., 
2013). In Chapter II, we described the identification of 10 C. 
trachomatis candidate T3SS effectors, including CT142, CT143 and 
CT144. Taken together, these observations strongly suggest that 
CT142, CT143 and CT144 could be virulence factors. In this Chapter, 
we describe a characterization of their encoding genes and of the 
expression and subcellular localization of CT142 and CT143 in 







3.3. MATERIALS AND METHODS 
Cell culture, bacterial strains and growth conditions 
HeLa 229 cells (ATCC) and HeLa HtTA-1 cells (ECACC) were 
maintained in DMEM (Life Technologies) supplemented with 10% 
(w/v) FBS (Life Technologies) at 37oC in a humidified atmosphere of 
5% [v/v] CO2. C. trachomatis serovar L2 strains 434/Bu (L2/434; from 
ATCC) and 25667R (L2/2566R; Peterson et al., 1990; kindly provided 
by Agathe Subtil) were propagated in HeLa 229 cells using standard 
techniques (Scidmore, 2005). Escherichia coli TOP10 (Life 
Technologies) was used for construction and purification of plasmids. 
E. coli BL21 (DE3) (Novagen) was used for recombinant protein 
expression. E. coli was routinely grown in liquid or solid LB medium 
with the appropriate antibiotics and supplements. 
 
DNA manipulations, plasmids, and primers 
The plasmids used in this Chapter and their main characteristics are 
detailed in Table A1 (Annexes). The DNA primers used in their 
construction are described in Table A2 (Annexes). Plasmids were 
constructed and purified with proof-reading Phusion DNA polymerase 
(Thermo Fisher Scientific), restriction enzymes (Thermo Fisher 
Scientific), T4 DNA Ligase (Life Technologies), DreamTaq DNA 
polymerase (Thermo Fisher Scientific), DNA clean & concentratorTM-5 
Kit and ZymocleanTM Gel DNA Recovery kit (Zymo Research), and 
purified with GeneElute Plasmid Miniprep kit (Sigma Aldrich), 
according to the instructions of the manufacturers. The backbone 
plasmids used in this work were pGEX-4T-2 (GE Healthcare), pET-
28b(+) (Novagen) and pMal-c (New England Biolabs), used for 
recombinant protein purification, and pEGFP-C1 used for transient 
transfection in mammalian cells. C. trachomatis genes were amplified 





by PCR from genomic DNA of strain 434/Bu using custom 
oligonucleotide primers (see Table A2 in annexes). Purified PCR 
products and vector were digested with the appropriate restriction 
enzymes (see Table A2 in annexes) and ligated. The accuracy of the 
nucleotide sequence of all the inserts in the constructed plasmids was 
checked by DNA sequencing. 
 
Infection of HeLa 229 cells with C. trachomatis 
For immunofluorescence analysis, 5 x 104 HeLa 229 cells were 
seeded in 24 well plates (2 cm2/well) previously filled with 13 mm 
glass coverslips (VWR). For immunoblotting 1 x 105 HeLa 229 cells 
were seeded in 24 well plates. Scaling-up was done accordingly (6 
well plate (10cm2/well), or tissue culture flasks with a surface area of 
25cm2 (T25), 75cm2 (T75) or 175cm2 (T175). The next day, cells were 
washed with HBSS and incubated 15 min at 37ºC in a humidified 
atmosphere of 5% [v/v] CO2, while the C. trachomatis inocula 
(previously titrated infectious particles, as described in Scidmore, 
2005) were prepared in SPG (0.2 mM sucrose, 17 mM Na2HPO4, 3 
mM NaH2PO4, 5 mM L-glutamic acid) in the appropriate volume: 0.2 
ml for 24 well plates, 0.5 ml for 6 well plates, 1 ml for T25, 3 ml for 
T75, or 6 ml for T175. HBSS was then removed and the C. 
trachomatis inocula were added and incubated for 1 h at 37ºC in a 
humidified atmosphere of 5% [v/v] CO2. At this point, the inocula were 
removed and RPMI 1640 medium supplemented with 10% (w/v) FBS, 
10 mM HEPES, 1 mM sodium pyruvate, 2 mM L-glutamate, and 10 
µg/ml of gentamicin was added. This step was considered time zero 






Transcription linkage analysis 
HeLa cells were infected with C. trachomatis strain L2/434 for 40 h. 
EBs were purified as described in Scidmore (2005) and RNA was 
isolated from the EBs using an NZY total RNA kit (NZYTech). cDNA 
was then obtained by RT-PCR by using random hexamers and 
iSCRIPT (Bio-Rad). As controls for the PCR reactions we also used 
as template the product of a typical reverse transcription reaction but 
without iSCRIPT (cDNA-) and C. trachomatis genomic DNA (gDNA) 
isolated from HeLa cells that were infected with C. trachomatis strain 
L2 434/Bu using a an NZY tissue gDNA kit (NZYTech). Specific 
primers-pair combinations (see Table A2 in Annexes) were designed 
in order to determine possible transcriptional linkages between ct141, 
ct142, ct143, ct144 and ct145. 
 
5´rapid amplification of cDNA ends (RACE) 
The identification of the transcription start site (TSS) of ct142 in C. 
trachomatis L2/434 was done by RACE, using a 5´/3´RACE kit 
(second generation; Roche). We used RNA isolated as described 
above from HeLa cells infected with C. trachomatis L2/434 for 40 h. 
The primers complementary to ct142 that were used are listed in 
Table A2 (Annexes). Final PCR amplification of double stranded 
cDNA was done with Phusion DNA polymerase (Thermo Fisher 
Scientific). PCR products were purified after agarose gel 
electrophoresis, using a High Pure PCR purification kit (Roche), and 
then subject to DNA sequencing. All these manipulations were done 
according to instructions from the manufacturers. 
 
Real-time quantitative PCR (RT-qPCR) 
The expression of ct142, ct143 and ct144 was compared in C. 
trachomatis strains L2/434 and plasmidless L2/25667R by 





determining mRNA levels at different times post-infection by RT-
qPCR. These experiments were done as previously described 
(Borges et al., 2010) and primers were designed using Primer 
Express (Applied Biosystems) (Borges et al., 2010). The RT-qPCR 
assays were done using the Bio-RAD CFX Manager, SsoFastTM 
EvagreenR supermix (Bio-Rad), and optical plates. At each time point, 
raw RT-qPCR data for each gene were normalized against the data 
obtained for the 16S rRNA transcript, as it was previously 
demonstrated that this is an adequate endogenous control (Borges et 
al., 2010). The final results were based on three independent 
experiments. 
 
Recombinant protein expression and purification 
E. coli BL21(DE3) carrying pGEX-4T-2 derived plasmids (encoding 
CT142, CT143, and CT144 with GST fused at their N-termini; GST-
CT142, GST-CT143, and GST-CT144), pMal-c derived plasmids 
(encoding CT142, CT143, and CT144 with MBP fused at their N-
termini; MBP-CT142, MBP-CT143, and MBP-CT144), and pET28b(+) 
derived plasmids (encoding CT142 and CT144 with a hexahistidine 
tag at their N-termini; 6xHis-CT142 and 6xHis-CT144) were used for 
recombinant protein expression by the auto-induction method 
(Studier, 2005). Bacterial cultures were grown for 4 h at 37ºC, with a 
shaking of 150 rpm, and then were shifted to 25ºC for an additional 
24h, with a shaking of 150 rpm. The cells were harvested by 
centrifugation at 10500 g for 15 min at 4ºC. 
 
Among the GST fusion proteins, in preliminary experiments neither 
GST-CT142 nor GST-CT144 were obtained in the soluble fraction, so 
only GST-CT143 was purified. The pellet of cells expressing GST-






mM DTT, lyzozyme (10 mg/ml) and benzonase® (Novagen). The 
cells were then lysed using BugBuster®  (Novagen) according to the 
instructions of the manufacturer (1 µl of benzonase per 1 ml of 
BugBuster® reagent). The lysates were centrifuged at 10500 g for 30 
min at 4ºC after which the supernatants were loaded onto equilibrated 
gluthathione sepharose beads (GE Healthcare) pre-packed in empty 
1 ml columns (MoBiTec). The column was washed 3 times with 5 
column volumes of binding buffer (PBS containing 0.05% [v/v], Triton 
X-100, and 1 mM DTT). After the washing step, the protein was 
eluted with 10mM gluthathione. All procedures were done with ice-
cold buffers. This process yielded a significant portion of soluble 
GST-CT143 fusion protein of the expected molecular mass, as 
judged by SDS-PAGE. 
 
For MBP fusion proteins, pellets of cells expressing MBP-CT142, 
MBP-CT143, or MBP-CT144 were resuspended in ice-cold column 
buffer (20 mM Tris-HCl [pH 7.4], 1 mM EDTA and 1 mM DTT). The 
cells were lysed by passing twice through a French Press in the 
presence of 1 mM PMSF. The lysates were then centrifuged at 10500 
g for 30 min at 4ºC after which the supernatants were loaded onto 
equilibrated amylose resin (New England Biolabs), according to the 
instructions of the manufacturer. The column was washed 12 times 
with 1 ml of column binding buffer, after which the protein was eluted 
with column buffer containing 10 mM maltose. 
 
For 6xHis-CT142 and 6xHis-CT144, both proteins remained insoluble 
after several conditions had been tested and therefore they were 
purified from inclusion bodies in denaturing conditions. For this, 
pellets of cells expressing 6xHis-CT142 or 6xHis-CT144 were 





resuspended in a buffer containing 50mM Tris-HCl (pH 8.0), 100mM 
NaCl, lyzozyme (10 mg/ml) and Benzonase® (Novagen) and then 
lysed using BugBuster® reagent (Novagen) according to the 
instructions of the manufacturer (1µl of benzonase per 1 ml of 
BugBuster® reagent). The lysates were centrifuged at 10500 g for 30 
min at 4ºC and the supernatant was discarded. Purification of 
inclusion bodies was done according to (Grenn & Sambrook, 2012). 
Briefly, pellets were washed in 9 volumes of a buffer containing 50 
mM Tris-HCl (pH 8.0), 100 mM NaCl, 0.5% [v/v] Triton X-100, 
resuspended in 6 ml of a buffer containing 100 mM Na2H2PO4, 10 mM 
Tris-HCl (pH 8.0) and 8 M urea, and incubated 30 min at 4ºC. The 
lysates were then centrifuged at 10500 g for 30 min at 4ºC and the 
supernatant was loaded onto equilibrated Ni-nitrilotriacetic acid (NTA) 
resin (Qiagen). Two washes were done with a buffer containing 100 
mM Na2H2PO4, 10 mM Tris-HCl (pH 6.3), and 8M urea, followed by 
consecutive elutions with a buffer containing 100 mM Na2H2PO4, 10 
mM Tris-HCl (pH 5.5), 8M urea and then with a buffer containing 100 
mM Na2H2PO4, 10mM Tris-HCl (pH 4.5), 8 M urea. 
 
Purified proteins were dialysed using Snake Skin Dialysis Tubing 
(PierceNet) according to the manufacturer´s instruction. 
 
Generation and purification of rabbit-anti CT143 antibodies 
Purified GST-CT143 was used to immunize New Zealand White 
rabbits for the production of polyclonal antisera (Davids 
Biotechnologie, Regensburg, Germany). For purification, the anti-
CT143 serum was firstly incubated with acetone powders (Spring & 
Wold, 1971) obtained from E. coli BL21 DE3 strain containing pGEX-






antibodies or any contaminant E. coli protein in purified GST-CT143. 
Secondly, anti-CT143 serum was affinity purified on 1 mg of MBP-
CT143 immobilized on a nitrocellulose membrane. The affinity-
purified antibodies were concentrated using Amicon Ultra-4 (Millipore) 
and quantified using NanoDrop 1000 (Thermo Fisher Scientific). 
 
Generation and purification of rabbit-anti CT142 antibodies 
Polyclonal antibodies against CT142 were generated against three 
synthetic peptides conjugated to ovalbumin: peptide 1 (46-50 amino 
acid residues) NH2-VKSISAKESFSVKRKC-COOH; peptide 2 (269-
274 amino acid residues) NH2-CKGGDYVDKSALSTLY-COOH; 
peptide 3 (124-140 amino acid residues) NH2-
QKLPLIGPSRLVYQSC-COOH (Metabion). The resulting antibodies 
were affinity purified on CNBr-sepharose matrix containing the 
respective peptides (Metabion).  
 
Antibodies 
The following primary antibodies were used: rabbit polyclonal anti-
CT142 (this work; 1:200 dilution for immunoblotting); rabbit polyclonal 
anti-CT143 (this work; 1:200 dilution for immunoblotting and 1:50 
dilution for immunofluorescence); mouse monoclonal anti chlamydial 
Hsp60 (A57-B9; Thermo Fisher Scientific; 1:1000 dilution for 
immunoblotting and 1:200 dilution for immunofluorescence); goat 
polyclonal anti- MOMP of C. trachomatis (ab34414; Abcam; 1:1000 
dilution for immunoblotting and 1:500 dilution for 
immunofluorescence); mouse anti-CT442 antibody (Li et al., 2008; 
1:200 dilution for immunofluorescence) mouse monoclonal anti-
tubulin (clone B-5-1-2; Sigma Aldrich; 1:1000 for immunoblotting); 
goat polyclonal anti GFP (SICGEN; 1:1000 for immunoblotting). 





For immunoblotting, the secondary antibodies used were all 
horseradish peroxidase (HRP)-conjugated (GE Healthcare and 
Jackson ImmunoResearch; used at 1:10000). For 
immunofluorescence, the following secondary antibodies were used: 
donkey anti-goat conjugated to cyanine 5 (Cy5) (Jackson 
ImmunoResearch Laboratories; 1:200), Alexa Fluor® -594 (AF594) 
conjugate AffiniPure donkey anti-goat (Jackson ImmunoResearch 
Laboratories; 1:200); Rhodamine RedTM–X-Conjugated AffiniPure 
donkey anti-rabbit (Jackson ImmunoResearch Laboratories; 1:200); 
and goat anti-mouse Alexa Fluor® Fluor-488 (AF488) (Jackson 
ImmunoResearch Laboratories; 1:200). 
 
Transient transfection of mammalian cells 
HeLa HtTA-1 cells (ECACC) were transfected with 250 ng of plasmid 
DNA by using the jetPEI reagent (Polyplus-Transfection), as detailed 
by the manufacturer. Briefly, DNA and JetPei reagent were mixed and 
incubated for 30 min at room temperature. The mixture was then 
added drop-wise to cells seeded the previous day on 24 well plates. 
The plates were centrifuged for 180 g for 5 min and then incubated at 
37oC in a humidified atmosphere of 5% [v/v] CO2. After 4 h, fresh 
medium was added to each well. 24 h later, transfected cells were 







To harvest infected or transfected HeLa cells, they were first washed 
once with PBS and then trypsinised with 50 µl (per well in a 24 well 
plate) of TrypLETM Express (Life Technologies) by incubation during 5 
min at 37ºC. The cells were then collected, pelleted by a brief 
centrifugation, washed 3 times with ice-cold PBS, and stored as cell 
pellets at -80ºC until use. Prior to immunoblotting the cell pellets were 
thawed, resuspended in an appropriate volume of SDS-PAGE loading 
buffer (Laemmli buffer 5 X: Tris-HCl 0.25M (pH 6.8), SDS 10 % [w/v], 
β-mercaptoethanol 0.5 M, Bromophenol Blue 0.5 % [w/v]) and the 
proteins in the extract were further denatured by an incubation of 5 
minutes at 100ºC. Samples were resolved by 12% [v/v] SDS-PAGE 
and transferred to 0.2 µm nitrocellulose membranes (Bio-Rad). 
Membranes were incubated in blocking solution (PBS containing 4% 
[w/v] non-fat dried milk and 0.2% [v/v] Tween-20 for 1 h at room 
temperature, with gentle rocking. Primary antibodies were diluted in 
blocking solution in an appropriate volume to cover all the area of the 
membrane and incubated overnight at 4ºC, with gentle rocking. The 
following day membranes were washed twice (in PBS containing 
Tween-20 0.2% [v/v]) and then incubated with the respective HRP-
conjugated secondary antibody. Western Lightning Plus-ECL (Perkin 
Elmer), and exposure to Amersham Hyperfilm ECL (GE Healthcare) 
were used for detection. 
 
Immunofluorescence microscopy 
Infected HeLa cells were fixed in either PBS containing 4% (w/v) 
paraformaldehyde (PFA) for 15 min or methanol (-20ºC) for 10 min. 
Cells were then washed with PBS and stored at 4ºC in PBS 
containing 10 mM NH4Cl solution. Immunostaining was performed at 
room temperature. Antibodies were diluted in PBS containing 10% 





[v/v] horse serum and (when fixation was done with PFA) 0.1% [v/v] 
Triton X-100 was added to allow permeabilization of cells. After 
immunolabeling, the cells were consecutively washed with PBS and 
H2O. The coverslips were mounted using Aqua-poly/Mount 
(Polysciences) on microscopy glass slides, and the cells were 
examined by conventional fluorescence microscopy or by confocal 
microscopy. Quantitative analyses of immunofluorescence images 







3.4.1. C. trachomatis ct142, ct143, and ct144 are organized in an 
operon 
Previously, RT-qPCR revealed similar levels of ct142, ct143 and 
ct144 mRNA and an identical profile of expression of these genes 
(Chapter II; Fig. 2.4). These results and the localization of the genes 
in the C. trachomatis chromosome (Fig. 3.1A) suggested that ct142, 
ct143 and ct144 could be organized in an operon. To directly examine 
this, we performed transcription linkage analyses. RNA was isolated 
from EBs purified from HeLa 229 cells infected by C. trachomatis 
L2/434 for 40 h and cDNA was obtained by RT-PCR. Specific primer 
pairs (Table A2; Annexes) were used in conventional PCR reactions 
to determine possible transcriptional linkages between ct142, ct143 
and ct144 (Fig. 3.1A) and genes upstream (ct141) and downstream 
(ct145). This showed that ct142, ct143 and ct144 are transcriptionally 
linked (Fig. 3.1A and 3.1B), indicating that they are organized in an 
operon. There was no detectable transcriptional linkage between 
ct141 and ct142 or between ct144 and ct145 (Fig. 3.1A and 3.1B). To 
precisely define the promoter of ct142, we determined its transcription 
start site (TSS) by 5´RACE using as template total RNA from HeLa 
229 cells infected by C. trachomatis L2/434 for 40h, and primers 
complementary to ct142 (Table A2; Annexes). By inspecting the 
nucleotide sequences immediately upstream from the determined 
TSS of ct142, for σ66, σ54, and σ28-like promoters (Mathews & Timms, 
2006), we only identified -10 and -35 regions possibly recognized by 
σ66 (Fig. 3.1A). 







Figure 3.1. Characterization of ct142, ct143, and ct144. (A) Genetic organization 
of ct142, ct143 and ct144 depicting the fragments amplified in the transcription 
linkage analyses, the transcriptional start site (TSS) determined by 5´RACE as well 
as the deduced -10 and -35 σ66-like promoter regions. (B) Transcription linkage 
analyses in C. trachomatis L2/434. cDNA+, PCR from cDNA generated with reverse 
transcriptase (RT) from total RNA isolated from EBs obtained from infected HeLa 229 
cells at 20 h p.i.; cDNA-, as cDNA+ but without RT; gDNA, PCR from total DNA 
isolated from cells infected with the C. trachomatis strain L2/434.  
 
3.4.2. Expression of ct142, ct143 and ct144 is downregulated in 
the plasmidless C. trachomatis L2/25667R strain 
Recent work revealed that the plasmid encoded Pgp4 protein is a 
regulator of plasmid genes and of multiple chromosomal genes, 
including ct142, ct143 and ct144 (Song et al., 2013). In order to 
confirm these observations, mRNA levels of ct142, ct143 and ct144 










Figure 3.2. RT-qPCR analyzes of the expression of ct142, ct143, and ct144 in C. 
trachomatis. The mRNA levels of ct142, ct143 and ct144 genes during the 
developmental cycle of C. trachomatis L2/434 and plasmidless L2/25667R were 
analyzed by RT-qPCR. The expression values resulted from raw RT-qPCR data of 
each gene normalized to that of the 16S rRNA gene. 
 
As expected, this showed that the expression of ct142, ct143 and 
ct144 is significantly reduced in the strain without the plasmid (Fig. 
3.2). In particular, at 30 h p.i., the mRNA levels of ct142, ct143, and 
ct144 were about 38-fold, 35-fold, and 7-fold higher, respectively, in 





strain L2/434 than in strain L2/25667R. Additionally, differently from 
what we observed in Chapter II and for unknown reasons, the mRNA 
levels of ct142 in strain 434/Bu were 2.5-fold higher relative to mRNA 
levels of ct143 and 4-fold higher relative to mRNA levels ct144 at 30 h 
p.i.. 
 
Overall, this confirms a role of the virulence plasmid in the regulation 
of the expression of ct142, ct143, and ct144. Furthermore, the 
apparently higher mRNA levels of ct142 relative to ct143 and ct144 
indicate that expression of these genes might be subject to additional 
distinct regulatory mechanisms. 
 
3.4.3. Generation of antibodies against CT142 and CT143 
To analyze the expression of CT142, CT143 and CT144 in C. 
trachomatis, and their subcellular localization in infected cells, we 
aimed to obtain antibodies against these proteins. For this, we 
constructed plasmids encoding for GST-CT142, GST-CT143 or GST-
CT144 fusion proteins. The plasmids were individually introduced in 
E. coli BL21 (DE3) and tested for expression and for solubility of the 
recombinant proteins in cell extracts. All proteins were expressed but 
only GST-CT143 was soluble (Fig 3.3A). Purified GST-CT143 (Fig. 
3.3B) was used for generation of anti-CT143 antibodies, which were 
subsequently purified (see Materials and Methods). 
 
Further attempts to obtain antibodies specifically recognizing CT142 
and CT144 using fusion proteins (purified and soluble MBP-CT142 
and MBP-CT144, or inclusion bodies containing 6x-His-CT142 and 
6xHis-CT144) were unsuccessful (data not shown). Finally, we 
attempted to raise antibodies specifically recognizing CT142 by 






were able to obtain antibodies against CT142 that performed well for 
immunoblotting, but not for immunofluorescence. 
 
To analyze the specificity of the anti-CT142 and anti-CT143 
antibodies, HeLa cells were transfected with plasmids encoding 
EGFP, EGFP-CT142 or EGFP-CT143. Extracts from the transfected 
cells were analyzed by immunoblotting comparing the anti-CT142 and 
anti-CT143 antibody relative to a commercial anti-GFP antibody (Fig. 
3.3C). Using either anti-CT142 or anti-GFP we detected a band for a 
protein migrating on SDS-PAGE according to a molecular mass of 
approximately 70 kDa that should correspond to EGFP-CT142 (Fig. 
3.3C). Equally, using either anti-CT143 or anti-GFP we detected a 
band for a protein migrating on SDS-PAGE according to a molecular 
mass of approximately 70 kDa that should correspond to EGFP-
CT143 (Fig. 3.3C). However, only anti-GFP, but not anti-CT142 or 
anti-CT143, detected a protein in cells transfected with the plasmid 
encoding EGFP alone (Fig. 3.3C). Furthermore, anti-CT142 
antibodies did not recognize GFP-CT143 and anti-CT143 antibodies 
did not recognize GFP-CT142 (Fig. 3.3C). These results indicated 
that the anti-CT142 and the anti-CT143 antibodies are specific and do 
not significantly recognise proteins endogenously expressed in HeLa 
cells. 
 
We then analyzed the expression of CT142 and CT143 by 
immunoblotting using extracts of HeLa cells, either uninfected or 
infected by C. trachomatis L2/434 for 2, 8, 14, 20, 26, 32, 38, 40 h 
(Fig. 3.4 A and B). Bands that migrated on SDS-PAGE according to a 
molecular mass compatible with CT142 (31.5 kDa) and CT143 (32 
kDa) could be detected from 20 h p.i., and more obviously from 26 h 





p.i. However, at 20 h p.i. the signal detected with each antibody was 




Figure 3.3. Generation and characterization of antibodies against CT142 and CT143. 
(A) E. coli BL21 (DE3) expressing either GST or GST-CT143 was grown for 24 h in auto-
induction conditions at 25ºC. Protein extracts were prepared using BugBuster® (Novagen) 
and insoluble (P) and soluble fractions (S) were analyzed by SDS-PAGE. (B) GST-CT143 
was purified from extracts of E. coli BL21 (DE3) (prepared as described in Materials and 
Methods) by gravity flow using a column packed with glutathione sepharose beads (GE 
Healthcare). Samples from the purification were collected and analyzed by SDS-PAGE: P: 
insoluble fraction; S: soluble fraction; FT: Flow through, W1-W3: wash fractions; E1-E4: 
Elution fractions. (C) Rabbits were immunized with purified GST-CT143 or with 3 synthetic 
peptides from CT142. The specificity of the resulting antibodies was determined by 
immunoblot analysis of extracts of HeLa cells either untransfected (NT) or transfected with 
plasmids encoding EGFP, EGFP-CT143 or EGFP-CT142. Anti-GFP, anti-CT142 or anti-








Figure 3.4. Expression of CT142 and CT143 in C. trachomatis L2/434. Expression 
of CT142 and CT143 during infection was assessed by immunoblotting with anti-
CT142 and anti-CT143 antibodies, using lysates from HeLa cells either uninfected 
(UI) or infected by C. trachomatis L2/434 from 2 to 44 h p.i.. The level of C. 
trachomatis major outer membrane protein (MOMP) was monitored to assess the 
expression of chlamydial proteins, and the host cell protein tubulin was used as 
loading control. 
 
3.4.4. Comparison of the expression of CT142 and CT143 in cells 
infected by C. trachomatis L2/434 or plasmidless L2/25667R  
In order to ascertain the specificity of the signals obtained with anti-
CT142 and anti-CT143 antibodies (Fig. 3.3 and 3.4), we analyzed 
extracts of HeLa cells infected by C. trachomatis L2/434 or 
L2/25667R (lacking the virulence plasmid) by immunoblotting. In 
extracts of HeLa cells infected by C. trachomatis L2/25667R, no 
bands migrating as proteins of about 32 kDa could be detected at any 
of the analyzed time points (Fig. 3.5). In contrast, in extracts from 
HeLa cells infected by C. trachomatis L2/434, we again detected 





bands migrating as proteins of about 32 kDa, which indicated that the 
antibodies can specifically detect CT142 or CT143 (Fig. 3.5). In this 
experiment, the anti-CT142 and anti-CT143 signal was only visible 
from 30 h p.i.  
 
Overall, this indicated that the anti-CT142 and anti-CT143 antibodies 
specifically detect CT142 and CT143, respectively, and further 
confirmed that expression of CT142 and CT143 is regulated by the 
Chlamydia virulence plasmid. 
 
 
Figure 3.5. Expression of CT142 and CT143 in C. trachomatis L2/434 and 
plasmidless L2/25667R. Extacts of HeLa cells either left uninfected (UI) or infected 
by C. trachomatis L2/434 or C. trachomatis L2/25667 for 15, 20, 30 or 40 h were 
probed with anti-CT142 (A) or anti-CT143 (B) antibodies. The level of MOMP was 
monitored to assess the expression of chlamydial proteins, and the host cell protein 






3.4.5. Analysis of the subcellular localization of CT143 in HeLa 
229 cells infected with C. trachomatis 
To analyze the subcellular localization of CT143 in HeLa cells 
infected by C. trachomatis L2/434 we followed a time course of 
infection from 8 to 30 h p.i.. As mentioned above, in control 
experiments we could not detect an immunofluorescence-specific 
signal with the anti-CT142 antibody. At different time-points, the cells 
were fixed, immunolabeled for CT143 and Hsp60 (which recognizes a 
Chlamydia cytosolic molecular chaperone), and then analyzed by 
indirect immunofluorescence confocal microscopy (Fig. 3.6). The 
labeling for Hsp60 (shown in green) allowed us to monitor the 
inclusion, because it labels each bacterium inside the vacuole. At 8 h 
p.i. we already detected Hsp60 labeling, but CT143 was not detected 
(Fig. 3.6). At 15 h p.i. we detected small but defined inclusions. At this 
time point, the signal for CT143 was not very intense and overlapped 
with the Hsp60 signal. However, at 20 h p.i., the signal for CT143 did 
not overlap with the Hsp60 signal; instead we started to distinguish 
discrete structures (Fig 3.6) that at 30 h p.i. were much more 
abundant (Fig. 3.6). These structures did not seem to co-localize with 
the Hsp60 signal but appeared to be within the inclusion lumen. The 
distinct pattern of localization of CT143 at 15, 20, and 30 h p.i., as 
detected by the anti-CT143 antibody, is shown in more detail in Fig 
3.7. 







Figure 3.6. Subcellular localization of CT143 in HeLa cells infected with C. 
trachomatis. HeLa 229 cells were infected by C. trachomatis L2/434 for 8, 15, 20 
and 30 h and then fixed with methanol. Fixed infected cells were immunolabeled with 
anti-CT143 and anti-Hsp60. Cells were analyzed by confocal immunofluorescence 
microscopy. Images are combined projections of multiple 0.2 µm z-sections. Scale 
bars represent 5 µm. The white box indicates the area selected to amplify the images 








Figure 3.7. Comparison of localization of CT143 between 15, 20 and 30 h p.i.. 
Images from Fig. 3.6 representing HeLa 229 cells infected with C. trachomatis 
L2/434 for 15, 20, and 30 h were zoomed 3-fold in the area delimited by a white box 
(see Fig. 3.6.). 
 
3.4.6. The immunofluorescence signal of CT143 is specific 
To verify the specificity of the immunofluorescence signal obtained 
with the anti-CT143 antibody, we first performed an antibody 
competition assay. Prior to labeling, anti-CT143 was incubated 
without any protein or in the presence of an excess (8 µg) of MBP, 
MBP-CT142 or MBP-CT143. As observed, HeLa cells infected for 30 
h by C. trachomatis L2/434 show a clear reduction of the 
immunofluorescence signal for CT143, only in the presence of MBP-
CT143 (Fig. 3.8A). In addition, we compared the immunofluorescence 
signal of CT143 in HeLa 229 cells infected for 30 h by C. trachomatis 
strains L2/434 or plasmidless L2/25667R. 







Figure 3.8. Specificity of the immufluorescence anti-CT143 signal. (A) HeLa 229 
cells were infected with C. trachomatis L2/434 for 30 h and fixed with methanol. 
Before labeling with anti-CT143 and anti-Hsp60 antibodies, anti-CT143 was 
incubated in the presence of an excess (8 µg) of MBP, MBP-CT142 or MBP-CT143, 
as indicated. (B) HeLa 229 cells were infected with C. trachomatis L2/434 or 
plasmidless L2/25667R, fixed at 30 h p.i. with methanol and immunolabeled with anti-
CT143 and anti-Hsp60. Cells were analyzed by confocal immunofluorescence 
microscopy. Images in panels A and B are combined projections of multiple 0.2 µm z-







This revealed that the CT143 immunofluorescence signal was 
drastically reduced in cells infected by the plasmidless C. trachomatis 
strain. Therefore, the immunofluorescence signal detected with the 
anti-CT143 antibody (Fig. 3.6 and 3.7) likely corresponds to CT143. 
 
3.4.7. CT143 localizes at the inclusion lumen and appears as 
globular structures 
In order to evaluate in more detail the localization of CT143 in HeLa 
cells infected by C. trachomatis, cells infected for 30 h were 
immunolabeled for CT143 as well as for other chlamydial proteins: 
anti-Hsp60, as before; MOMP, which recognizes C. trachomatis 
major outer membrane protein; and anti-CT442, which recognizes an 
inclusion membrane (Inc) protein (Bannantine et al., 2000; Liu et al., 
2010) (Fig. 3.9). We further confirmed that CT143 appeared mostly 
as intra-inclusion globular structures that sometimes overlap with the 
chlamydial inclusion membrane (Fig. 3.9A). The immunofluorescence 
signal from the anti-CT143 antibody did not co-localize with the 
bacterial signal from the anti-MOMP or anti-Hsp60 antibodies (Fig. 
3.9A). We then measured the area of each of the 
immunofluorescence signals analyzed (CT143, Hsp60 and MOMP), 
and confirmed that the area for CT143 is considerably smaller than 
the area for the cytosolic (Hsp60) and outer membrane (MOMP) 
bacterial markers (Fig. 3.9 B). This ruled out the possibility that the 
signal obtained with anti-CT143 could, for some unknown reason, 
correspond to labeling of only a few bacteria inside the inclusion. 
Overall, these results suggested that CT143 might be secreted into 

















Figure 3.9. Subcellular localization of CT143 relative to Hsp60, MOMP and Inc 
CT442 (A) HeLa 229 cells were infected with C. trachomatis L2/434 for 30 h, fixed 
with methanol, and immunolabeled for CT143 and anti-Hsp60 (upper panel), CT143 
and MOMP (middle/upper panel), MOMP and Hsp60 (middle/lower panel), or 
CT143/Inc CT442 (lower panel). Cells were analyzed by confocal 
immunofluorescence microscopy. Images correspond to single z sections. Scale 
bars, 5 µm. The images were zoomed 5-fold in the area delimited by a white box. (B) 
Comparison of the area of the signal of CT143, MOMP and Hsp60. Measurement of 
the immunofluorescence area of signal for CT143, Hsp60 and MOMP was done 
using Fiji software (Schindelin et al., 2012) for at least 120, 90, and 90 particles, 
respectively (chosen from 3 independent images). P-values were calculated by a 
two-tailed unpaired Student’s t-test. 
  






In this Chapter, we found that C. trachomatis ct142, ct143 and ct144 
are organized in an operon and their expression in driven by a 
putative σ66 promoter upstream from the start codon of ct142. The 
expression profile of ct142, ct143 and ct144 (mid/late cycle) 
suggested two different timings for these proteins to act. One would 
be that these proteins could act mainly at mid and late cycle. 
Alternatively these proteins could accumulate adjacent to the EBs 
and have an important role in exit from the host cells or subsequent 
invasion. We also further confirmed previous studies indicating that 
expression of ct142, ct143, and ct144 is dependent on the C. 
trachomatis virulence plasmid (Carlson et al., 2008; Gong et al., 
2013), and more specifically on plasmid-encoded Pgp4 (Song et al., 
2013). The ct142, ct143, and ct144 genes encode three proteins that 
were found in Chapter II to be candidate T3SS substrates. Using 
antibodies against CT142 and CT143 we confirmed that the proteins 
are expressed in C. trachomatis L2/434 during infection of HeLa cells. 
Furthermore, using anti-CT143 antibodies we showed that CT143 
localizes in globular structures within the inclusion that do not co-
localize with the signal for the bacteria, which suggest secretion of 
CT143 into the vacuolar lumen. Overall, these observations are 
consistent with a role of CT142, CT143 and CT144 in virulence 
(expression of the encoding genes is dependent on the virulence 
plasmid and at least CT142 and CT143 are produced in C. 
trachomatis), but they are at odds with the idea that they might be 
T3SS effectors, as in this scenario we would expect to find CT143 in 







To analyze the expression and subcellular localization of CT142, 
CT143 and CT144 it was essential to obtain antibodies against these 
proteins. Several attempts to raise antibodies against CT144 were 
unsuccessful, so this analysis could not be done for CT144. The 
reasons for our lack of success in obtaining antibodies for this protein 
are unclear. We can speculate that the protein has very low 
immunogenicity or that the antibodies generated against the fusion 
proteins used did not recognize any epitopes of the protein in its 
native conformation when expressed in the context of infection. 
Furthermore, the antibodies against CT142 could only be used in 
immunoblotting and not in immunofluorescence microscopy. To 
circumvent these difficulties, as described in the next Chapter, we 
took advantage of the newly described methods for introducing 
expression plasmids in C. trachomatis to construct strains expressing 
epitope-tagged CT142, CT143, and CT144 (see Chapter IV). 
 
An important finding described in this Chapter was the localization of 
CT143 in the lumen of the inclusion. As mentioned above, this was 
surprising because, assuming it is a T3SS effector, we would expect 
to detect the protein within the cytoplasm of host cells. Therefore, 
different approaches were used to demonstrate the specificity of the 
immunofluorescence signal revealing this intra-lumenal localization. 
Furthermore, to rule out a possible artifact in the fixation process, we 
used both PFA or methanol as fixation agents and in both conditions 
we always detected the same globular structures when labeling with 
anti-CT143 antibodies (data not shown). We cannot exclude that 
CT143 is translocated into the host cell cytosol but in levels that are 
too low to be detected by immunofluorescence microscopy. Based on 
our findings we propose that at about 15 h p.i. CT143 begins to 





accumulate inside the bacteria and at 20 h p.i. it starts being secreted 
into the lumen of the inclusion.  
 
CT143 is not the first C. trachomatis protein found to localize inside 
the lumen of the inclusion. CT049 (Pls1) and CT050 (Pls2) (see 
section 1.4.9.6., below), paralogously related to the passenger 
domain of the polymorphic membrane protein PmpC, were observed 
by immunofluorescence microscopy as globular structures within the 
inclusion lumen and possibly at the inclusion membrane (Jorgensen 
& Valdivia, 2008). These proteins lack classical signal peptides and 
were not described as T3SS substrates. How these proteins are 
secreted into the lumen of the inclusion is not clearly understood. Two 
other proteins, CT620 and CT621 that are likely T3SS substrates 
belonging to a family of proteins containing a DUF582 domain of 
unknown function (Muschiol et al., 2011) (see section 1.4.8.4., 
below), are expressed at middle and late phases of the infectious 
cycle. Immunolocalization examination in infected HeLa cells 
revealed that CT620 and CT621 localized in the host cell cytoplasm 
and nuclei as well as in the lumen of the inclusion, where they do not 
associate with bacterial markers (Muschiol et al., 2011).  
 
The possible function of CT143, CT049, CT050, CT620, and CT621 
within the inclusion lumen is unclear. However, there is increasing 
evidence that the Chlamydia inclusion is not a closed compartment, 
but rather a complex and highly interactive space where contacts 
between bacterial and host molecules might occur. In fact, the 
inclusion lumen contains at least glycogen (Carlson et al., 2008; 
Chiappino et al., 1995), and lipid droplets (Cocchiaro et al., 2008). 
The possible interaction of CT143, CT049, CT050, CT620, and 







Obviously, a function of CT143 (and of CT142 and CT144) could be 
related to activities that have been attributed to the Chlamydia 
virulence plasmid, such as stimulation of pro-inflammatory cytokines 
(O’Connell et al., 2011) infectivity (O’Connell et al., 2007), 
accumulation of glycogen granules in the inclusion (Matsumoto et al., 
1998) or intra-inclusion Brownian-like movement (Carlson et al., 
2008). Furthermore, recent transcriptome analysis of HeLa cells 
infected with either a plasmid-bearing C. trachomatis strain or with its 
isogenic plasmid-deficient strain show that in the strain containing the 
plasmid there is a significant increase in the levels of expression of 
many human genes involved in inflammation, chemoattraction, cell 
growth and fibrosis (Porcella et al., 2015). However, it is unclear if 
CT142, CT143 and CT144 are involved in such functions, and how 
this could be related to the localization of CT143 in the lumen of the 
inclusion. To help start addressing these and other questions, we 
thought it was important to determine the subcellular localization of 
CT142 and CT144, which is described in the following Chapter. 
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Virulence of C. trachomatis is related to a type III secretion system 
(T3SS). In Chapter II, we described a screen for C. trachomatis T3SS 
substrates using Yersinia enterocolitica as heterologous host. Among 
others, we identified CT142, CT143, and CT144 as putative T3SS 
substrates. In Chapter III, we showed that ct142, ct143 and ct144 are 
organized in an operon. Furthermore, we described that CT142 and 
CT143 are expressed in C. trachomatis during infection of HeLa cells, 
and that endogenous CT143 appeared as intra-inclusion globular 
structures that did not overly co-localize with the bacterial signal. In 
this Chapter, using recently described methods for transformation of 
C. trachomatis, we constructed strains carrying plasmids expressing 
CT142, CT143, or CT144 with a C-terminal 2HA epitope tag (CT142-
2HA, CT143-2HA, CT144-2HA) under the control of the ct142 
promoter. Immunofluorescence (IF) microscopy analyses of HeLa 
cells infected by the newly constructed strains revealed that CT142-
2HA, CT143-2HA or CT144-2HA show a subcellular localization 
similar to endogenous CT143. Moreover, IF microscopy of HeLa cells 
infected by C. trachomatis carrying a plasmid simultaneously 
expressing CT142, CT143, and CT144-2HA under the control of the 
ct142 promoter revealed co-localization between the IF signals of 
CT144-2HA and CT143. Immunoprecipitation experiments using Y. 
enterocolitica as heterologous host suggested that CT142 could self-
interact, bind to CT143, and perhaps also to CT144. Based on these 
results, we propose that CT142, CT143, and CT144 could form a 
complex of unknown function in the inclusion lumen after their 








The obligate intracellular human pathogen Chlamydia trachomatis 
encodes for a type III secretion system (T3SS) (Stephens et al., 
1998), a virulence mechanism used by many bacterial pathogens to 
manipulate eukaryotic host cells by injecting them with T3SS effector 
proteins (Cornelis, 2006). In Chapter II, using Yersinia enterocolitica 
has heterologous host we identified 10 putative C. trachomatis 
proteins with a high likelihood of being T3S substrates, which 
included CT142, CT143 and CT144. In Chapter III, we analyzed the 
genetic organization of ct142, ct143 and ct144 as well as the 
expression of CT142 and CT143 in HeLa cells infected by C. 
trachomatis. Additionally, by immunofluorescence microscopy we 
observed that CT143 localizes in globular structures in the lumen of 
the chlamydial vacuole (known as inclusion), not overly co-localizing 
with bacterial cytosolic or outer membrane markers. 
 
Like other intracellular obligate microorganisms, it has been very 
challenging to develop genetic tools to manipulate C. trachomatis. 
However, in recent years different methods were described allowing 
for introduction of plasmid DNA into C. trachomatis, for ectopic 
expression (Agaisse & Derré, 2013; Bauler & Hackstadt, 2014; Wang 
et al., 2011) and for directed inactivation of C. trachomatis genes 
(Johnson & Fisher, 2013; Kari et al., 2011; Kokes et al., 2015; Mishra 
et al., 2012; Nguyen & Valdivia, 2013). 
 
Transformation of C. trachomatis allowed, very recently, for major 
advances in Chlamydia research. The identification of inclusion 
membrane proteins (Inc proteins) regarding their localization and 
interacting partners has benefitted greatly by the development of 





transformation techniques (Agaisse & Derré, 2014; Almeida and 
Mota, unpublished; Bauler & Hackstadt, 2014; Dumoux et al., 2015; 
Weber et al., 2015). Furthermore, the newly identified TepP effector, 
was identified in a study that was the first example of genetic 
validation of the function of a T3SS effector in C. trachomatis (Chen 
et al., 2014). 
 
In this Chapter, we have used the recently developed methods for 
ectopic expression of proteins in C. trachomatis, to confirm and 
analyze the subcellular localization of CT142, CT143, and CT144 in 





4.3. MATERIALS AND METHODS 
Cell culture, bacterial strains and growth conditions 
HeLa 229 cells (ATCC) and Vero cells (ECACC) were maintained in 
DMEM (Life Technologies) supplemented with 10% [v/v] FBS (Life 
Technologies) (complete DMEM) at 37oC in a humidified atmosphere 
of 5% [v/v] CO2. C. trachomatis serovar L2 strain 434/Bu (L2/434; 
ATCC) was propagated in HeLa 229 cells using standard techniques 
(Scidmore, 2005), Escherichia coli TOP10 (Life Technologies) was 
used for construction and purification of the plasmids. Yersinia 
enterocolitica ΔHOPEMT (MRS40 pIML421 [yopHΔ1-352, yopOΔ65-558, 
yopP23, yopE21, yopM23, yopT135]), deficient for the Yersinia Yop T3S 
effectors H, O, P, E, M, and T, but T3S-proficient (Iriarte & Cornelis, 
1998) was used for co-immunoprecipitation assays. E. coli or Y. 
enterocolitica were routinely grown in liquid or solid Luria-Bertani (LB) 
medium with the appropriate antibiotics and supplements. Plasmids 
were introduced into E. coli or Y. enterocolitica by electroporation. 
 
DNA manipulations, plasmids, and primers 
The plasmids used in this Chapter and their main characteristics are 
detailed in Table A1 (Annexes). The DNA primers used in their 
construction are described in Table A2 (Annexes). DNA 
manipulations were done as described in Chapter III. 
 
Infection of HeLa 229 cells with C. trachomatis 
Infection of HeLa 229 cells with C. trachomatis was done as 
described in Chapter III. 
  





Transformation of C. trachomatis 
The following procedure was adapted from Derré et al, 2013. The 
plasmid DNA used for transformation of C. trachomatis was isolated 
from E. coli K12 ER2925 (dam- dcm-) (New England Biolabs) using 
the NZYMidiprep Kit (NZTech). HeLa 229 cells were cultured as 
described above. Penicilin G and cyclohexamide were from Sigma-
Aldrich. The optimal penicillin concentration to select transformants 
was 1 U/ml. Once established, the transformed C. trachomatis strains 
were cultured in the presence of 10 U/ml. 
 
The procedure was initiated by the addition of 6 µg of plasmid DNA to 
200 µl of CaCl2 buffer (10 mM Tris, 50 mM CaCl2 pH 7.4). Then, 20 µl 
of previously thawed and vortexed C. trachomatis EBs [prepared and 
titrated as described in Scidmore (2005)] were added to the DNA and 
CaCl2 buffer mixture, and mixed by pipetting up and down. This 
mixture was then incubated for 30 min at room temperature. During 
this incubation period, 4x106 HeLa cells were trypsinized, washed 
once in PBS, pelleted by centrifugation at 150 g, and resuspended in 
200 µl of CaCl2 buffer. After the 30 min incubation, the 200 µl of 
resuspended HeLa cells were added to the mixture of DNA and C. 
trachomatis EBs and incubated for an additional 20 min, pipetting up 
and down every 5 min. At the end of this incubation period, 200 µl of 
DNA and C. trachomatis EBs mixture was added very gently to an 8.5 
cm2 dish containing 3 ml of DMEM. After mixing well, the cells were 
incubated for about 2 days (44 h) at 37ºC in the presence of 5% [v/v] 
CO2.  
 
After this incubation of ∼2 days, most of the cells were infected and 
wild-type inclusions were easily observed by phase-contrast 





H2O and lysed by osmotic shock (10 min incubation in 2 ml of sterile 
H2O). Cells were scrapped, centrifuged at 150 g for 5 min, and 750 µl 
of the supernatant was mixed in 3 ml of SPG (0.25 M sucrose, 10 mM 
sodium phosphate, 5 mM glutamic acid). This mixture (containing C. 
trachomatis EBs) was added to 4x106 of HeLa cells previously 
washed with HBSS (Life Technologies), which had been seeded the 
day before in a tissue culture flask with a surface area of 75 cm2 
(T75). After 1 h of incubation, the supernatant was removed and 10 
ml of complete DMEM containing 0.3 U/ml of penicillin and 1 µg/ml of 
cycloheximide was added. The cells were then incubated again for 
about 2 days (44 h) at 37ºC in the presence of 5% [v/v] CO2. 
 
After this second incubation of about 2 days, phase contrast 
microscopy typically revealed that the majority of the cells were 
infected, showing large but aberrant inclusions. At this point, the 
media was removed from the T75 flask and the infected cells were 
scrapped with 3 ml of ice-cold SPG. The cells were then lysed by 
sonication (using a UP 200S Ultrasonicator Processor, Hielscher; 2 
pulses of 20 s with 100 W and a cycle of 0.5). Then, 3 ml of the 
supernatant was split in two parts of 1.5 ml that were used to infect 
two sets of 1.3x106 HeLa cells seeded the day before in 2 tissue 
culture flasks with a surface area of 25 cm2 (T25). After 1 h of 
incubation, the inoculum was removed and 10 ml of complete DMEM 
media containing 0.3 U/ml of penicillin and 1 µg/ml of cycloheximide 
was added. The cells were then incubated for about 3 days (72 h) at 
37ºC in the presence of 5% [v/v] CO2. 
 
After this third incubation, it was usual not to detect many inclusions 
by phase contrast microscopy and those seen were usually aberrant. 
In any instance, the old media was removed from the two T25 flasks 





and the cells were scrapped in 1.5 ml of ice-cold SPG (duplicate T25 
flasks were lysed in the same 1.5 ml solution). Cells were lysed by 
sonication (as described above) and centrifuged (at 150 g for 5 min, 
25oC) and the 1.5 ml lysate was used to infect 1.3x106 HeLa cells 
seeded the day before in 1 T25 flasks. After 1 h of incubation, the 
inoculum was removed and 10 ml of DMEM medium containing 1 
U/ml of penicillin and 1 µg/ml of cycloheximide was added. The cells 
were incubated again for about 3 days (72 h) at 37ºC in the presence 
of 5% [v/v] CO2. 
 
After this fourth incubation, if the transformation was successful, wild-
type inclusions were easily detected by phase-contrast microscopy. 
At this point, the old media was removed from the T25 flasks and the 
infected cells were scrapped in 1 ml of ice-cold SPG. Cells were 
again lysed by sonication (as described above), centrifuged (at 150 g 
for 5 min, 25oC), and 50 µl of the lysate was used to infect 1.3x106 
HeLa cells seeded the day before in T25 flasks. At this point samples 
of the lysates were stored in aliquots in 10% [v/v] FBS at -80ºC. After 
1 h of incubation, the inoculum was removed and 10 ml of DMEM 
medium containing 1 U/ml of penicillin and 1 µg/ml of cycloheximide 
was added. The cells were incubated again for about 3 days (72 h) at 
37ºC in the presence of 5% [v/v] CO2. 
 
C. trachomatis transformants were selected after 2 additional 
passages in 1 U/ml of penicillin and 1 extra passage in 10 U/ml of 
penicillin. The amplification process was repeated until enough 
infectious particles were recovered to generate a frozen stock and 
proceed to clonal isolation (see below). The list of C. trachomatis 






Clonal isolation of C. trachomatis strains by plaque assay 
purification 
The following procedure was adapted from Nguyen & Valdivia (2013). 
First, 4x105 Vero cells were seeded per well in a 6-well plate. Cells 
were incubated at 37ºC in the presence of 5% [v/v] CO2 for about 24 
h and allowed to form a confluent and homogeneous monolayer. 
Aliquots of infectious particles of the transformed C. trachomatis 
strains were thawed on ice and six 10-fold serial dilutions in a volume 
of 1 ml were done. Prior to infection, Vero cells were washed once 
with HBSS. Each well was infected with 500 µl of the respective 
dilution and swirled to ensure an even mixture. The infected plates 
were centrifuged at 2700 g for 30 min at 15ºC. The media was then 
replaced with complete DMEM containing 1 U/ml of penicillin and 1 
µg/ml of cycloheximide and the cells were incubated at 37ºC in the 
presence of 5% [v/v] CO2 for 24 h.  
 
An overlay solution of 0.54 % (w/v) Seakam® agarose (Lonza) in 
DMEM containing 10% (v/v) FBS, 1 U/ml of penicillin and 1 µg/ml of 
cycloheximide was prepared and kept in a warm water bath at 55ºC 
before adding to the infected cells. The media was carefully aspirated 
from each well of the 6-well plates with the infected Vero cells and 2 
ml of the overlay solution was quickly added to each well. Agarose 
was allowed to completely solidify at room temperature for 15 min. 
Additionally, after the overlay solution had solidified, 2 ml of complete 
DMEM was added on top. Cells were then incubated at 37ºC in the 
presence of 5% [v/v] CO2 for 6 days. At this point, plaques were 
usually visible to the eye.  
 
Isolated plaques were picked using a 200 µl sterile barrier pipette tip. 
Tips were then placed in a 1.5 ml tube previously loaded with 100 µl 





of complete DMEM containing 1 U/ml of penicillin and 1 µg/ml of 
cycloheximide. Media was carefully removed from a 96-well plate 
seeded the day before with 1x104 Vero cells per well, and the 100 µl 
of complete DMEM containing each plaque were added. After 
inoculating the wells, the 96-well plate was centrifuged at 2200 g for 
30 min at 15ºC. Cells were incubated at 37ºC in the presence of 5% 
[v/v] CO2 for 2 days.  
 
Each well of the 96-well plate containing Vero cells infected with 
plaque purified C. trachomatis were lysed by osmotic shock through 
incubation in 100 µl of H2O for 10 min. After this, 100 µl of SPG 2X 
(0.4 mM sucrose, 34 mM Na2HPO4, 6 mM NaH2PO4, 10 mM L-
glutamic acid) was added to each well. This 200 µl solution containing 
the infectious particles was then added to each well of a 24 well plate 
seeded the previous day with 2x105 HeLa cells per well. Infection 
proceeded as described above. This way each plaque-purified clone 
was propagated into HeLa cells providing a higher amount of viable 
bacteria to be stored. Stock aliquots were stored in 10% [v/v] FBS at -
80ºC. 
 
Quantification of infectious progeny  
HeLa cells infected by C. trachomatis strains for different times were 
lysed by osmotic shock (10 min incubation in sterile H2O). Dilutions of 
these lysates in SPG were used to infect freshly seeded HeLa cells. 
The newly infected cells were fixed after 24 h p.i., C. trachomatis 
bacteria were immunolabeled using anti-MOMP antibodies (see 
below), and the number of inclusion forming units (IFUs/ml) was 
calculated after determination of the number of infected cells/field of 







The following primary antibodies were used: rabbit polyclonal anti-
CT143 (generation and purification described in chapter III; 1:50 
dilution for immunofluorescence); rat monoclonal anti-HA (3F10; 
Roche; 1:1000 dilution for immunoblotting and 1:200 dilution for 
immunofluorescence); mouse monoclonal anti chlamydial Hsp60 
(A57-B9; Thermo Fisher Scientific; 1:1000 dilution for immunoblotting 
and 1:200 dilution for immunofluorescence); goat polyclonal anti-
major outer membrane protein (MOMP) of C. trachomatis (ab34414; 
Abcam; 1:1000 dilution for immunoblotting); mouse monoclonal anti-
tubulin (clone B-5-1-2; Sigma Aldrich; 1:1000 for immunoblotting); 
rabbit polyclonal anti-Myc (ab9106; Abcam; 1:1000 for 
immunoblotting); mouse monoclonal anti HA (HA-7; Sigma Aldrich; 
used for co-immunoprecipitation) and mouse monoclonal anti Myc 
(9E10; Sigma Aldrich; used for co-immunoprecipitation).  
 
For immunoblotting the secondary antibodies used were all 
horseradish peroxidase (HRP)-conjugated (GE Healthcare and 
Jackson ImmunoResearch; used at 1:10000).  
 
For immunofluorescence microscopy, we used the following 
secondary antibodies: Rhodamine RedTM–X-Conjugated AffiniPure 
Donkey anti-rabbit (Jackson ImmunoResearch Laboratories; 1:200); 
goat anti-mouse Alexa Fluor® 488 (AF488) (Jackson 
ImmunoResearch Laboratories; 1:200); anti-rat conjugated to 
rhodamine RedX (Jackson ImmunoResearch Laboratories; 1:200) 









Immunoblotting and immunofluorescence microscopy 
Immunoblotting and immunofluorescence microscopy were done as 
described in Chapter III. 
 
Co-immunoprecipitation  
Co-immunoprecipitation experiments were done essentially as 
described in (Pais et al., 2013). Strains used included derivatives of 
Y. enterocolitica ΔHOPEMT carrying pBAD/Myc-His A (Life 
Technologies) encoding C-terminally Myc-tagged C. trachomatis 
CT142 under the control of the E. coli arabinose promoter (PBAD) and 
pBBR1MCS-2 (Kovach et al., 1995) derivatives encoding C-terminally 
hemaglutittinin (HA)-tagged CT142, CT143 and CT144 under the 
control of the promoter of the Yersinia T3SS effector gene yopE 
(PyopE). Overnight cultures were diluted to an OD600 of 0.1 in BHI 
supplemented with 5 mM of CaCl2 and the appropriate antibiotics 
(non-secreting conditions). The bacterial cultures were incubated for 
2 h at 26ºC, at 150 rpm, and then shifted to 37ºC (to induce 
expression from the yopE promoter) and incubated for an additional 4 
h at 150 rpm. At the time of the temperature shift, 0.2% (w/v) L-
arabinose was added to the cultures to induce expression under 
control of pBAD. After the 4 h incubation at 37ºC, bacterial cultures 
were transferred to ice and the equivalent of 5 OD600 units were 
centrifuged at 4500 g for 10 min at 4ºC. The bacterial cells were 
washed once with ice-cold PBS and lysed in co-immunoprecipitation 
(co-IP) buffer (20 mM Tris-HCl, pH 8.0; 150 mM NaCl; 1% [v/v] Triton 
X-100) using the BugBuster® reagent (Novagen). After centrifugation 
at 17000 g for 10 min at 4ºC, the lysate supernatant was pre-cleared 
with 20 µl of Pierce Protein G agarose (Thermo Fisher Scientific), 
which had been previously washed with ice-cold co-IP buffer, by 





cleared lysate was collected for further analysis (input), and the 
remaining was incubated with 10 µl of Pierce Protein G agarose that 
had been previously incubated with 5 µg of mouse monoclonal anti 
HA (HA-7; Sigma Aldrich) or with 5 µg of mouse monoclonal anti Myc 
(9E10; Sigma Aldrich) for 1 h 30 min at 4ºC end-over-end rotation. 
The IP reactions were carried out overnight at 4ºC with end-over-end 
rotation. The samples were then centrifuged at 500 g for 2 min at 4ºC 
and washed 3 times with ice-cold co-IP buffer. Finally, 25 µl of 
Laemmli SDS-PAGE loading buffer (Laemmli buffer 5 X: Tris-HCl 
0.25M (pH 6.8), SDS 10 % [w/v], β-mercaptoethanol 0.5 M, 
Bromophenol Blue 0.5 % [w/v]) was added to the agarose beads and 
the samples were incubated for 5 min at 100ºC (output). Input and 


















4.4.1. Ectopic expression of CT143-2HA in C. trachomatis from 
the incD promoter 
To understand if the observed localization of endogenous CT143 in 
the inclusion lumen could be recapitulated by epitope-tagged and 
ectopically expressed CT143, we constructed a derivative of C. 
trachomatis L2/434 carrying a plasmid encoding CT143 with a C-
terminal 2HA epitope-tag (CT143-2HA). In this plasmid, ct143 is 
expressed under the control of the promoter of the gene encoding C. 
trachomatis inclusion membrane D (IncD; PincD) and its transcription is 
also halted by the incD terminator. These elements (PincD and incD 
terminator) have been employed successfully to express different 
fluorescent proteins (GFP, mCherry and CFP) in C. trachomatis by 
the same cloning vector we used (p2TK2-SW2) (Agaisse & Derré, 
2013). 
 
We first analyzed the expression of CT143-2HA in C. trachomatis. 
For this, HeLa 229 cells were inoculated with the C. trachomatis 
recombinant strain expressing CT143-2HA, or with the parental 
L2/434 strain. Whole cell extracts were prepared at 5, 20, 30 and 40 h 
p.i., and expression of CT143-2HA was analyzed by immunoblotting 
with anti-HA antibodies (Fig.4.1A). While no HA signal was detected 
in extracts of cells infected by the parental L2/434 strain, expression 
of CT143-2HA could be detected from 20 h p.i. in extracts of cells 
infected by the recombinant strain (Fig.4.1A). Although CT143-2HA 
could also be detected at 30 and 40 h p.i., slightly higher levels of 






Next, we examined the subcellular localization of CT143-2HA in HeLa 
cells infected as described above by the recombinant C. trachomatis 
strain, but fixed at 20 and 30 h p.i. The cells were then 
immunolabeled with anti-Hsp60 (Hsp60 is a cytosolic C. trachomatis 
housekeeping chaperone, and therefore this antibody labels the 
bacteria) and anti-HA antibodies, followed by appropriate fluorophore-
conjugated antibodies. The cells were then analyzed by 
immunofluorescence microscopy, which both at 20 h p.i. and at 30 h 
p.i. revealed a perfect co-localization between CT143-2HA and 
Hsp60 (Fig. 4.1B). Similar results were obtained with C. trachomatis 
strains expressing CT142-2HA or CT144-2HA under control of PincD 
(data not shown). At earlier time-points of infection (1 h p.i. and 3 h 
p.i) it appeared that the CT143-2HA immunofluorescence signal was 
adjacent, but not co-localizing with the bacteria (i.e., with Hsp60 
immunofluorescence signal), but this was not investigated in further 
detail (data not shown). 
 
4.4.2. Ectopic expression of CT142-2HA, CT143-2HA and CT144-
2HA in C. trachomatis from the ct142 promoter 
Because the signal observed for CT143-2HA in the strain expressing 
the protein in a plasmid under the control of the PincD differed 
drastically from what we had seen for the endogenous protein 
(compare Fig. 4.1B with Figs. 3.7 and 3.9 in Chapter III), we 
wondered if this was due to the higher levels of expression of the 
ectopically expressed protein (the plasmid has a copy number of 4-6) 
or because of the different promoters driving expression of CT143 
(PincD and promoter of the ct142-ct143-ct144 operon, Pct142).  
 







Figure 4.1. Expression and subcellular localization of CT143-2HA, when 
expressed under control of the incD promoter. HeLa 229 cells were infected by 
either parental C. trachomatis L2/434 strain or recombinant C. trachomatis 
expressing CT143-2HA under the control of the incD promoter. (A) At 5, 20, 30, and 
40 h p.i. the cells were processed for immunoblotting using anti-HA antibodies. 
Expression of C. trachomatis MOMP was monitored to control the number of bacteria 
on each lane, and tubulin was used as loading control of host cell proteins. (B) At 20 
and 30 h p.i. cells infected by the recombinant strain were fixed with methanol, 
immunolabeled with anti-HA and anti-Hsp60 antibodies, and with appropriate 
fluorophore-conjugated antibodies. Stained cells were analyzed by confocal 
immunofluorescence microscopy. Images are combined projections of multiple 0.2 
µm z-sections. Scale bars, 5 µm. 
 
We therefore constructed four C. trachomatis recombinant strains 
derived from L2/434 strain, each encoding a plasmid derived from 





i) a strain harbouring a plasmid encoding CT142-2HA 
expressed from Pct142; 
ii) a strain harbouring a plasmid encoding CT143-2HA 
expressed from the Pct142; 
iii) a strain harbouring a plasmid encoding CT144-2HA 
expressed from Pct142; 
iv) a strain harbouring a plasmid encoding untagged CT142 and 
CT143, and CT144-2HA. 
In all four plasmids, transcription is driven from the Pct142, as in the 
chromosome of C. trachomatis, and transcription is halted by the incD 
terminator (Agaisse & Derré, 2013). 
 
We performed control experiments to confirm that the constructed 
strains were not affected in their growth characteristics and 
expressed the expected proteins. First, a one-step growth curve 
analysis, in which we quantified the number of infectious progeny at 
different times of infection of HeLa cells, revealed that the four newly 
constructed strains grew at rates comparable to the parental L2/434 
strain (Fig. 4.2B). This indicated that the overall physiology of the 
strains was not affected by the plasmids or by overexpression of 
CT142, CT143, and/or CT144. Second, by immunoblotting using 
extracts of HeLa cells infected for 30 h by the L2/434 parental strain 
or by each recombinant strain (using anti-HA antibodies), we 
confirmed that the HA-tagged proteins were expressed and that they 
migrated on SDS-PAGE according to their predicted molecular mass 
(CT142-2HA, 33.5 kDa; CT143-2HA, 34 kDa; CT144-2HA, 34 kDa) 
(Fig. 4.2C). However, in the strain expressing CT142-2HA we 
detected 2 different bands (Fig. 4.2C), an observation that needs to 
be further verified. 






Figure 4.2. C. trachomatis strains ectopically expressing CT142-2HA, CT143-
2HA and/or CT144-2HA from the ct142 promoter. (A) Schematic representation of 
the genes present in the plasmid of each recombinant C. trachomatis strain. (B) 
Parental C. trachomatis L2/434 strain and the derived transformed strains exhibit 
similar growth kinetics. One step growth curves were conducted in HeLa 229 cells 
infected with the respective strains at a MOI of 50 and recoverable IFUs were 
determined at various times p.i., as detailed in Materials and Methods. (C) 
Expression of CT142-2HA, CT143-2HA and CT144-2HA during infection was 
assessed by immunoblotting with anti-HA antibodies, using extracts from HeLa cells 
infected for 30 h with: (1) parental strain L2/434; (2) strain bearing plasmid encoding 
CT142-2HA; (3) strain bearing plasmid encoding CT143-2HA; (4) strain bearing 
plasmid encoding CT144-2HA; (5) strain bearing plasmid encoding CT142-CT143-
CT144-2HA. Expression of C. trachomatis MOMP was monitored to control the 







Next, we followed the expression of CT142-2HA, CT143-2HA, and 
CT144-2HA by immunoblotting of extracts of HeLa cells either 
uninfected or infected for different times (2, 8, 15, 20, 30 and 40 h) 
with each of the C. trachomatis strains expressing these proteins. 
Expression of CT142-2HA, CT143-2HA and CT144-2HA could be 
detected from 20 h p.i., but the protein levels were higher at 30 or 40 
h p.i. (Fig. 4.3). For CT142 and CT143 the profile of expression 
observed by imunoblotting was similar to that observed for the 




Figure 4.3 Kinetics of expression of CT142-2HA, CT143-2HA, and CT144-2HA in 
recombinant C. trachomatis strains. Expression of CT142-2HA (A), CT143-2HA 
(B) CT144-2HA (C and D) at the depicted times of infection by bacteria expressing 
the indicated proteins in a plasmid was assessed by immunoblotting with anti-HA 
antibodies to probe extracts of HeLa cells either left uninfected (UI) or that had been 
inoculated with strains expressing the indicated proteins. Expression of C. 
trachomatis MOMP was monitored to control the number of bacteria on each lane, 
and tubulin was used as loading control of host cell proteins. 





4.4.3. Analysis of the subcellular localization of CT142-2HA, 
CT143-2HA, and CT144-2HA in infected HeLa 229 cells 
To analyze the subcellular localization of CT142-2HA, CT143-2HA 
and CT144-2HA expressed in the plasmid from the Pct142, we 
inoculated HeLa cells with each of the C. trachomatis strains 
represented in Fig. 4.2A. The cells were fixed at 2, 8, 15, 20, and 30 h 
p.i. and were then immunolabeled for HA (to visualize CT142, CT143, 
or CT144) and for Hsp60, followed by the appropriate fluorophore-
conjugated secondary antibodies. The cells were then analyzed by 
immunofluorescence microscopy (Fig. 4.4 A-D). In all cases, at 2 and 
8 h p.i. the Hsp60 labeling could already be seen (small green dots; 
Fig. 4.4). Although at these time-points we also sometimes detected a 
signal for HA (small red dots; Fig. 4.4), we cannot rule out that this 
signal is due to background. At 15 h p.i. we could observe in all cases 
small but defined chlamydial inclusions (Fig. 4.4). Furthermore, at this 
time point, in all cases, we could detect a signal for HA that was 
clearly distinct from background and that overlapped with the signal 
for Hsp60 (Fig. 4.4). However, at 20 h p.i., the signal for CT142-2HA 
(Fig. 4.4A), CT143-2HA (Fig. 4.4B) or CT144-2HA (Fig. 4.4C and 
4.4D), while still clearly distinct from background, did not overlap with 
the signal of Hsp60. At this time point (20 h p.i.), and in all cases, we 
started to distinguish globular structures revealed by the HA signal 
(Fig. 4.4) that at 30 h p.i. were much more abundant (Fig. 4.4). These 
globular structures did not seem to co-localize with the Hsp60 signal, 


























Figure 4.4. Subcellular localization of CT142-2HA, CT143-2HA and CT144-2HA in 
infected HeLa cells. HeLa 229 cells were infected for 2, 8, 15, 20 or 30 h with derivatives 
of C. trachomatis L2 strain 434/Bu ectopically expressing CT142-2HA (A), CT143-2HA 
(B), CT144-2HA (C), or CT142-CT143-CT144-2HA (D) from a plasmid. At these time-
points the cells were fixed with methanol, immunolabeled with anti-HA and anti-Hsp60 
antibodies, and appropriate fluorophore-conjugated secondary antibodies, and analyzed 
by confocal immunofluorescence microscopy. Images are combined projections of 
multiple 0.2 µm z-sections. Scale bars, 5 µm. In the area delimited by a white square (left 
panel), images were magnified 3X and the respective amplification is shown with both 





This indicated a shift in the subcellular localization of each of the 
proteins (CT142-2HA, CT143-2HA, CT144-2HA) from the bacteria 
(i.e., co-localization with Hsp60) at 15 h p.i. to the lumen of the 
inclusion (i.e. no co-localization with Hsp60 but within the boundaries 
of its labeling) at 20 h p.i. and thereafter. 
 
We then analyzed in more detail the HA immunofluorescence signal 
observed at 30 h p.i. in HeLa cells infected with the C. trachomatis 
strains ectopically expressing CT142-2HA, CT143-2HA, or CT144-
2HA (Fig. 4.5). This confirmed that the globular structures revealed by 
the HA immunofluorescence signal of each of the ectopically 
expressed proteins did not overlap with the Hsp60 signal (Fig 4.5). 
Additionally, the area defined by the HA immunofluorescence signal 
for each ectopically expressed protein was smaller than the area 
defined by the Hsp60 immunofluorescence signal, suggesting that the 
observed globular structures are not bacteria (Fig. 4.4D). The 
observations illustrated in Fig. 4.4 and Fig. 4.5 essentially re-
capitulated those previously done for endogenous CT143 using an 












Figure 4.5. Subcellular localization of CT142-2HA, CT143-2HA, and CT144-2HA in 
HeLa cells infected for 30 h. HeLa cells infected for 30 h with C. trachomatis strains 
ectopically expressing CT142-2HA (A), CT143-2HA (B), or CT144-2HA (C), were fixed 
and immunolabeled with anti-HA and anti-Hsp60 antibodies as described in the legend of 
Figure 4.3. Cells were analyzed by confocal immunofluorescence microscopy. Images are 
single z sections. Scale bars, 5 µm. In the area delimited by a white square (left panel), 
images were magnified 3X and the respective amplification is shown with both channels 
(merge/zoom) or with each channel individually (Hsp60 and HA). (D) Comparison of the 
area of the immunofluorescence signal of CT143 (from Chapter III, used for comparative 
purposes), CT142-2HA, CT143-2HA, CT144-2HA, and Hsp60. Measurements were done 
using using Fiji software (Schindelin et al., 2012) for at least 120 (CT143), 100 (CT142-
2HA), 90 (CT143-2HA), 90 (CT144-2HA) and 90 (Hsp60) particles, chosen from 3 





4.4.4. CT143 and CT144-2HA co-localize in the lumen of the 
inclusion 
We next asked if the immunofluorescence signal of CT143 would co-
localize with the immunofluorescence signal of CT144-2HA. For this, 
HeLa 229 cells were infected for 30 h by the C. trachomatis L2/434 
derivative carrying a plasmid expressing CT142, CT143 and CT144-
2HA. The cells were then fixed and immunolabeled using anti-CT143 
and anti-HA antibodies, and appropriate fluorophore-conjugated 
antibodies. Analysis of these cells by immunofluorescence 
microscopy revealed a near perfect co-localization between CT143 




Figure 4.6. Subcellular localization of CT143 and CT144-2HA. HeLa 229 cells 
were infected for 30 by C. trachomatis L2/434 with a plasmid carrying pct142-ct142-
ct143-ct144-2HA and then fixed with methanol. Fixed infected cells were 
immunolabeled with anti-CT143 and anti-HA antibodies, and with appropriate 
fluorophore-conjugated antibodies. Stained cells were analyzed by confocal 
immunofluorescence microscopy. Images are combined projections of multiple 0.2 
µm z-sections. Scale bars, 5 µm. In the area delimited by a white square (upper 









4.4.5. Analysis of protein-protein interactions between CT142, 
CT143, and CT144 
The appearance of endogenous CT143 and ectopically expressed 
CT142-2HA, CT143-2HA or CT144-2HA in infected cells as globular 
structures within the inclusion lumen, which at least in the case of 
CT144-2HA co-localize with CT143, led us to hypothesize that these 
structures could be a multi-protein complex. Therefore using Y. 
enterocolitica as heterologous expression host, we analyzed by co-
immunoprecipitations (co-IP), if these proteins can interact. 
 
Y. enterocolitica ΔHOPEMT strains carrying a plasmid encoding C-
terminally Myc-tagged CT142 (CT142-Myc) under the control of the 
E. coli arabinose promoter (PBAD) and a plasmid encoding CT142-HA, 
CT143-HA or CT144-HA under the control of the promoter of the 
Yersinia T3SS effector gene yopE (PyopE) were grown in conditions 
where no protein secretion by the T3SS occurs (5 mM of free Ca2+ 
ions). The bacterial cells were lysed and proteins in the lysate 
supernatants (input) were immunoprecipitated with mouse 
monoclonal anti-HA (Fig. 4.7A) or anti-Myc (Fig. 4.7B) antibodies 
bound to Protein G agarose beads (output). The input and output 
fractions were analyzed by immunoblotting with rabbit polyclonal anti-
Myc and rat monoclonal anti-HA antibodies. 
 
When CT142-Myc and CT142-HA were co-expressed, CT142-Myc 
was pulled down by the IP with the HA antibody (Fig. 4.7A) and 
CT142-HA was pulled down by the IP with the Myc antibody (Fig. 
4.7B), indicating that CT142 can interact with itself. In the same 
manner when CT142-Myc and CT-143-HA were co-expressed, 
CT142-Myc was pulled-down in the IP with HA antibody (Fig. 4.7A) 





antibody (Fig. 4.7B), indicating that CT142 and CT143 can interact. 
CT144 was only obtained in small amounts in cell lysates, and the 
results obtained in the Co-IPs involving this protein were not 
conclusive. However, we occasionally could detect a pull-down of 
CT142-Myc by the IP of CT144-HA with the HA antibody (Fig. 4.7). 
These results indicated that CT142 can bind to itself and to CT143, 
and possibly also to CT144.  







Figure 4.7 CT142 can interact with itself and with CT143. Y. enterocolitica 
ΔHOPEMT strains expressing the indicated proteins were grown in conditions 
blocking the activity of its T3SS (5 mM  of Ca2+ ions). The bacterial cells were lysed 
and proteins in the lysate supernatants (input) were immunoprecipitated with mouse 
monoclonal anti-HA (A) or anti-Myc (B) antibodies bound to Protein G agarose beads 
(output). The input and output fractions from the immunoprecipitations (IPs) were 








In this Chapter, we used the recently developed methods for 
transformation of C. trachomatis to ectopically express CT142-2HA, 
CT143-2HA and CT144-2HA under the control of Pct142. This allowed 
us to further confirm the localization of CT143 in globular structures 
within the inclusion lumen in infected HeLa cells from 20 h p.i., which 
was described for the endogenous protein in Chapter III. 
Furthermore, we could extend this observation to CT142 and CT144. 
In addition, the intralumenal globular structures labeled by anti-CT143 
antibodies co-localized with those labeled by anti-HA antibodies in 
cells infected by a C. trachomatis strain co-expressing CT142, CT143 
and CT144-2HA under the control of Pct142 in a plasmid. Finally, we 
showed that CT142 can interact with itself and with CT143, while an 
interaction between CT142 and CT144 was also detected (but was 
not reproducible). Overall, these results indicated that CT142, CT143, 
and CT144 could be secreted into the inclusion lumen where they 
might form large protein complexes of unknown function.  
 
The subcellular localization of ectopically expressed CT142-2HA, 
CT143-2HA, and CT144-2HA in infected HeLa cells is quite distinct at 
15 h p.i. and at 20 h p.i. While at 15 h p.i. CT142-2HA, CT143-2HA, 
and CT144-2HA apparently localize within the bacteria, at 20 h p.i. 
and thereafter, the proteins appear as globular structures within the 
inclusion lumen that do not co-localize with the bacteria. Similar 
observations had been made for endogenous CT143 (Chapter III). 
This result suggests that CT142, CT143 and CT144 are expressed at 
mid stages of the infection (15 h p.i.), after which they start being 
secreted from the bacteria into the lumen of the inclusion.  
 





In Chapter II, using Yersinia enterocolitica as heterologous host we 
identified CT142, CT143 and CT144 as proteins with a high likelihood 
of being T3SS substrates. The T3SS injectisome is a complex 
nanomachine that allows bacteria to deliver protein effectors across 
eukaryotic cellular membranes (Cornelis, 2006). However, secretion 
of CT142, CT143 and CT144 differs from the classical T3SS 
mechanism described for effectors as they appear to be transported 
only across the two bacterial membranes into the lumen of the 
inclusion, not reaching the host cell cytosol. Several hypotheses 
could explain this observation: i) the classical T3S model might not 
apply to all type III secreted proteins in Chlamydia. In fact, other 
chlamydial proteins were found to be secreted into the inclusion 
lumen like CT620 and CT621 (Muschiol et al., 2011), or CT049 and 
CT050 (Jorgensen & Valdivia, 2008); ii) CT142, CT143 and CT144 
could be translocated across the inclusion membrane but its levels 
within the host cytosol cannot be detected by immunofluorescence 
microscopy. This could be tested by using the recently described 
BlaM-fusion reporter assays (Mueller & Fields, 2015) directly in HeLa 
cells infected with C. trachomatis; or iii) there are examples of T3S 
substrates that are not effectors as is the case of the components of 
the injectiosome and translocator proteins of the T3SS apparatus 
(Cornelis, 2006). In this scenario CT142, CT143 and CT144 could 
belong to this category of proteins. 
 
Additionally, we observed that the subcellular localization of CT142-
2HA, CT143-2HA, and CT144-2HA at 30 h p.i. was drastically 
different when they were expressed from the exogenous C. 
trachomatis incD promoter (not shown for CT142 and CT144) than 
when they were expressed from their own common endogenous 





proteins were apparently retained inside the bacteria while under the 
control of the ct142 promoter they were found within the inclusion 
lumen as observed for endogenous CT143 (Chapter III). Such a 
dramatic change in localization of these proteins indicates that 
regulation of their presumed secretion into the lumen of the inclusion 
is tightly associated with the transcriptional control of their expression. 
In early time points (before 2 h p.i.), it is however possible that 
CT143-2HA expressed under the control of the PincD promoter is 
secreted into the host cell cytosol, but these observations still need to 
be confirmed. These results suggest that different promoters might 
direct T3SS substrates during a specific time of the C. trachomatis 
cycle.  
 
When expressing epitope-tagged CT142, CT143, and CT144 in Y. 
enterocolitica, we detected interactions between CT142-CT142, 
CT142-CT143 and possibly between CT142-CT144. Additionally, 
when ectopically expressed in C. trachomatis, CT143 and CT144-
2HA also appear to localise in close proximity. These observations 
suggest that these proteins might form a complex in the inclusion 
lumen. In our model, we propose that CT142 could function as a 
nucleating protein (Fig. 4.8). The function of this complex, however, 
still remains to be elucidated. 
 
In order to confirm the observed interactions, additional biochemical 
validation will be necessary. We have attempted to do pull down 
assays using extracts from HeLa 229 cells infected with C. 
trachomatis L2/434, the plasmidless C. trachomatis L2 strain 25667R 
or any of the strains ectopically expressing CT142-2HA, CT143-2HA 
or CT144-2HA and used HA antibodies cross-linked to a protein G 
resin. However, the results obtained were inconclusive (data not 





shown). Alternatively, pull down assays could be done using purified 
GST-CT143, MBP-CT142, MBP-CT143 or MBP-CT144 immobilized 
to a resin and extracts of HeLa 229 cells infected with all the C. 




Figure 4.8 Model for possible interactions between CT142-CT142, CT143-CT143 
and possibly CT142-CT144. Schematic representation of the predicted interactions 
between CT142, CT143 and CT144, based on the co-IP experiments. 
 
Further experiments are also necessary to prove that a complex is 
formed and to understand the nature of its function. Ideally this could 
be done using knock-out mutants for CT142, CT143 and CT144 
together with complementation plasmids encoding for the respective 
protein that was knocked-out. Another approach would be to 
construct a series of C. trachomatis recombinant strains derived from 
L2/434 strain, each encoding a plasmid derived from p2TK2-SW2 
(Agaisse & Derré, 2013) in which pgp4 was deleted and have all 
possible combinations of the three proteins: i) each of the three 
proteins expressed individually; ii) expression of pairwise 





from the same plasmid. In all cases the expression would have to be 
driven from a conditional promoter (not regulated by pgp4, e.g Ptet; 
(Bauler & Hackstadt, 2014; Wickstrum et al., 2013)) and proteins 
would be carrying an HA epitope. With this approach we could 
determine if CT142 is indeed necessary to nucleate the formation of 
the proposed complex. A broader approach to chlamydial genetics, 
using all the recently developed methods will definitively help us to 
elucidate the role for these novel likely virulence factors in the 
developmental cycle of C. trachomatis.  
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The author of this dissertation has written this chapter based on the referred 






Gram-negative bacteria possess different macromolecular structures, 
known as type III, type IV, or type VI secretion systems, for delivery of 
effector proteins directly from the bacterial cytoplasm into eukaryotic 
or prokaryotic host cells (see Chapter I, section 1.4.1) (Costa et al., 
2015). The proteins that are delivered into host cells, the effector 
proteins, have the capacity to modulate a variety of cellular functions 
(Galán, 2009). Although many effectors have been elegantly 
described in many bacterial systems in the last decades, there are 
still a considerable number of candidate effectors in many bacteria 
that have not yet been described. This is indeed the case of 
Chlamydia trachomatis whose obligate intracellular lifestyle has 
further limited research in this area. In fact, relatively few chlamydial 
effectors have been characterized to date (see Chapter I, section 
1.4.8). 
 
The main goal of this project was to identify and characterize novel C. 
trachomatis type III secretion system (T3SS) effector proteins. The 
first part of the work involved a screen in the heterologous host 
Yersinia enterocolitica in order to identify novel chlamydial candidate 
effectors. It revealed 10 C. trachomatis proteins (CT053, CT105, 
CT142, CT143, CT144, CT161, CT338, CT429, CT656, and CT849) 
of yet unknown function that have a high likelihood of being effectors 
delivered by C. trachomatis into the host cell (Chapter 2). Among the 
proteins highlighted in the screen, CT142, CT143 and CT144 were 
chosen to be further characterized in this work. In addition to being 
putative T3SS effectors, it had been previously shown that expression 
of ct142, ct143 and ct144 is transcriptionally regulated by the 
Chlamydia-virulence plasmid (Carlson et al., 2008; Song et al., 2013), 
reinforcing the probability that these proteins are virulence factors. 






CT142, CT143, and CT144 localize within the lumen of the bacterial 
vacuole but outside from the bacterial cells. Furthermore, we provide 
evidence that these proteins might interact with each other and form a 
protein complex within the lumen of the inclusion (Fig. 5.1). 
Altogether, this work contributed to increase our knowledge on the 
identity of C. trachomatis T3SS substrates, and supported that some 
of these substrates might be released into the inclusion lumen where 
they might have a functional role. This intriguing possibility needs to 




Figure 5.1. CT142, CT143 and CT144 could form a complex in the lumen of the 
inclusion. Schematic representation of the predicted interactions between CT142, 
CT143 and CT144, based on the co-immunoprecipitation experiments. We propose 
that the indicated proteins might form a complex in the lumen of the chlamydial 
inclusion. 
 
5.1. Distribution of CT142, CT143, and CT144 among Chlamydiae 
PSI-BLAST analysis (Altschul et al., 1997) revealed that CT142, 
CT143 and CT144 are highly conserved in all C. trachomatis serovars 
(> 95% identity in CT142, > 96% identity in CT143 and > 90% identity 
in CT144) (data not shown) and are also conserved in 
Chlamydiaceae (Table 5.1). However, PSI-BLAST analysis failed to 
identify any significant sequence similarity with proteins from the 








Table 5.1. Identification of orthologues of C. trachomatis CT142 








 cover Id cover Id cover Id 





C. muridarum 99% 71% 100% 74% 100% 68% 
C. psittaci 83% 41% 93% 45% 98% 39% 
C. abortus 99% 39% 93% 44% 98% 37% 
C. caviae 96% 39% 93% 41% 96% 38% 
C. pecorum 95% 34% 94% 37% 96% 40% 
C. felis 95% 37% 97% 41% 98% 36% 
C. avium 96% 42% 99% 39% 98% 36% 
C. gallinacea 96% 41% 100% 42% 98% 37% 
C. suis  100% 77% 100% 79% 99% 73% 
Parachlamydiaceae No Hits No Hits No Hits 
Waddliaceae No Hits No Hits No Hits 
Simkaniaceae No Hits No Hits No Hits 
Criblamydiaceae No Hits No Hits No Hits 
a Orthologues of the C. trachomatis proteins CT142, CT143 and CT144 in other 
Chlamydiae were searched by PSI-BLAST (Altschul et al., 1997). An individual PSI-
BLAST search was performed between each protein (using the corresponding amino 
acid sequence from C. trachomatis serovar L2 strain 434/Bu: CTL0397, CTL0398 
and CTL0399, respectively) and a representative strain from each Chlamydia spp. 
(C. pneumoniae strain CWL029, C. muridarum strain Nigg., C. psittaci strain Mat116, 
C. abortus strain S26/3, C. caviae strain GPIC, C. pecorum PV3056/3, C. felis Fe/C-
56, C. avium strain 10DC88, C. gallinacea 08-1274/3, C. suis strain MD56). Another 
individual PSI-BLAST search was performed between each protein and members of 
the other Chlamydiae families. The families Rhabdochlamydiaceae, 
Piscichlamydeacea, Chlavichlamydiaceae and Parilichlamydiaceae were excluded 
from our search because they are not include in the genome database. Cover, 






The syntenic organization of CT142, CT143, and CT144 is 
maintained in the majority of the Chlamydia spp. (Fig. 5.2). 
Interestingly, in C. pneumoniae there is a duplication of the 
orthologue of ct143 and the order of the genes is altered (Table 5.1 
and Fig. 5.2). The reason for this occurrence is not clearly 
understood. Nevertheless, the conserved nature of these genes is an 
indication of their importance in the biology of Chlamydia. In 
particular, the exclusive presence of CT142, CT143, and CT144 
orthologues within Chlamydia spp. suggests a role of these proteins 








Figure 5.2. Genetic organization of ct142 (depicted in green), ct143 (depicted in red) and ct144 (depicted in pink). Syntenic organization of 
the three genes is illustrated in C. trachomatis serovar A (strain A/HAR-13), C. trachomatis serovar B (strain B/Jali20/OT), C. trachomatis 
serovar D (strain D/UW-3/CX) as well as in C. muridarum Nigg, C. abortus S26/3, C. caviae GPIC, C. felis Fe/C-56 and C. pneumoniae 






5.2. Subcellular localization of CT142, CT143 and CT144 
Our analyses of immunofluorescence microscopy of the subcellular 
localization of endogenous CT143 or ectopically expressed CT142-
2HA, CT143-2HA and CT144-2HA in HeLa cells infected by C. 
trachomatis serovar L2 strain 434/Bu (L2/434, or each respective 
derivative recombinant strain) revealed these proteins within the 
bacteria (at 15 h p.i.) and outside of the bacteria within the inclusion 
lumen (from 20 h p.i.). To our surprise, we could never detect the 
proteins in the cytoplasm of the host cell, as would be expected for 
T3SS effectors. Other proteins have been found to localize at the 
inclusion lumen: Pls1/CT049 and Pls2/CT050 (Jorgensen & Valdivia, 
2008), which have not been demonstrated to be T3SS substrates, 
CT620 and CT621, which have been shown to be T3SS substrates 
using S. flexneri as heterologous host (Muschiol et al., 2011) and the 
chlamydial glycogen enzymes (GlgA, GlgB, GlgX, GlgP and MalQ) 
that have been recently described to possess T3S signals and to 
accumulate in the inclusion lumen (Gehre et al., 2016). However, 
CT620, CT621 and GlgA have also been shown to localize within the 
host cell cytoplasm (Lu et al., 2013; Muschiol et al., 2011). Assuming 
that at least CT142, CT143, CT144, CT620, CT621 and the 
chlamydial glycogen enzymes are T3SS substrates, their localization 
within the inclusion lumen does not fit the classical model where 
T3SS effector proteins are translocated directly from the bacterial 
cytoplasm into the host cell cytosol. These observations raise the 
possibility that the C. trachomatis T3SS could have a different mode 
of action than in the organisms were it has been more thoroughly 
characterized. 
 
A unique feature of the C. trachomatis T3SS is an apparent 






pore within the host cell plasma membrane (during entry) and within 
the inclusion membrane (during the intracellular bacterial 
development and replication): CopB and CopB2, and CopD and 
CopD2. For CopB and CopB2, it has been found that CopB is 
detected early during infection, while CopB2 is detected throughout 
the developmental cycle (Chellas-Géry et al., 2011). Likewise, earlier 
studies in C. pneumoniae revealed the presence of two distinct 
translocator chaperones (Yersinia spp., lcrH homologues), one acting 
on early stages of infection and the second during the developmental 
cycle (Ouellette et al., 2005). Furthermore, in many T3SSs a 
hydrophilic translocator protein forms either a tip complex, such as 
LcrV in Yersinia spp. (Mueller, 2005), or a filament, such as EspA in 
Escherichia coli (Knutton et al., 1998), which serve as link between 
the injectisome and the translocon (Mueller et al., 2008). However, 
such hydrophilic translocator has not been found yet in C. 
trachomatis. Although CT584 has been initially proposed to form a tip 
complex in Chlamydia (Markham et al., 2009), the recent 
determination of the three-dimensional structure of the protein 
indicates that this should not be the case (Stone et al., 2012). While 
such link between the C. trachomatis injectisome and translocon 
might eventually be found, one can also speculate that in this 
bacterium some T3SS substrates are released into the inclusion 
lumen and either remain there (as could be the case of CT142, 
CT143, and CT144) or afterwards gain access to the host cell 
cytoplasm (as could be the case of CT620 and CT621). 
 
It is clear that there are mechanisms for transport of proteins from the 
inclusion lumen into the host cell cytoplasm. For example, C. 
trachomatis effectors CPAF or Tsp/CT441 as well as the candidate 






dependent mechanism (Chen et al., 2010; Lei et al., 2011; Qi et al., 
2011; Yang et al., 2015b; Zhong, 2011) into the inclusion lumen and 
from there gain access to the host cell cytosol by an unknown 
mechanism. One hypothesis is that proteins located in the inclusion 
lumen may be exported into the host cell cytosol via outer membrane 
vesicles (OMVs) (Bonnington & Kuehn, 2014; Zhong, 2011). 
 
According to the recently proposed working model for the T3SS 
during the chlamydial developmental cycle (Ferrell & Fields, 2015) 
(see Fig. 1.8, Chapter I), we could imagine a scenario where CT142, 
CT143, CT144, CT620, CT621, and possibly other mid/late cycle 
T3SS substrates, would be secreted into the inclusion lumen during 
the process of RB detachment from the inclusion membrane, before 
the event of association of the CopN gatekeeper to the bacterial 
cytoplasmic side of the apparatus. This would imply that these 
proteins would be secreted during the RB-EB conversion process. In 
contrast to the synchronized replication of RBs, it is known that the 
conversion of RBs to EBs occurs in a non-synchronized manner 
(Moulder, 1991). In fact, the timing of appearance of CT142, CT143 
and CT144 in the lumen of the chlamydial inclusion could reflect the 
RB-EB conversion step: no protein detected in the inclusion lumen 
until approximately 20 h p.i., very low levels of protein observed at 20 
h p.i. and an increment in amount of detected protein towards later 
times in the developmental cycle (30 and 40 h p.i.). According to this 
hypothesis, it would be possible to imagine T3S occurring during 
detachment of RBs from the inclusion membrane, which would 
consequently explain the presence of T3S substrates in the lumen of 
the inclusion. This model would clearly imply a complex regulatory 







5.3. Possible functions for the proposed CT142-CT143-CT144 
protein complex  
It is possible that CT142, CT143 and CT144 are T3SS substrates but 
not T3SS effectors. In this scenario, these proteins could be 
components or regulators of the T3SS apparatus itself. Highly 
speculative possibilities would be that they from the needle tip 
complex or that they could be somehow involved in the activation of 
the system prior to the invasion step of the cycle. Alternatively, and 
bearing in mind the timing of expression and secretion of these T3SS 
substrates, the function of CT142, CT143, CT144, could be as 
effector proteins logically associated with late intracellular survival, 
host cell exit or the invasion step of the developmental cycle. Another 
obvious association for these proteins is the relation of activities that 
have been attributed to the Chlamydia virulence plasmid, such as 
stimulation of pro-inflammatory cytokines (O’Connell et al., 2011) 
infectivity (O’Connell et al., 2007), accumulation of glycogen granules 
in the inclusion (Matsumoto et al., 1998) or intra-inclusion Brownian-
like movement (Carlson et al., 2008). Interestingly, recent work has 
shown that chlamydial exit from host cells is not only regulated by the 
plasmid transcriptional regulator Pgp4 but is also dependent on the 
chlamydial T3SS (Yang et al., 2015a). It is therefore a possibility that 
CT142, CT143, and CT144 could play a role in the chlamydial exit 







The work developed in this thesis revealed ten novel candidate C. 
trachomatis effector proteins: CT053, CT105, CT142, CT143, 
CT144, CT161, CT338, CT429, CT656, and CT849. CT142, CT143 
and CT144 were further described to be secreted into the lumen of 
the chlamydial inclusion but their function remains to be determined. 
These proteins, among others, might not fit the classical definition of 
‘effector protein’, since direct interaction with the host cell has not 
been verified yet. 
 
We believe that this study will lead way for future lines of research in 
the field of chlamydial effector proteins, namely in understanding how 
these proteins act and which cellular mechanisms are targeted by 
each protein. In fact, at least one candidate T3SS effector detected in 
our screen, CT105, has been recently demonstrated in our lab to be 
translocated into the host cell by C. trachomatis (Pais and Mota, 
unpublished). Others remain to be tested more thoroughly as possible 
effector proteins. Characterization of the whole set of chlamydial 
effector proteins, and understanding how they contribute to 
intracellular survival and to the subversion of the host cell, will 








Altschul, S. F., Madden, T. L., Schäffer, A. A., Zhang, J., Zhang, Z., Miller, W. & 
Lipman, D. J. (1997). Gapped BLAST and PSI-BLAST: a new generation of 
protein database search programs. Nucleic Acids Res 25(17), 3389–3402. 
Bonnington, K. E. & Kuehn, M. J. (2014). Protein selection and export via outer 
membrane vesicles. Biochim Biophys Acta - Mol Cell Res 1843, 1612–1619. 
Carlson, J. H., Whitmire, W. M., Crane, D. D., Wicke, L., Virtaneva, K., 
Sturdevant, D. E., Kupko, J. J., Porcella, S. F., Martinez-Orengo, N. & other 
authors. (2008). The Chlamydia trachomatis plasmid is a transcriptional 
regulator of chromosomal genes and a virulence factor. Infect Immun 76(6), 
2273–2283. 
Chellas-Géry, B., Wolf, K., Tisoncik, J., Hackstadt, T. & Fields, K. A. (2011). 
Biochemical and localization analyses of putative type III secretion translocator 
proteins CopB and CopB2 of Chlamydia trachomatis reveal significant 
distinctions. Infect Immun 79(8), 3036–3045. 
Chen, D., Lei, L., Lu, C., Flores, R., DeLisa, M. P., Roberts, T. C., Romesberg, F. 
E. & Zhong, G. (2010). Secretion of the chlamydial virulence factor CPAF 
requires the Sec-dependent pathway. Microbiology 156(10), 3031–3040. 
Costa, T. R. D., Felisberto-Rodrigues, C., Meir, A., Prevost, M. S., Redzej, A., 
Trokter, M. & Waksman, G. (2015). Secretion systems in Gram-negative 
bacteria: structural and mechanistic insights. Nat Rev Microbiol 13, 343–359. 
Ferrell, J. C. & Fields, K. A. (2015). A working model for the type III secretion 
mechanism in Chlamydia. Microbes Infect 18, 84–92. 
Galán, J. E. (2009). Common Themes in the Design and Function of Bacterial 
Effectors. Cell Host Microbe 5, 571–579. 
Gehre, L., Gorgette, O., Perrinet, S., Prevost, M.-C., Ducatez, M., Giebel, A. M., 
Nelson, D. E., Ball, S. G. & Subtil, A. (2016). Sequestration of host 
metabolism by an intracellular pathogen. elife 5, e12552. 
Jorgensen, I. & Valdivia, R. H. (2008). Pmp-like proteins Pls1 and Pls2 are secreted 
into the lumen of the Chlamydia trachomatis inclusion. Infect Immun 76(9), 
3940–3950. 
Knutton, S., Rosenshine, I., Pallen, M. J., Nisan, I., Neves, B. C., Bain, C., Wolff, 
C., Dougan, G. & Frankel, G. (1998). A novel EspA-associated surface 
organelle of enteropathogenic Escherichia coli involved in protein translocation 
into epithelial cells. EMBO J 17(8), 2166–2176. 
Lei, L., Qi, M., Budrys, N., Schenken, R. & Zhong, G. (2011). Localization of 
Chlamydia trachomatis hypothetical protein CT311 in host cell cytoplasm. 
Microb Pathog 51(3), 101–109. 
Lu, C., Lei, L., Peng, B., Tang, L., Ding, H., Gong, S., Li, Z., Wu, Y. & Zhong, G. 
(2013). Chlamydia trachomatis GlgA Is Secreted into Host Cell Cytoplasm. 
PLoS One 8(7), e68764. 
Markham, A. P., Jaafar, Z. A., Kemege, K. E., Middaugh, C. R. & Hefty, P. S. 
(2009). Biophysical characterization of Chlamydia trachomatis CT584 supports 
its potential role as a type III secretion needle tip protein. Biochemistry 48(43), 
10353–10361. 
Matsumoto, A., Izutsu, H., Miyashita, N. & Ohuchi, M. (1998). Plaque Formation 
by and Plaque Cloning of Chlamydia trachomatis Biovar Trachoma These 
include!: Plaque Formation by and Plaque Cloning of Chlamydia trachomatis 
Biovar Trachoma 36(10), 3013–3019. 
Moulder, J. W. (1991). Interaction of Chlamydiae and host cells in vitro. Microbiol 







Mueller, C. A. (2005). The V-Antigen of Yersinia Forms a Distinct Structure at the Tip 
of Injectisome Needles. Science 310, 674–676. 
Mueller, C. A., Broz, P. & Cornelis, G. R. (2008). The type III secretion system tip 
complex and translocon. Mol Microbiol 68(5), 1085–1095. 
Muschiol, S., Boncompain, G., Vromman, F., Dehoux, P., Normark, S., 
Henriques-Normark, B. & Subtil, A. (2011). Identification of a family of 
effectors secreted by the type III secretion system that are conserved in 
pathogenic Chlamydiae. Infect Immun 79(2), 571–580. 
O’Connell, C. M., Ingalls, R. R., Andrews Jr., C. W., Scurlock, A. M. & Darville, T. 
(2007). Plasmid-deficient Chlamydia muridarum fail to induce immune 
pathology and protect against oviduct disease. J Immunol 179, 4027–4034. 
O’Connell, C. M., AbdelRahman, Y. M., Green, E., Darville, H. K., Saira, K., 
Smith, B., Darville, T., Scurlock, A. M., Meyer, C. R. & Belland, R. J. (2011). 
Toll-like receptor 2 activation by Chlamydia trachomatis is plasmid dependent, 
and plasmid-responsive chromosomal loci are coordinately regulated in 
response to glucose limitation by C. trachomatis but not by C. muridarum. 
Infect Immun 79(3), 1044–1056. 
Ouellette, S. P., Abdelrahman, Y. M., Belland, R. J. & Byrne, G. I. (2005). The 
Chlamydia pneumoniae type III secretion-related lcrH gene clusters are 
developmentally expressed operons. J Bacteriol 187, 7853–6. 
Qi, M., Lei, L., Gong, S., Liu, Q., DeLisa, M. P. & Zhong, G. (2011). Chlamydia 
trachomatis secretion of an immunodominant hypothetical protein (CT795) into 
host cell cytoplasm. J Bacteriol 193(10), 2498–2509. 
Song, L., Carlson, J. H., Whitmire, W. M., Kari, L., Virtaneva, K., Sturdevant, D. 
E., Watkins, H., Zhou, B., Sturdevant, G. L. & other authors. (2013). 
Chlamydia trachomatis plasmid-encoded Pgp4 is a transcriptional regulator of 
virulence-associated genes. Infect Immun 81(3), 636–644. 
Stone, C. B., Sugiman-Marangos, S., Bulir, D. C., Clayden, R. C., Leighton, T. L., 
Slootstra, J. W., Junop, M. S. & Mahony, J. B. (2012). Structural 
characterization of a novel Chlamydia pneumoniae type III secretion-
associated protein, Cpn0803. PLoS One 7(1), e30220. 
Yang, C., Starr, T., Song, L., Carlson, J. H., Sturdevant, G. L., Beare, P. A., 
Whitmire, W. M. & Caldwell, H. D. (2015a). Chlamydial lytic exit from host 
cells is plasmid regulated. MBio 6(6), e01648–15. 
Yang, Z., Tang, L., Sun, X., Chai, J. & Zhong, G. (2015b). Characterization of 
CPAF critical residues and secretion during Chlamydia trachomatis infection. 
Infect Immun 83(6), 2234–2241. 
Zhong, G. (2011). Chlamydia trachomatis secretion of proteases for manipulating 
































































TABLE A1. Plasmids used in this work. 
 
  
Name Characteristics and usea Source/Ref. Chapter 
pCX340 Derivative of pBR322. Expresses mature TEM-1 β-lactamase 
(Charpentier & 
Oswald, 2004) II 
pLJM3 
Low copy vector, derivative of 
pBBR1MCS-2 (Kovach et al., 1995). 
Expresses YopE under the control of 
its own promoter (PyopE).  
(Marenne et 
al., 2003) II  
pFA3 Derivative of pLJM3. Expresses TEM-1 under the control of  PyopE 
(Almeida et al., 
2012) II  
pET28b(+) E. coli expression vector allowing N or C-terminal His-tag fusions (KmR) Novagen III 
pGEX-4T-2 
E. coli expression vector to generate 
fusions to the C-terminus of GST 
(AmpR) 
GE Healthcare III 
pMal-c 
E. coli expression vector to generate 





Mammalian transfection vector (KmR) 
to generate fusions to the C-terminus 
of EGFP. 
Clontech III 
p2TK2-SW2 C. trachomatis expression vector. (AmpR) 
(Agaisse & 
Derré, 2013) IV 
pBAD/Myc-
His A 
pBR322-derived expression vector. E. 
coli arabinose inducible promoter 




E. coli low-copy cloning and 
expression vector (KmR)  
(Kovach et al., 
1995) IV 
pCM13 
Derivative of pLJM3. Expresses 
CT01620-TEM-1 under the control of 
PyopE 
This study II 
pFA38 
Derivative of pLJM3. Expresses 
CT01720-TEM-1 under the control of 
PyopE 
This study II 
pFA39 
Derivative of pLJM3. Expresses 
CT03120-TEM-1 under the control of 
PyopE 
This study II  
pCM4 
Derivative of pLJM3. Expresses 
CT05120-TEM-1 under the control of 
PyopE 
This study II  
pCM5 
Derivative of pLJM3. Expresses 
CT05320-TEM-1 under the control of 
PyopE 
This study II 
pFA41 
Derivative of pLJM3. Expresses 
CT06620-TEM-1 under the control of 
PyopE 
This study II 
pCM14 
Derivative of pLJM3. Expresses 
CT08020-TEM-1 under the control of 
PyopE 






TABLE A1. Continued. 
Name Characteristics and usea Source/Ref. Chapter 
pRM10 
Derivative of pLJM3. Expresses 
CT08220-TEM-1 under the control of 
PyopE 
This study II 
pRM11 
Derivative of pLJM3. Expresses 
CT10520-TEM-1 under the control of 
PyopE 
This study II 
pRM12 
Derivative of pLJM3. Expresses 
CT14220-TEM-1 under the control of 
PyopE 
This study II 
pMC24 
Derivative of pLJM3. Expresses 
CT14320-TEM-1 under the control of 
PyopE 
This study II 
pMC25 
Derivative of pLJM3. Expresses 
CT14420-TEM-1 under the control of 
PyopE 
This study II 
pFA42 
Derivative of pLJM3. Expresses 
CT15320-TEM-1 under the control of 
PyopE 
This study II  
pCM6 
Derivative of pLJM3. Expresses 
CT16120-TEM-1 under the control of 
PyopE 
This study II 
pCM15 
Derivative of pLJM3. Expresses 
CT17220-TEM-1 under the control of 
PyopE 
This study II 
pCM16 
Derivative of pLJM3. Expresses 
CT20320-TEM-1 under the control of 
PyopE 
This study II 
pFA43 
Derivative of pLJM3. Expresses 
CT27320-TEM-1 under the control of 
PyopE 
This study II 
pCM17 
Derivative of pLJM3. Expresses 
CT27720-TEM-1 under the control of 
PyopE 
This study II 
pCM18 
Derivative of pLJM3. Expresses 
CT28920-TEM-1 under the control of 
PyopE 
This study II 
pRM13 
Derivative of pLJM3. Expresses 
CT30920-TEM-1 under the control of 
PyopE 
This study II 
pCM19 
Derivative of pLJM3. Expresses 
CT33020-TEM-1 under the control of 
PyopE 
This study II 
pCM20 
Derivative of pLJM3. Expresses 
CT33820-TEM-1 under the control of 
PyopE 
This study II 
pFA44 
Derivative of pLJM3. Expresses 
CT38620-TEM-1 under the control of 
PyopE 








TABLE A1. Continued. 
Name Characteristics and usea Source/Ref. Chapter 
pFA45 
Derivative of pLJM3. Expresses 
CT42520-TEM-1 under the control of 
PyopE 
This study II 
pFA46 
Derivative of pLJM3. Expresses 
CT42920-TEM-1 under the control of 
PyopE 
This study II 
pFA47 
Derivative of pLJM3. Expresses 
CT50420-TEM-1 under the control of 
PyopE 
This study II 
pFA48 
Derivative of pLJM3. Expresses 
CT53820-TEM-1 under the control of 
PyopE 
This study II 
pCM21 
Derivative of pLJM3. Expresses 
CT56820-TEM-1 under the control of 
PyopE 
This study II 
pFA49 
Derivative of pLJM3. Expresses 
CT57720-TEM-1 under the control of 
PyopE 
This study II 
pRM16 
Derivative of pLJM3. Expresses 
CT58320-TEM-1 under the control of 
PyopE 
This study II 
pFA50 
Derivative of pLJM3. Expresses 
CT58420-TEM-1 under the control of 
PyopE 
This study II 
pFA51 
Derivative of pLJM3. Expresses 
CT59020-TEM-1 under the control of 
PyopE 
This study II 
pFA52 
Derivative of pLJM3. Expresses 
CT63120-TEM-1 under the control of 
PyopE 
This study II 
pFA53 
Derivative of pLJM3. Expresses 
CT63520-TEM-1 under the control of 
PyopE 
This study II 
pCM8 
Derivative of pLJM3. Expresses 
CT65620-TEM-1 under the control of 
PyopE 
This study II 
pRM20 
Derivative of pLJM3. Expresses 
CT69620-TEM-1 under the control of 
PyopE 
This study II 
pCM9 
Derivative of pLJM3. Expresses 
CT70220-TEM-1 under the control of 
PyopE 
This study II 
pFA57 
Derivative of pLJM3. Expresses 
CT76820-TEM-1 under the control of 
PyopE 
This study II 
pCM22 
Derivative of pLJM3. Expresses 
CT77920-TEM-1 under the control of 
PyopE 







TABLE A1. Continued. 
Name Characteristics and usea Source/Ref. Chapter 
pFA58 
Derivative of pLJM3. Expresses 
CT81420-TEM-1 under the 
control of PyopE 
This study II 
pFA59 
Derivative of pLJM3. Expresses 
CT83720-TEM-1 under the 
control of PyopE 
This study II 
pCM11 
Derivative of pLJM3. Expresses 
CT84520-TEM-1 under the 
control of PyopE 
This study II 
pFA60 
Derivative of pLJM3. Expresses 
CT84920-TEM-1 under the 
control of PyopE 
This study II 
pRM15 
Derivative of pLJM3. Expresses 
CT86320-TEM-1 under the 
control of PyopE 
This study II 
pFA37 
Derivative of pLJM3. Expresses 
RplJ20-TEM-1 under the control 
of PyopE 
This study II 
pFA55 
Derivative of pLJM3. Expresses 
CT69420-TEM-1 under the 
control of PyopE 
This study II 
pMC1 
Derivative of pLJM3. Expresses 
CT016-HA under the control of 
PyopE 
This study II 
pMC7 
Derivative of pLJM3. Expresses 
CT051-HA under the control of 
PyopE 
This study II 
pMC2 
Derivative of pLJM3. Expresses 
CT053-HA under the control of 
PyopE 
This study II 
pMC3 
Derivative of pLJM3. Expresses 
CT080-HA under the control of 
PyopE 
This study II 
pRM1 
Derivative of pLJM3. Expresses 
CT082-HA under the control of 
PyopE 
This study II 
pRM7 
Derivative of pLJM3. Expresses 
CT105-HA under the control of 
PyopE 
This study II 
pRM2 
Derivative of pLJM3. Expresses 
CT142-HA under the control of 
PyopE 
This study II, IV 
pMC13 
Derivative of pLJM3. Expresses 
CT143-HA under the control of 
PyopE 
This study II, IV 
pMC5 
Derivative of pLJM3. Expresses 
CT144-HA under the control of 
PyopE 







TABLE A1. Continued. 
Name Characteristics and usea Source/Ref. Chapter 
pFA62 
Derivative of pLJM3. Expresses 
CT153-HA under the control of 
PyopE 
This study II 
pMC6 
Derivative of pLJM3. Expresses 
CT161-HA under the control of 
PyopE 
This study II 
pMC14 
Derivative of pLJM3. Expresses 
CT172-HA under the control of 
PyopE 
This study II 
pMC20 
Derivative of pLJM3. Expresses 
CT203-HA under the control of 
PyopE 
This study II 
pFA63 
Derivative of pLJM3. Expresses 
CT273-HA under the control of 
PyopE 
This study II 
pMC22 
Derivative of pLJM3. Expresses 
CT277-HA under the control of 
PyopE 
This study II 
pMC18 
Derivative of pLJM3. Expresses 
CT289-HA under the control of 
PyopE 
This study II 
pRM3 
Derivative of pLJM3. Expresses 
CT309-HA under the control of 
PyopE 
This study II 
pMC15 
Derivative of pLJM3. Expresses 
CT330-HA under the control of 
PyopE 
This study II 
pMC19 
Derivative of pLJM3. Expresses 
CT338-HA under the control of 
PyopE 
This study II 
pFA64 
Derivative of pLJM3. Expresses 
CT386-HA under the control of 
PyopE 
This study II 
pFA65 
Derivative of pLJM3. Expresses 
CT425-HA under the control of 
PyopE 
This study II 
pFA66 
Derivative of pLJM3. Expresses 
CT429-HA under the control of 
PyopE 
This study II 
pFA67 
Derivative of pLJM3. Expresses 
CT504-HA under the control of 
PyopE 
This study II 
pMC7 
Derivative of pLJM3. Expresses 
CT568-HA under the control of 
PyopE 
This study II 
pRM6 
Derivative of pLJM3. Expresses 
CT583-HA under the control of 
PyopE 








TABLE A1. Continued. 
Name Characteristics and usea Source/Ref. Chapter 
pFA68 
Derivative of pLJM3. Expresses 
CT631-HA under the control of 
PyopE 
This study II 
pMC8 
Derivative of pLJM3. Expresses 
CT656-HA under the control of 
PyopE 
This study II 
pCM12 
Derivative of pLJM3. Expresses 
CT694-HA under the control of 
PyopE 
This study II 
pRM18 
Derivative of pLJM3. Expresses 
CT696-HA under the control of 
PyopE 
This study II 
pMC9 
Derivative of pLJM3. Expresses 
CT702-HA under the control of 
PyopE 
This study II 
pMC10 
Derivative of pLJM3. Expresses 
CT779-HA under the control of 
PyopE 
This study II 
pMC21 
Derivative of pLJM3. Expresses 
CT845-HA under the control of 
PyopE 
This study II 
pFA70 
Derivative of pLJM3. Expresses 
CT849-HA under the control of 
PyopE 
This study II 
pRM5 
Derivative of pLJM3. Expresses 
CT863-HA under the control of 
PyopE 
This study II 
pFA61 Derivative of pLJM3. Expresses RplJ-HA under the control of PyopE This study II 
pMC31 Derivative of pET28b(+). Encodes 
6XHis-tagged CT142 (KmR) 
This study III 
pMC32 Derivative of pET28b(+). Encodes 
6X His-tagged CT143. (KmR) 
This study III 
pMC33 Derivative of pET28b(+). 6X His-
tagged CT144. (KmR) 
This study III 
pMC46 Derivative of pGEX-4T-2. 
Encodes GST-CT142. (AmpR) 
This study III 
pMC47 Derivative of pGEX-4T-2. 
Encodes GST-CT143. (AmpR) 
This study III 
pMC48 Derivative of pGEX-4T-2. 
Encodes GST-CT144. (AmpR) 
This study III 
pMC56 Derivative of pMal-c. Encodes 
MBP-CT143. (AmpR)   
This study III 
pCM33 Derivative of pMal-c. Encodes 
MBP-CT142 (AmpR)  
This study III 
pCM38 Derivative of pMal-c. Encodes 
MBP-CT144 (AmpR)  
This study III 
pSG1 Derivative of pEGFP-C1. Encodes 
EGFP-CT142 (KmR) 







TABLE A1. Continued. 
Name Characteristics and usea Source/Ref. Chapter 
pSG2 Derivative of pEGFP-C1. Encodes EGFP-CT143 (KmR) This study III 
pMC68 
Derivative of p2TK2-SW2. 
Encodes CT142-2XHA under the 
control of PincD (AmpR) 
This study IV 
pSVP253 
Derivative of p2TK2-SW2. 
Encodes CT143-2XHA under the 
control of PincD (AmpR) 
This study IV 
pMC69 
Derivative of p2TK2-SW2. 
Encodes CT144-2XHA under the 
control of PincD (AmpR) 
This study IV 
pMC70 
Derivative of p2TK2-SW2. 
Encodes CT142-2XHA under the 
control of Pct142 (AmpR) 
This study IV 
pMC71 
Derivative of p2TK2-SW2. 
Encodes CT143-2XHA under the 
control of Pct142 (AmpR) 
This study IV 
pMC72 
Derivative of p2TK2-SW2. 
Encodes CT144-2XHA under the 
control of Pct142 (AmpR) 
This study IV 
pMC73 
Derivative of p2TK2-SW2. 
Encodes CT142-CT143-CT144-
2XHA under the control of Pct142 
(AmpR) 
This study IV 
pSVP84 Derivative of pBAD/Myc-HisA. 
Encodes CT142-Myc-His  
This study IV 






















TABLE A2. DNA primers used in this work. 
Code Description  Sequence Restriction enzymea 
28 Used to amplify the 5’ 
region of genes 
cloned in pLJM3 to 
construct TEM-1 
hybrids by overlapping 
PCR 
GATTAAGTTGGGTAACGCC - 
60 Used to amplify tem-1 





67 Used to amplify tem-1 











































































TABLE A2. Continued. 
Code Description  Sequence Restriction enzymea 





























































































TABLE A2. Continued. 
Code Description  Sequence Restriction enzymea 




























171 Used to construct 






172 Used to construct 

















175 Used to construct 





176 Used to construct 

















179 Used to construct 






180 Used to construct 

















183 Used to construct 











TABLE A2. Continued. 
Code Description  Sequence Restriction enzymea 
184 Used to construct 

















187 Used to construct 





188 Used to construct 
















195 Used to construct 






196 Used to construct 


















199 Used to construct 





200 Used to construct 














































TABLE A2. Continued. 
Code Description  Sequence Restriction enzymea 



















































































































TABLE A2. Continued. 
Code Description  Sequence Restriction enzymea 







241 Used to construct 











243 Used to construct 




























































































TABLE A2. Continued. 
Code Description  Sequence Restriction enzymea 

































































325 Used to construct 






326 Used to construct 





327 Used to construct 





328 Used to construct 

















696 Used to construct 












TABLE A2. Continued. 
Code Description  Sequence Restriction enzymea 
697 Used to construct 





700 Used to construct 





701 Used to construct 





702 Used to construct 





703 Used to construct 





704 Used to construct 





705 Used to construct 





706 Used to construct 






707 Used to construct 






708 Used to construct 





709 Used to construct 





710 Used to construct 





711 Used to construct 





712 Used to construct 





713 Used to construct 





714 Used to construct 





715 Used to construct 





716 Used to construct 











TABLE A2. Continued. 
Code Description  Sequence Restriction enzymea 
717 Used to construct 





718 Used to construct 





719 Used to construct 





722 Used to construct 





723 Used to construct 





724 Used to construct 





725 Used to construct 





726 Used to construct 





727 Used to construct 





728 Used to construct 






729 Used to construct 






732 Used to construct 





733 Used to construct 












416 Used to  




















490 Used to  


















TABLE A2. Continued. 
Code Description  Sequence Restriction enzymea 





























893 Used to  
construct pCM38 
GAT CGG ATC CAC AAC 
ACC AGA TAA TAA TAC 
BamHI 

































GATC GG TAC C AAC GGA 
GCC TTC TAG CTA TTT TG 
KpnI 
 
1553 Used to  
construct pMC68 by 
overlapping PCR 
 
ATC TGT CGA AGT GAG 
GTT T ATG AGT GAT TCT 
GAC AAA ATT ATT AAT G 
- 
1554 Used to  
construct pMC68 by 
overlapping PCR 
 
C ATT AAT AAT TTT GTC 
AGA ATC ACT CAT A AAC 
CTC ACT TCG ACA GAT 
- 
1555 Used to  
construct pMC68 and 
pMC70 
GATC GCG GCC GCG TCC 
TCC TAT CTC TGG GTA TAC 
G 
NotI 
1556 Used to  
construct pSVP253 by 
overlapping PCR 
ATC TGT CGA AGT GAG 
GTT T ATG AAG AAA CCA 
GTA TTT ACA GG 
- 
 
1557 Used to  
construct pSVP253 by 
overlapping PCR 
CC TGT AAA TAC TGG TTT 
CTT CAT A AAC CTC ACT 
TCG ACA GAT 
- 
 




GATC GCG GCC GCG ATC 




1559 Used to  
construct pMC68  
by overlapping PCR 
 
ATC TGT CGA AGT GAG 
GTT T ATG ACA ACA CCA 
GAT AAT AAT AC 
- 
1560 Used to  
construct pMC68 by 
overlapping PCR 
GT ATT ATT ATC TGG TGT 
TGT CAT A AAC CTC ACT 
TCG ACA GAT 
- 
1561 Used to  
construct pMC68, 
pMC72 and pMC73 
GATC GCG GCC GCG AGG 










TABLE A2. Continued. 
Code Description  Sequence Restriction enzymea 
1652 Used to  
construct pMC70, 





1653 Used to  
construct pMC71  






1654 Used to  
construct pMC71 






1655 Used to  
construct pMC72 





454 Used to  
construct pSVP84 
GATC TC ATG AGT GAT TCT 
GAC AAA  ATT ATT AAT GAT 
TGT CG  
BspHI 
 
455 Used to  
construct pSVP84 
GATC GG TAC CAG TCC 




1237 Used for trasncription 






1238 Used for trasncription 
linkage analysis  
 (CT141-CT142) 
GGGAGTCTTTCTCCGGGC - 
1239 Used for trasncription 






1240 Used for trasncription 
linkage analysis  
 (CT142-CT143) 
CCCTTTAACTAGTGCACC - 




















1255 Used for 5´RACE  




1256 Used for 5´RACE 




1257 Used for 5´RACE 










TABLE A2. Continued. 
Code Description  Sequence Restriction enzymea 
16SrRN
A-9  



















































































CT656-A Used for  
RT-qPCR 
AGACCAGTTGCGGCAAGCT - 






















TABLE A3. C. trachomatis strains used in this work 
Strain (Code) Plasmid used in 
transformation 
Description  Source/ 
Reference 
Chapter 
L2 (434/Bu) - Wild-type ATCC II, III, IV 
L2 (25667R) - Serovar L2 strain lacking 
the virulence plasmid 
(Peterson 
et al., 1990) 
III 
13 L2 (434/Bu) + 
pMC68 
PincD-ct142-HA-incD term This Study IV 
  4  L2 (434/Bu) + 
pSVP253 
PincD-ct143-HA-incD term This Study IV 
  9  L2 (434/Bu) + 
pMC69 
PincD-ct144-HA-incD term This Study IV 




This Study IV 




This Study IV 




This Study IV 











TABLE A4. Summary of results obtained from T3S signals 
C. trachomatis protein name 
T3S assays CTxxx20-TEM-1 proteins 
ΔHOPEMT ΔHOPEMT  ΔYscU 
strain D/UW3 strain L2/434 % secretion Result Result average SEM N 
CT016 CTL0271 24,0 10,3 4 S NS 
CT017 CTL0272 1,3 0,5 4 NS NT 
CT031 CTL0286 2,8 1,0 6 NS NT 
CT051 CTL0307 0,5 0,2 4 NS NT 
CT053 CTL0309 5,6 1,6 9 S NS 
CT066 CTL0322 0,6 0,6 4 NS NT 
CT080 CTL0336 1,0 0,5 4 NS NT 
CT082 CTL0338 11,3 3,1 5 S NS 
CT105 CTL0360 40,2 10,2 5 S NS 
CT142 CTL0397 9,6 2,4 6 S NS 
CT143 CTL0398 5,4 2,7 6 S NS 
CT144 CTL0399 11,8 3,0 5 S NS 
CT153 CTL0408 17,9 6,3 4 S NS 
CT161 CTL0417 6,9 1,8 4 S NS 
CT172 CTL0425 9,6 3,2 7 S NS 
CT203 CTL0455 10,6 3,6 5 S NS 
CT273 CTL0525 28,1 11,2 4 S NS 
CT277 CTL0529 1,4 0,9 4 NS NT 
CT289 CTL0541 39,0 12,6 4 S NS 
CT309 CTL0561 6,2 1,9 5 S NT 
CT330 CTL0584 3,9 1,9 6 NS NT 
CT338 CTL0592 36,8 9,8 5 S NS 
CT386 CTL0642 33,4 9,0 4 S NS 
CT425 CTL0684 31,5 9,6 4 S NS 
CT429 CTL0688 28,7 7,8 4 S NS 
CT504 CTL0766 20,7 6,5 4 S NS 
CT538 CTL0800 2,4 1,0 4 NS NT 
CT568 CTL0831 0,7 0,4 4 NS NT 
CT577 CTL0840 0,6 0,6 4 NS NT 
CT583 CTL0846 8,9 1,7 5 S NS 
CT584 CTL0847 2,4 1,3 5 NS NT 
CT590 CTL0853 1,5 1,4 4 NS (?) NT 
CT631 CTL0895 26,1 4,0 4 S NS 
CT635 CTL0003 0,0 0,0 4 NS NT 
CT656 CTL0025 28,6 7,5 4 S NS 
CT694 CTL0063 55,8 4,7 18 S NS 
CT696 CTL0065 10,2 2,8 6 S NS 
CT702 CTL0071 0,9 0,4 4 NS NT 
CT768 CTL0137 0,0 0,0 4 NS NT 
CT779 CTL0148 31,2 5,5 4 S NS 
CT814 CTL0185 0,0 0,0 4 NS NT 
CT837 CTL0209 2,5 1,6 4 NS NT 
CT845 CTL0217 1,5 0,8 4 NS (?) NT 
CT849 CTL0221 20,3 5,0 4 S NS 
CT863 CTL0238 1,4 0,9 4 NS (?) NT 
RplJ RplJ 1,5 0,6 17 NS NS 







TABLE A5. Summary of results obtained from T3S of C. trachomatis full-
length proteins  
C. trachomatis protein name 
T3S assays CTxxxFL-HA proteins 
ΔHOPEMT ΔHOPEMT  ΔYscU 
strain D/UW3 strain L2/434 % secretion Result Result average SEM N 
CT016 CTL0271 ND ND ND NS (?) NT 
CT017 CTL0272 ND ND ND NT NT 
CT031 CTL0286 ND ND ND NT NT 
CT051 CTL0307 ND ND ND NT NT 
CT053 CTL0309 6,0 2,3 4 S NS 
CT066 CTL0322 ND ND ND NT NT 
CT080 CTL0336 ND ND ND NT NT 
CT082 CTL0338 32,9 12,6 5 S NS 
CT105 CTL0360 8,5 2,8 6 S NS 
CT142 CTL0397 2,3 1,0 4 S NS 
CT143 CTL0398 13,2 2,2 5 S NS 
CT144 CTL0399 5,0 0,9 4 S NS 
CT153 CTL0408 0,9 0,3 6 NS NT 
CT161 CTL0417 9,0 1,8 4 S NS 
CT172 CTL0425 0,6 0,1 5 NS NT 
CT203 CTL0455 0,5 0,1 5 NS NT 
CT273 CTL0525 0,2 0,1 2 NS (?) NT 
CT277 CTL0529 ND ND ND NT NT 
CT289 CTL0541 0,4 0,1 3 NS (?) NT 
CT309 CTL0561 0,4 0,2 3 NS (?) NT 
CT330 CTL0584 ND ND ND NT NT 
CT338 CTL0592 2,2 0,7 5 S NS 
CT386 CTL0642 0,5 0,1 7 NS NT 
CT425 CTL0684 0,3 0,1 7 NS NT 
CT429 CTL0688 2,2 0,4 6 S NS 
CT504 CTL0766 1,0 0,3 7 NS NT 
CT538 CTL0800 ND ND ND NT NT 
CT568 CTL0831 ND ND ND NT NT 
CT577 CTL0840 ND ND ND NT NT 
CT583 CTL0846 14,4 3,1 8 S NS (?) 
CT584 CTL0847 ND ND ND NT NT 
CT590 CTL0853 ND ND ND NT NT 
CT631 CTL0895 ND ND ND NS (?) NT 
CT635 CTL0003 ND ND ND NT NT 
CT656 CTL0025 26,9 10,3 5 S NT 
CT694 CTL0063 20,8 2,7 10 S NS 
CT696 CTL0065 ND ND ND NS (?) NT 
CT702 CTL0071 ND ND ND NT NT 
CT768 CTL0137 ND ND ND NT NT 
CT779 CTL0148 1,1 0,4 6 NS NT 
CT814 CTL0185 ND ND ND NT NT 
CT837 CTL0209 ND ND ND NT NT 
CT845 CTL0217 ND ND ND NT NT 
CT849 CTL0221 9,7 2,5 5 S NS 
CT863 CTL0238 ND ND ND NT NT 
RplJ RplJ 0,1 0,0 13 NS NS 







TABLE A6. Comparison of results obtained in analyses of T3S signals in 
proteins of C. trachomatis and to in silico prediction methods 
Observed Results           
T3S   assays 









b Modlabc T3_MMd 
CT016 S NS (?) NS NS NS NS 
CT017 NS NT NS NS NS NS 
CT031 NS NT NS NS NS NS 
CT051 NS NT NS NS NS S 
CT053 S S NS NS NS S 
CT066 NS NT NS NS NS S 
CT080 NS NT NS S NS NS 
CT082 S S S S S S 
CT105 S S S S S S 
CT142 S S NS S NS S 
CT143 S S NS NS S S 
CT144 S S S NS NS S 
CT153 S NS NS NS NS NS 
CT161 S S NS NS NS NS 
CT172 S NS NS NS NS NS 
CT203 S NS NS NS NS NS 
CT273 S NS (?) S NS NS S 
CT277 NS NT NS NS NS NS 
CT289 S NS (?) NS NS NS NS 
CT309 S NS (?) S S NS NS 
CT330 NS NT NS NS NS NS 
CT338 S S NS NS NS NS 
CT386 S NS NS NS NS NS 
CT425 S NS NS NS NS NS 
CT429 S S NS NS NS NS 
CT504 S NS NS NS NS NS 
CT538 NS NT NS NS NS S 
CT568 NS NT NS NS NS NS 
CT577 NS NT S NS NS S 
CT583 S S NS S NS S 
CT584 NS NT NS NS NS NS 
CT590 NS (?) NT NS NS NS NS 
CT631 S NS (?) NS NS NS S 
CT635 NS NT NS NS NS S 
CT656 S S S NS S S 
CT694 S S S S S S 
CT696 S NS (?) NS S NS NS 
CT702 NS NT NS NS NS NS 
CT768 NS NT NS NS NS S 
CT779 S NS NS NS NS S 
CT814 NS NT NS NS NS NS 
CT837 NS NT NS NS NS NS 
CT845 NS (?) NT NS NS NS NS 
CT849 S S S S NS S 
CT863 NS (?) NT S S S S 
RplJ NS NS NS NS NS NS 
S, Secreted; NS, Not Secreted; NT, Not Tested; ND, Not Determined; (?), Unclear Result. a) 
Using animal set and sensitive settings (cutoff 0.95) (Arnold et al., 2009); b) Using information 
from Table 3 in (Samudrala et al., 2009); c) Using Neural Network to predict T3S signal 
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